

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/25466 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/867**,  
15/90, 5/10, 7/01, A61K 48/00

(UK) Limited, Medawar Centre, Robert Robinson Avenue,  
The Oxford Science Park, Oxford OX4 4GA (GB).

(21) International Application Number: PCT/GB00/03837

(74) Agents: **HARDING, Charles, Thomas** et al.; D Young &  
Co., 21 New Fetter Lane, London EC4A 1DA (GB).

(22) International Filing Date: 5 October 2000 (05.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9923558.2 5 October 1999 (05.10.1999) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SLINGSBY, Jason**  
[GB/GB]; 91 Lacy Road, Putney, London SW15 1NR  
(GB). **KINGSMAN, Susan, Mary** [GB/GB]; Oxford  
BioMedica (UK) Limited, Medawar Centre, Robert  
Robinson Avenue, The Oxford Science Park, Oxford  
OX4 4GA (GB). **ROHLL, Jonathan** [GB/GB]; Oxford  
BioMedica (UK) Limited, Medawar Centre, Robert Robin-  
son Avenue, The Oxford Science Park, Oxford OX4 4GA  
(GB). **SLADE, Andrew** [GB/GB]; Oxford BioMedica

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: PRODUCER CELL FOR THE PRODUCTION OF RETROVIRAL VECTORS

(57) Abstract: A method is provided for modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.



WO 01/25466 A1

## PRODUCER CELL FOR THE PRODUCTION OF RETROVIRAL VECTORS

## FIELD OF THE INVENTION

5

The present invention relates to retroviral vectors, in particular to high titre regulatable retroviral vectors.

## BACKGROUND TO THE INVENTION

10

Retroviruses have been proposed as a delivery system (otherwise expressed as a delivery vehicle or delivery vector) for *inter alia* the transfer of a nucleotide sequence of interest (NOI), or a plurality of NOIs, to one or more sites of interest. The transfer can occur *in vitro*, *ex vivo*, *in vivo*, or combinations thereof. When used in this fashion, the retroviruses are typically called retroviral vectors or recombinant retroviral vectors. Retroviral vectors have been exploited to study various aspects of the retrovirus life cycle, including receptor usage, reverse transcription and RNA packaging (reviewed by Miller, 1992 Curr Top Microbiol Immunol 158:1-24).

20 In a typical recombinant retroviral vector for use in gene therapy, at least part of one or more of the *gag*, *pol* and *env* protein coding regions may be removed from the virus. This makes the retroviral vector replication-defective. The removed portions may even be replaced by a NOI in order to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs - resulting in, for example, a therapeutic effect. Thus, the transfer of a NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest - such as a targetted cell or a targetted cell population.

30

It is possible to propagate and isolate quantities of retroviral vectors (e.g. to prepare suitable titres of the retroviral vector) for subsequent transduction of, for example, a site of interest by using a combination of a packaging or helper cell line and a recombinant vector.

-2-

In some instances, propagation and isolation may entail isolation of the retroviral *gag*, *pol* and *env* genes and their separate introduction into a host cell to produce a “packaging cell line”. The packaging cell line produces the proteins required for packaging retroviral RNA but it does not produce RNA-containing retroviral vectors. However, when a  
5 recombinant vector carrying a NOI and a *psi* region is introduced into the packaging cell line, the helper proteins can package the *psi*-positive recombinant vector to produce the recombinant virus stock. This can be used to infect cells to introduce the NOI into the genome of the cells. The recombinant virus whose genome lacks all genes required to make viral proteins can infect only once and cannot propagate. Hence, the NOI is  
10 introduced into the host cell genome without the generation of potentially harmful retrovirus. A summary of the available packaging lines is presented in “Retroviruses” (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).

15 Retroviral packaging cell lines have been developed to produce retroviral vectors. These cell lines are designed to express three components, which may be located on three separate expression constructs. The *gag/pol* expression construct encodes structural and enzymatic components required in particle formation, maturation, reverse transcription and integration. The envelope (*env*) construct expresses a retroviral or non-retroviral  
20 envelope protein, which mediates viral entry into cells by binding to its cognate receptor. The third expression construct produces the retroviral RNA genome containing a *psi* region, which is packaged into mature, enveloped retroviral particles.

It has been observed that different methods, such as electroporation, transfection and  
25 retroviral transduction, which have been used to introduce the retroviral expression construct for the RNA genome, termed “the genome”, into packaging cells produce different results. These different results can include different end points or “yield” of retroviral producer lines resulting from the derived cell lines. Moreover, electroporation and transfection methods can be problematic in the sense that the titre levels are not always  
30 at a satisfactory level.

By way of example, the transfection of a plasmid DNA construct into packaging cells from a MLV packaging cell line of human origin, called FLYA13, yielded low retroviral

-3-

vector titres even when different transfection reagents such as calcium phosphate precipitation and fugene transfection reagent were used. The average titres from selected stably transfected cell lines clones ranged from about  $10^3$  to about  $10^4$  per ml. In addition, clones generated by electroporation of constructs gave similar titres of from about  $10^3$  to about  $10^4$  per ml with no clones identified producing at  $>10^5$  per ml. However, when MLV vector particles are prepared in a transient transfection system with a different envelope pseudotype to the packaging cell, and used to transduce a retroviral packaging cell, stably transduced cell lines made by this transduction method produce retrovirus at  $10^6$  to  $10^7$  per ml. Therefore, these results suggest that retroviral transduction is a preferred method for genome introduction into packaging cell lines in order to generate high titre producer cell lines. However, when retroviral transduction is used to introduce a regulated/inactivated retroviral vector genome into packaging cell lines, the regulated retroviral vectors may not be produced in sufficient quantities from these cell lines.

15

By way of example, some retroviral vectors may comprise (i) internal expression constructs which are themselves regulated or (ii) regulated elements which are present in retroviral 3' LTR sequences, either by design or by their nature. Examples of these regulated vectors include but are not limited to hypoxic regulated vectors and self inactivating (SIN) vectors. If transduced producer cell lines are generated with these regulated vectors, the regulated or inactivated 3' U3 sequence of the LTR is copied to the 5' LTR by the process of retroviral reverse transcription and integration. Therefore, in the producer cell line, the 5' U3 promoter sequence directing expression of retroviral RNA genomes is identical to the regulated or inactivated 3' U3 promoter. This will result in very low levels of retroviral genome production and consequently low titres of functional retrovirus vectors being produced.

One example of such a regulated retroviral system includes MLV and lentivirus vector constructs where the 3' retroviral U3 enhancer element is replaced with a hypoxia responsive element (HRE) or other physiologically regulated, tumour specific or tissue-specific promoters. When these vectors are used to make a transduced producer cell line, the 3' U3 sequence containing the HRE element is copied to the 5' LTR position and retroviral genomes will only be produced under hypoxic conditions or chemical mimics

30

-4-

of hypoxia, such as heavy metal ions and desferrioxamine. Such a requirement for "induction for retroviral production" is not preferable as the different hypoxia induction protocols negatively affect retroviral producer cell viability.

5 By way of further example, lentivector U3 enhancers are dependent on the transactivator TAT for transcriptional activation. Therefore, a lentivector producer cell line generated by transduction requires the presence of TAT for high level expression of the lentivector genome construct. The expression of TAT is not preferable in such a packaging cell line and therefore, in the absence of TAT, only very low titres will be produced from  
10 transduced producer cells generated in this way.

Another example of a regulated retroviral systems includes MLV or lentivirus self-inactivating (SIN) vectors. These vectors contain deletions of the elements in their 3' U3 sequences responsible for transcriptional activity. Therefore, on transduction of target  
15 cells, the transcriptionally inactive 3' U3 sequence is copied to the 5' LTR position. In standard configurations, an internal expression cassette directs therapeutic or marker gene expression. However, if SIN vectors are used to make a transduced retroviral producer line, there will be no transcriptional elements present to direct high levels of retroviral RNA genome expression.

20

Although it is possible to carry out retroviral transduction with much lower-titre vector stocks, for practical reasons, high-titre retrovirus is desirable, especially when a large number of cells must be infected. In addition, high titres are a requirement for transduction of a large percentage of certain cell types. For example, the frequency of  
25 human hematopoietic progenitor cell infection is strongly dependent on vector titre, and useful frequencies of infection occur only with very high-titre stocks (Hock and Miller 1986 Nature 320: 275-277; Hogge and Humphries 1987 Blood 69: 611-617). In these cases, it is not sufficient simply to expose the cells to a larger volume of virus to compensate for a low virus titre. On the contrary, in some cases, the concentration of  
30 infectious vector virions may be critical to promote efficient transduction.

## SUMMARY OF THE INVENTION

We have now shown that it is possible to obtain transduced producer cells capable of producing high titre regulated retroviral vectors by replacing at least the 3'LTR of the integrated provirus using a recombinase based system. Thus whereas with the prior art, the U3 region of the 3'LTR is the same as that of the U3 region of the 5' LTR (and vice versa for the U5 region) in the provirus due to the way in which the viral vector integrates, the introduction of, for example, a replacement 3'LTR results in a provirus that has a 5'LTR and a 3'LTR that differ. The packaged viral vectors produced by transcription of the proviral genome within the producer cells may then ultimately be used to transduce target cells where the regulatable sequences present in the 3'LTR of the provirus in the producer cells are then present in the 5'LTR of the provirus in the target cells and consequently regulate transcription from the provirus as required.

This allows the introduction of a 3'LTR, for example a regulatable 3'LTR, into the provirus that was not desirable in the original viral vector used to transduce the producer cells since the consequential appearance of the regulatable 3'LTR U3 sequences in the 5'LTR in the provirus may lead to a reduced viral titre.

Consequently, the present invention allows transduced producer cells to be constructed that are capable of producing high titre regulated retroviral vectors by virtue of comprising a 5'LTR that directs high level expression of the viral genome in the producer cell and a different 3'LTR which as a result of the process of integration into a target cell will then result in a provirus in the target cell genome that exhibits regulatable expression.

In particular, the present invention allows the modification of a provirus integrated into the genome of the producer cells that have been selected for their high titre virus production such that the resulting packaged viral particles produced from the provirus may be used to transduce target cells resulting in a provirus integrated into the genome of the target cells that has a different, and preferably regulatable 5'LTR to that of the producer cell provirus.

-6-

The present invention is not limited to replacement of the 3'LTR of the provirus in the high titre producer cells, but may also include replacement of the 5'LTR and other viral sequences and/or the introduction of NOIs by the use of suitable constructs, as shown in the Figures.

5

Accordingly, the present invention provides a method of modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase  
10 recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.

15 Preferably the LTR is a heterologous regulatable LTR.

The present invention further provides a nucleic acid vector comprising a 5' recombinase recognition sequence, a regulatable LTR and a 3' recombinase recognition sequence in that order.

20

In any of the above aspects and embodiments of the invention, preferably the construct, nucleic acid molecule and/or nucleic acid vector further comprises at least one NOI between the 5' recombinase recognition sequence and the regulatable LTR.

25 Preferably the construct, nucleic acid molecule and/or nucleic acid vector further comprises a 5'LTR and/or a packaging signal

In one embodiment of the invention, the LTR is inactive/transcriptionally quiescent.

30 The construct, nucleic acid molecule and/or nucleic acid vector of the invention may be used in a recombinase assisted method to introduce a regulated LTR into a proviral genome integrated into a producer cell genome.

-7-

The present invention also provides a producer cell obtainable by the method of the invention, preferably a high titre producer cells. Also provided is an infectious retroviral particle obtained by the above method.

- 5 The present invention further provides a high titre producer cell comprising integrated into its genome a provirus, which provirus comprises a recombinase recognition site, a 5' LTR and a 3'LTR which 3'LTR differs from the 5'LTR. Such a producer cell will typically have been produced by the method of the invention.
- 10 Preferably the 5'LTR and the 3'LTR referred to for the purposes of comparison are both "active". The term "active" within the present context means transcriptionally active, that is to say, the 5'LTR comprises a promoter that directs transcription of the viral genome and the 3'LTR comprises a transcriptional stop sequence to terminate transcription. This distinction is relevant since if a provirus produced by the method of the invention
- 15 comprises more than one 5' LTR or 3'LTR, at least one but not all must be active to allow viral production. Further, if the provirus comprises more than one 3'LTR then it is generally the upstream one that will be active since transcription will tend not to read through to the downstream 3' LTR.
- 20 In addition, where the method of the invention results in an insertion of a 3'LTR upstream of the original 3'LTR, the comparison should be performed between the additional 3'LTR and the original 5'LTR and not the two original LTRs. Thus it is permitted to have a 5'LTR and 3'LTR within the same provirus that are the same provided that there is also a 5'LTR and 3'LTR that differ.
- 25 In another aspect, the present invention provides a derived producer cell comprising integrated into its genome a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the
- 30 producer cell.



-8-

Preferably the first 5' LTR comprising 5'R and 5' U5 sequences is derivable from a first vector; the second NOI operably linked to a second regulatable 3' LTR is derivable from a second vector; and the third 3'LTR is derivable from the first vector.

- 5 In a preferred embodiment, the first vector further comprises an internal LTR located upstream of the first NOI and downstream of the packaging signal wherein the internal LTR comprises a heterologous U3 sequence linked to heterologous R and U5 sequences.

Preferably the heterologous R and U5 sequences are lentiviral derivable R and U5  
10 sequences, such as EIAV R and U5 sequences.

In a further preferred embodiment, the third 3'LTR is transcriptionally active but expression is directed away from the second regulatable 3'LTR.

- 15 In another embodiment, the second vector comprises a second NOI operably linked to a second regulatable 3'LTR comprising at least one recombinase recognition sequence. Preferably the second regulatable 3'LTR comprises a deletion in the U3 sequences in the 3'LTR.

- 20 Preferably, the second NOI comprises a discistronic construct, more preferably a discistronic construct comprising a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.

The present invention further provides in another embodiment, a method for producing a  
25 high titre regulatable retroviral vector, the method comprising the steps of:

- (i) providing a derived producer cell comprising integrated into its genome a first vector;  
(ii) introducing a second vector into the derived producer cell using a recombinase assisted method; wherein the derived producer cell comprises a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a  
30 second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the derived producer cell.

-9-

The present invention also provides the use of a recombinase assisted mechanism to introduce a regulated 3'LTR into a derived producer cell line to produce a high titre regulated retroviral vector.

- 5 Aspects of the present invention are also presented in the accompanying claims and in the following description and discussion.

These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section heading are not necessarily limited to  
10 that particular section heading.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is advantageous because:

15

(i) it enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

(ii) it removes the uncertainty associated with the process of producer cell line derivation  
20 and the necessity to screen large numbers of producer cell lines each time a new retroviral expression construct is introduced into a producer cell line.

(iii) it greatly facilitates the generation of high titre retroviral stocks without the use of marker genes (such as but not limited to  $\beta$ -galactosidase, green fluorescent protein) and  
25 antibiotic resistance genes.

(iv) it avoids the derivation of low titre transfected producer cell lines or the use of hypoxic conditions or chemical mimics for production from traditionally derived transduced producer lines.

30

(v) it enables the production of SIN vectors by stable cell line producer technology. Previously, SIN vectors have not been amenable to production by stable cell line producer technology because the deletion of the 3'U3 sequence resulted in at least a tenfold lower

-10-

titre of self-inactivating (SIN) vectors in comparison with vectors having intact LTRs. Consequently, SIN vectors have had to be prepared using transfection-based transient expression systems.

## 5 PRODUCER CELL

The high titre regulated retroviral vector particles of the present invention are typically generated in a suitable producer cell. Producer cells are generally mammalian cells but can be, for example, insect cells. A producer cell may be a packaging cell containing the  
10 virus structural genes, normally integrated into its genome into which the regulated retroviral vectors of the present invention are introduced. Alternatively the producer cell may be transfected with nucleic acid sequences encoding structural components, such as *gag/pol/env* on one or more vectors such as plasmids, adenovirus vectors, herpes viral vectors or any method known to deliver functional DNA into target cells. The vectors  
15 according to the present invention are then introduced into the packaging cell by the methods of the present invention.

As used herein, the term “producer cell” or “vector producing cell” refers to a cell which contains all the elements necessary for production of regulated retroviral vector particles  
20 and regulated retroviral delivery systems.

Preferably, the producer cell is obtainable from a stable producer cell line.

Preferably, the producer cell is obtainable from a derived stable producer cell line.  
25

Preferably, the producer cell is obtainable from a derived producer cell line

As used herein, the term “derived producer cell line” is a transduced producer cell line which has been screened and selected for high expression of a marker gene. Such cell  
30 lines contain retroviral insertions in integration sites that support high level expression from the retroviral genome. The term “derived producer cell line” is used interchangeably with the term “derived stable producer cell line” and the term “stable producer cell line

-11-

Preferably the derived producer cell line includes but is not limited to a retroviral and/or a lentiviral producer cell.

5 Preferably the derived producer cell line is an HIV or EIAV producer cell line, more preferably an EIAV producer cell line.

10 Preferably the envelope protein sequences, and nucleocapsid sequences are all stably integrated in the producer and/or packaging cell. However, one or more of these sequences could also exist in episomal form and gene expression could occur from the episome.

#### PACKAGING CELL

15 As used herein, the term “packaging cell” refers to a cell which contains those elements necessary for production of infectious recombinant virus which are lacking in a recombinant viral vector. Typically, such packaging cells contain one or more expression cassettes which are capable of expressing viral structural proteins (such as *gag*, *pol* and *env*) but they do not contain a packaging signal.

20 The term “packaging signal” which is referred to interchangeably as “packaging sequence” or “*psi*” is used in reference to the non-coding sequence required for encapsidation of retroviral RNA strands during viral particle formation.

25 Packaging cell lines suitable for use with the above-described vector constructs may be readily prepared (see also WO 92/05266), and utilised to create producer cell lines for the production of retroviral vector particles. As already mentioned, a summary of the available packaging lines is presented in “Retroviruses” (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).

30 The packaging cell lines are useful for providing the gene products necessary to encapsidate and provide a membrane protein for a high titre regulated retrovirus vector and regulated nucleic gene delivery vehicle production. When regulated retrovirus sequences are introduced into the packaging cell lines, such sequences are encapsidated

-12-

with the nucleocapsid (*gag/pol*) proteins and these units then bud through the cell membrane to become surrounded in cell membrane and to contain the envelope protein produced in the packaging cell line. These infectious regulated retroviruses are useful as infectious units *per se* or as gene delivery vectors.

5

The packaging cell may be a cell cultured *in vitro* such as a tissue culture cell line. Suitable cell lines include but are not limited to mammalian cells such as murine fibroblast derived cell lines or human cell lines. Preferably the packaging cell line is a human cell line, such as for example: HEK293, 293-T, TE671, HT1080.

10

Alternatively, the packaging cell may be a cell derived from the individual to be treated such as a monocyte, macrophage, blood cell or fibroblast. The cell may be isolated from an individual and the packaging and vector components administered *ex vivo* followed by re-administration of the autologous packaging cells.

15

Methods for introducing retroviral packaging and vector components into packaging/producer cells are described in the present invention.

Preferably the method of the present invention utilises a recombinase assisted mechanism.

20

Preferably the method of the present invention utilises a recombinase assisted mechanism which facilitates the production of high titre regulated retroviral vectors from the producer cells of the present invention.

## 25 RECOMBINASE ASSISTED MECHANISM

As used herein, the term "recombinase assisted system" includes but is not limited to a system using the Cre recombinase / loxP recognition sites of bacteriophage P1 or the site-specific FLP recombinase of *S. cerevisiae* which catalyses recombination events between

30 34 bp FLP recognition targets (FRTs).

The site-specific FLP recombinase of *S. cerevisiae* which catalyses recombination events between 34 bp FLP recognition targets (FRTs) has been configured into DNA constructs

-13-

in order to generate high level producer cell lines using recombinase-assisted recombination events (Karreman *et al.* (1996) NAR 24, 1616-1624). A similar system has been developed using the Cre recombinase / loxP recognition sites of bacteriophage P1. This was configured into a retroviral genome such that high titre retroviral producer cell lines were generated (Vanin *et al.* (1997) J Virol 71, 7820-7826). However, the use of the second method (Vanin *et al. ibid*) has centered around the exchange of the central portions of a retroviral cassette using a recombinase-assisted system. Moreover, these methods have used genes encoding selectable markers such as neo<sup>R</sup> and puro<sup>R</sup> (Vanin *et al. ibid*) and luciferase and puro<sup>R</sup> linked by an IRES sequence (Karreman *et al. ibid*). Karreman and Vanin do not demonstrate or *suggest* that: (i) a regulated or inactive 3'U3 sequence of the 3'LTR can be introduced into a producer cell via a recombinase-assisted mechanism or (ii) that therapeutic genes under the control of a regulated LTR may be introduced into a producer cell line via a recombinase assisted step. Vanin *et al. ibid* suggests that his Cre-mediated recombination approach to retroviral producer cell line production may be used in combination with other modifications which should result in improved vector performance. Vanin *et al. ibid* also suggests that his approach provides a means to generate high titre SIN vectors. However, there is no worked example and in fact no enabling disclosure because the skilled person would not have been aware, on the basis of the Vanin *et al.* paper, of the necessary modifications to make the suggested approach work. Vanin *et al.* makes no reference to hypoxic regulated vectors and/or regulated/inactivated lentiviral vectors.

#### LTRs

As already indicated, each retroviral genome comprises genes called *gag*, *pol* and *env* which code for virion proteins and enzymes. In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. They also serve as enhancer-promoter sequences. In other words, the LTRs can control the expression of the viral gene. Encapsidation of the retroviral RNAs occurs by virtue of a *psi* sequence located at the 5' end of the viral genome.

-14-

As used herein, the term “long terminal repeat (LTR) is used in reference to domains of base pairs located at the end of retroviral DNAs.

The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.

For ease of understanding, a simple, generic structures (not to scale) of the RNA and the DNA forms of the MLV retroviral genome is presented in Figure 7 in which the elementary features of the LTRs and the relative positioning of *gag/pol* and *env* are indicated. Please note that (i) *gag/pol* and *env* are normally not spaced apart; and (ii) the overlap normally present between the *pol* and *env* genes and the poly A tail normally present at the 3' end of the RNA transcript are not illustrated in Figure 7.

As shown in Figure 7, the basic molecular organisation of an infectious retroviral RNA genome is (5') R - U5 - *gag/pol*, *env* - U3-R (3'). In a defective retroviral vector genome *gag*, *pol* and *env* may be absent or not functional. The R regions at both ends of the RNA are repeated sequences. U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome respectively.

Upon cellular transduction, reverse transcription of the virion RNA into double stranded DNA takes place in the cytoplasm and involves two jumps of the reverse transcriptase from the 5' terminus to the 3' terminus of the template molecule. The result of these jumps is a duplication of sequences located at the 5' and 3' ends of the virion RNA. These sequences then occur fused in tandem on both ends of the viral DNA, forming the long terminal repeats (LTRs) which comprise R U5 and U3 regions. On completion of the reverse transcription, the viral DNA is translocated into the nucleus where the linear copy of the retroviral genome, called a preintegration complex (PIC), is randomly inserted into chromosomal DNA with the aid of the virion integrase to form a stable provirus. The number of possible sites of integration into the host cellular genome is very large and very widely distributed.

-15-

Preferably the retroviral genome is introduced into packaging cell lines using retroviral transduction.

5 Preferably retroviral vector particles (such as MLV vector particles) are prepared in a transient expression system with a different envelope pseudotype to the packaging cell, and used to transduce a retroviral packaging cell.

Preferably the retroviral transduction step identifies retroviral insertions in integration sites that support high level expression of the resulting regulated retroviral genome.

10

Preferably stable transduced producer cell lines made by this initial retroviral transduction step produce retrovirus at titres of at least  $10^6$  per ml, such as from about  $10^6$  to about  $10^7$  per ml, more preferably at least about  $10^7$  per ml.

15 HIGH TITRE

As used herein, the term "high titre" means an effective amount of a retroviral vector or particle which is capable of transducing a target site such as a cell.

20 As used herein, the term "effective amount" means an amount of a regulated retroviral or lentiviral vector or vector particle which is sufficient to induce expression of an NOI at a target site.

Preferably the titre is from at least  $10^6$  retrovirus particles per ml, such as from about  $10^6$  to about  $10^7$  per ml, more preferably at least about  $10^7$  retrovirus particles per ml.

25

## TRANSCRIPTIONAL CONTROL

30 The control of proviral transcription remains largely with the noncoding sequences of the viral LTR. The site of transcription initiation is at the boundary between U3 and R in the left hand side LTR (as shown in Figure 7) and the site of poly (A) addition (termination) is at the boundary between R and U5 in the right hand side LTR (as shown in Figure 7). The 3'U3 sequence contains most of the transcriptional control elements of the provirus,



-16-

which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.

#### REGULABLE LTRs

5

AN LTR present, for example, in the construct of the invention and as a 3'LTR in the provirus of the producer cell of the invention may be a native LTR or a heterologous regulatable LTR. It may also be a transcriptionally quiescent LTR for use in SIN vector technology.

10

As used herein, the terms "regulatable LTR" and "regulatable 3'LTR" include vectors which contain responsive elements which are present in retroviral 3' LTR sequences, either by design or by their nature. As used herein, vectors comprising a "regulatable 3'LTR" are referred to as "regulated retroviral vectors". Within the regulatable 3'LTR region, the 3'U3 sequence contains most of the transcriptional control elements of the provirus, which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.

15

Responsive elements include but are not limited to elements which comprise, for example, promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins and/or elements which have been modified to render them inactive. As used herein, the term "modified" includes but is not limited to silencing, disabling, mutating, deleting or removing all of the U3 sequence or a part thereof.

20

The term "regulated LTR" also includes an inactive LTR such that the resulting provirus in the target cell can not produce a packagable viral genome (self-inactivating (SIN) vector technology) - see the Examples and Figure 6 for a particular embodiment.

25

30

## ENHANCER

As used herein, the term “enhancer” includes a DNA sequence which binds other protein components of the transcription initiation complex and thus facilitates the initiation of transcription directed by its associated promoter.

In one preferred embodiment of the present invention, the enhancer is an ischaemic like response element (ILRE).

## 10 ILRE

The term “ischaemia like response element” - otherwise written as ILRE - includes an element that is responsive to or is active under conditions of ischaemia or conditions that are like ischaemia or are caused by ischaemia. By way of example, conditions that are like ischaemia or are caused by ischaemia include hypoxia and/or low glucose concentration(s).

The term “hypoxia” means a condition under which a particular organ or tissue receives an inadequate supply of oxygen.

20

Ischaemia can be an insufficient supply of blood to a specific organ or tissue. A consequence of decreased blood supply is an inadequate supply of oxygen to the organ or tissue (hypoxia). Prolonged hypoxia may result in injury to the affected organ or tissue.

25 A preferred ILRE is an hypoxia response element (HRE).

## HRE

In one preferred aspect of the present invention, there is hypoxia or ischaemia regulatable expression of the retroviral vector components. In this regard, hypoxia is a powerful regulator of gene expression in a wide range of different cell types and acts by the induction of the activity of hypoxia-inducible transcription factors such as hypoxia inducible factor-1 (HIF-1; Wang & Semenza 1993 Proc Natl Acad Sci 90:430), which

30

-18-

bind to cognate DNA recognition sites, the hypoxia-responsive elements (HREs) on various gene promoters. Dachs *et al* (1997 Nature Med 5: 515) have used a multimeric form of the HRE from the mouse phosphoglycerate kinase-1 (PGK-1) gene (Firth *et al* 1994 Proc Natl Acad Sci 91:6496-6500) to control expression of both marker and  
5 therapeutic genes by human fibrosarcoma cells in response to hypoxia *in vitro* and within solid tumours *in vivo* (Dachs *et al ibid*).

Hypoxia response enhancer elements (HREEs) have also been found in association with a number of genes including the erythropoietin (EPO) gene (Madan *et al* 1993 Proc Natl  
10 Acad Sci 90: 3928; Semenza and Wang 1992 Mol Cell Biol 1992 12: 5447-5454). Other HREEs have been isolated from regulatory regions of both the muscle glycolytic enzyme pyruvate kinase (PKM) gene (Takenaka *et al* 1989 J Biol Chem 264: 2363-2367), the human muscle-specific  $\beta$ -enolase gene (ENO3; Peshavaria and Day 1991 Biochem J 275: 427-433 ) and the endothelin-1 (ET-1) gene (Inoue *et al* 1989 J Biol Chem 264: 14954-  
15 14959).

Preferably the HRE of the present invention is selected from, for example, the erythropoietin HRE element (HREE1), muscle pyruvate kinase (PKM), HRE element, phosphoglycerate kinase (PGK) HRE, B-enolase (enolase 3; ENO3) HRE element,  
20 endothelin-1 (ET-1)HRE element and metallothionein II (MTII) HRE element.

#### RESPONSIVE ELEMENT

Preferably the ILRE is used in combination with a transcriptional regulatory element ,  
25 such as a promoter, which transcriptional regulatory element is preferably active in one or more selected cell type(s), preferably being only active in one cell type.

As outlined above, this combination aspect of the present invention is called a responsive element.

30

Preferably the responsive element comprises at least the ILRE as herein defined.

-19-

Non-limiting examples of such a responsive element are presented as OBHRE1 and XiaMac. Another non-limiting example includes the ILRE in use in conjunction with an MLV promoter and/or a tissue restricted ischaemic responsive promoter. These responsive elements are disclosed in WO99/15684.

5

Other examples of suitable tissue restricted promoters/enhancers are those which are highly active in tumour cells such as a promoter/enhancer from a *MUC1* gene, a *CEA* gene or a *5T4* antigen gene. The alpha fetoprotein (AFP) promoter is also a tumour-specific promoter. One preferred promoter-enhancer combination is a human  
10 cytomegalovirus (hCMV) major immediate early (MIE) promoter/enhancer combination.

## PROMOTER

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase  
15 binding site.

The promoter may be located in the retroviral 5' LTR to control the expression of a cDNA encoding an NOI.

20 Preferably the NOI is capable of being expressed from the retrovirus genome such as from endogenous retroviral promoters in the long terminal repeat (LTR)

Preferably the NOI is expressed from a heterologous promoter to which the heterologous gene or sequence is operably linked.

25

Alternatively, the promoter may be an internal promoter.

Preferably the NOI is expressed from an internal promoter.

30 Vectors containing internal promoters have also been widely used to express multiple genes. An internal promoter makes it possible to exploit promoter/enhancer combinations other than those found in the viral LTR for driving gene expression. Multiple internal promoters can be included in a retroviral vector and it has proved

-20-

possible to express at least three different cDNAs each from its own promoter (Overell *et al* 1988 Mol Cell Biol 8: 1803-1808). Internal ribosomal entry site (IRES) elements have also been used to allow translation of multiple coding regions from either a single mRNA or from fusion proteins that can then be expressed from an open reading frame.

5

## TISSUE SPECIFIC PROMOTERS

The promoter of the present invention may be constitutively efficient, or may be tissue or temporally restricted in their activity.

10

Preferably the promoter is a constitutive promoter such as CMV.

Preferably the promoters of the present invention are tissue specific.

15 That is, they are capable of driving transcription of a NOI or NOI(s) in one tissue while remaining largely "silent" in other tissue types.

The term "tissue specific" means a promoter which is not restricted in activity to a single tissue type but which nevertheless shows selectivity in that they may be active in one  
20 group of tissues and less active or silent in another group.

The level of expression of an NOI or NOIs under the control of a particular promoter may be modulated by manipulating the promoter region. For example, different domains within a promoter region may possess different gene regulatory activities. The roles of  
25 these different regions are typically assessed using vector constructs having different variants of the promoter with specific regions deleted (that is, deletion analysis). This approach may be used to identify, for example, the smallest region capable of conferring tissue specificity or the smallest region conferring hypoxia sensitivity.

30 A number of tissue specific promoters, described above, may be particularly advantageous in practising the present invention. In most instances, these promoters may be isolated as convenient restriction digestion fragments suitable for cloning in a selected vector. Alternatively, promoter fragments may be isolated using the polymerase chain

-21-

reaction. Cloning of the amplified fragments may be facilitated by incorporating restriction sites at the 5' end of the primers.

5 The NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and enhancer.

Preferably the ischaemic responsive promoter is a tissue restricted ischaemic responsive promoter.

10 Preferably the tissue restricted ischaemic responsive promoter is a macrophage specific promoter restricted by repression.

Preferably the tissue restricted ischaemic responsive promoter is an endothelium specific promoter.

15

Preferably the regulated retroviral vector of the present invention is an ILRE regulated retroviral vector.

20 Preferably the regulated retroviral vector of the present invention is an ILRE regulated lentiviral vector.

Preferably the regulated retroviral vector of the present invention is an autoregulated hypoxia responsive lentiviral vector.

25 Preferably the regulated retroviral vector of the present invention is regulated by glucose concentration.

30 For example, the glucose-regulated proteins (grp's) such as grp78 and grp94 are highly conserved proteins known to be induced by glucose deprivation (Attenello and Lee 1984 Science 226 187-190). The grp 78 gene is expressed at low levels in most normal healthy tissues under the influence of basal level promoter elements but has at least two critical "stress inducible regulatory elements" upstream of the TATA element (Attenello 1984 *ibid*; Gazit *et al* 1995 Cancer Res 55: 1660-1663). Attachment to a truncated 632 base

-22-

pair sequence of the 5' end of the *grp78* promoter confers high inducibility to glucose deprivation on reporter genes *in vitro* (Gazit *et al* 1995 *ibid*). Furthermore, this promoter sequence in retroviral vectors was capable of driving a high level expression of a reporter gene in tumour cells in murine fibrosarcomas, particularly in central relatively ischaemic/fibrotic sites (Gazit *et al* 1995 *ibid*).

Preferably the regulated retroviral vector of the present invention is a self-inactivating (SIN) vector.

By way of example, self-inactivating retroviral vectors have been constructed by deleting the transcriptional enhancers or the enhancers and promoter in the U3 region of the 3' LTR. After a round of vector reverse transcription and integration, these changes are copied into both the 5' and the 3' LTRs producing a transcriptionally inactive provirus (Yu *et al* 1986 Proc Natl Acad Sci 83: 3194-3198; Dougherty and Temin 1987 Proc Natl Acad Sci 84: 1197-1201; Hawley *et al* 1987 Proc Natl Acad Sci 84: 2406-2410; Yee *et al* 1987 Proc Natl Acad Sci 91: 9564-9568). However, any promoter(s) internal to the LTRs in such vectors will still be transcriptionally active. This strategy has been employed to eliminate effects of the enhancers and promoters in the viral LTRs on transcription from internally placed genes. Such effects include increased transcription (Jolly *et al* 1983 Nucleic Acids Res 11: 1855-1872) or suppression of transcription (Emerman and Temin 1984 Cell 39: 449-467). This strategy can also be used to eliminate downstream transcription from the 3' LTR into genomic DNA (Herman and Coffin 1987 Science 236: 845-848). This is of particular concern in human gene therapy where it is of critical importance to prevent the adventitious activation of an endogenous oncogene.

## RETROVIRAL VECTORS

The regulated retroviral vector of the present invention includes but is not limited to: murine leukemia virus (MLV), human immunodeficiency virus (HIV), equine infectious anaemia virus (EIAV), feline immunodeficiency virus (FIV), caprine encephalitis-arthritis virus (CAEV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV),

-23-

Abelson murine leukemia virus (A-MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV).

5 A detailed list of retroviruses may be found in Coffin *et al* ("Retroviruses" 1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763).

Preferred vectors for use in accordance with the present invention are retroviral vectors, such as MLV vectors.

10 Preferably the recombinant retroviral vectors of the present invention are lentiviral vectors, more preferably HIV or EIAV vectors.

#### LENTIVIRAL VECTORS

15 The lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to: the human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype "slow virus" visna/maedi virus (VMV), as well as the related caprine arthritis-  
20 encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).

A distinction between the lentivirus family and other types of retroviruses is that  
25 lentiviruses have the capability to infect both dividing and non-dividing cells (Lewis *et al* 1992 EMBO. J 11: 3053-3058; Lewis and Emerman 1994 J. Virol. 68: 510-516). In contrast, other retroviruses - such as MLV - are unable to infect non-dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue.

30 Preferred vectors for use in accordance with the present invention are recombinant retroviral vectors, in particular recombinant lentiviral vectors, in particular minimal lentiviral vectors which are disclosed in WO 99/32646 and in WO98/17815.



-24-

## VECTOR

As used herein, a "vector" denotes a tool that allows or facilitates the transfer of an entity from one environment to another. In accordance with the present invention, and by way of example, some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell. Optionally, once within the target cell, the vector may then serve to maintain the heterologous DNA within the cell or may act as a unit of DNA replication. Examples of vectors used in recombinant DNA techniques include plasmids, chromosomes, artificial chromosomes or viruses.

## OPERABLY LINKED

The term "operably linked" denotes a relationship between a regulatory region (typically a promoter element, but may include an enhancer element) and the coding region of a gene, whereby the transcription of the coding region is under the control of the regulatory region.

## DERIVABLE

The term "derivable" is used in its normal sense as meaning a nucleotide sequence such as an LTR or a part thereof which need not necessarily be obtained from an vector such as a retroviral vector but instead could be derived therefrom. By way of example, the sequence may be prepared synthetically or by use of recombinant DNA techniques.

## VECTOR PARTICLES

In the present invention, several terms are used interchangeably. Thus, "virion", "virus", "viral particle", "retroviral particle", "retrovirus", and "vector particle" mean virus and virus-like particles that are capable of introducing a nucleic acid into a cell through a viral-like entry mechanism. Such vector particles can, under certain circumstances, mediate the transfer of NOIs into the cells they infect. A retrovirus is capable of reverse

-25-

transcribing its genetic material into DNA and incorporating this genetic material into a target cell's DNA upon transduction. Such cells are designated herein as "target cells".

5 A vector particle includes the following components: a retrovirus nucleic acid, which may contain one or more NOIs, a nucleocapsid encapsidating the nucleic acid, the nucleocapsid comprising nucleocapsid protein of a retrovirus, and a membrane surrounding the nucleocapsid.

#### NUCLEOCAPSID

10

The term "nucleocapsid" refers to at least the group specific viral core proteins (*gag*) and the viral polymerase (*pol*) of a retrovirus genome. These proteins encapsidate the retrovirus-packagable sequences and themselves are further surrounded by a membrane containing an envelope glycoprotein.

15

Preferably a high titre retroviral vector is produced using a codon optimised *gag* and a codon optimised *pol* or a codon optimised *env*.

#### CODON OPTIMISATION

20

As used herein, the terms "codon optimised" and "codon optimisation" refer to an improvement in codon usage. By way of example, alterations to the coding sequences for viral components may improve the sequences for codon usage in the mammalian cells or  
25 other cells which are to act as the producer cells for retroviral vector particle production. This is referred to as "codon optimisation". Many retroviruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art  
30 for mammalian cells, as well as for a variety of other organisms.

Preferably a high titre lentiviral vector is produced using a codon optimised *gag* and a codon optimised *pol* or a codon optimised *env*.

-26-

Preferably a high titre retroviral vector is produced using a modified and/or extended packaging signal.

#### PACKAGING SIGNAL

5

As used herein, the term “packaging signal” or “packaging sequence” refers to sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle. Several retroviral vectors use the minimal packaging signal (also referred to as the psi sequence) needed for encapsidation of the viral genome.

10 By way of example, this minimal packaging signal encompasses bases 212 to 563 of the Mo-MLV genome (Mann et al 1983: Cell 33: 153).

As used herein, the term “extended packaging signal” or “extended packaging sequence” refers to the use of sequences around the psi sequence with further extension into the gag  
15 gene. The inclusion of these additional packaging sequences may increase the efficiency of insertion of vector RNA into viral particles.

Preferably a high titre lentiviral vector is produced using a modified packaging signal.

20 Preferably the lentiviral construct is based on an EIAV vector genome where all the accessory genes are removed except Rev.

#### ACCESSORY GENES

25 As used herein, the term “accessory genes” refer to a variety of virally encoded accessory proteins capable of modulating various aspects of retroviral replication and infectivity. These proteins are discussed in Coffin et al (ibid) (Chapters 6 and 7). Examples of accessory proteins in lentiviral vectors include but are not limited to tat, rev, nef, vpr, vpu, vif, vpx. An example of a lentiviral vector useful in the present invention is one which  
30 has all of the accessory genes removed except rev.

Preferably the production of lentiviral vector particles is increased by about 10 fold in the presence of EIAV Rev.

-27-

## ENV

If the retroviral component includes an *env* nucleotide sequence, then all or part of that sequence can be optionally replaced with all or part of another *env* nucleotide sequence such as, by way of example, the amphotropic Env protein designated 4070A or the influenza haemagglutinin (HA) or the vesicular stomatitis virus G (VSV-G) protein. Replacement of the *env* gene with a heterologous *env* gene is an example of a technique or strategy called pseudotyping. Pseudotyping is not a new phenomenon and examples may be found in WO-A-98/05759, WO-A-98/05754, WO-A-97/17457, WO-A-96/09400, WO-A-91/00047 and Mebatsion *et al* 1997 Cell 90, 841-847.

In one preferred aspect, the retroviral vector of the present invention has been pseudotyped. In this regard, pseudotyping can confer one or more advantages. For example, with the lentiviral vectors, the *env* gene product of the HIV based vectors would restrict these vectors to infecting only cells that express a protein called CD4. But if the *env* gene in these vectors has been substituted with *env* sequences from other RNA viruses, then they may have a broader infectious spectrum (Verma and Somia 1997 Nature 389:239-242). By way of example, workers have pseudotyped an HIV based vector with the glycoprotein from VSV (Verma and Somia 1997 *ibid*).

20

In another alternative, the Env protein may be a modified Env protein such as a mutant or engineered Env protein. Modifications may be made or selected to introduce targeting ability or to reduce toxicity or for another purpose (Valsecia-Wittman *et al* 1996 J Virol 70: 2056-64; Nilson *et al* 1996 Gene Therapy 3: 280-6; Fielding *et al* 1998 Blood 9: 1802 and references cited therein).

25

## TARGET CELL

As used herein the term "target cell" simply refers to a cell which the regulated retroviral vector of the present invention, whether native or targeted, is capable of infecting or transducing.

30

-28-

The lentiviral vector particle according to the invention will be capable of transducing cells which are slowly-dividing, and which non-lentiviruses such as MLV would not be able to efficiently transduce. Slowly-dividing cells divide once in about every three to four days including certain tumour cells. Although tumours contain rapidly dividing cells, some tumour cells especially those in the centre of the tumour, divide infrequently.

Alternatively the target cell may be a growth-arrested cell capable of undergoing cell division such as a cell in a central portion of a tumour mass or a stem cell such as a haematopoietic stem cell or a CD34-positive cell.

As a further alternative, the target cell may be a precursor of a differentiated cell such as a monocyte precursor, a CD33-positive cell, or a myeloid precursor.

As a further alternative, the target cell may be a differentiated cell such as a neuron, astrocyte, glial cell, microglial cell, macrophage, monocyte, epithelial cell, endothelial cell, hepatocyte, spermatocyte, spermatid or spermatozoa.

Target cells may be transduced either *in vitro* after isolation from a human individual or may be transduced directly *in vivo*.

NOI

In accordance with the present invention, it is possible to manipulate the viral genome or the regulated retroviral vector nucleotide sequence, so that viral genes are replaced or supplemented with one or more NOIs which may be heterologous NOIs.

The term "heterologous" refers to a nucleic acid sequence or protein sequence linked to a nucleic acid or protein sequence which it is not naturally linked.

With the present invention, the term NOI (i.e. nucleotide sequence of interest) includes any suitable nucleotide sequence, which need not necessarily be a complete naturally occurring DNA sequence. Thus, the DNA sequence can be, for example, a synthetic DNA sequence, a recombinant DNA sequence (i.e. prepared by use of recombinant DNA techniques), a cDNA sequence or a partial genomic DNA sequence, including

-29-

combinations thereof. The DNA sequence need not be a coding region. If it is a coding region, it need not be an entire coding region. In addition, the DNA sequence can be in a sense orientation or in an anti-sense orientation. Preferably, it is in a sense orientation. Preferably, the DNA is or comprises cDNA.

5

The NOI(s) may be any one or more of selection gene(s), marker gene(s) and therapeutic gene(s). As used herein, the term "selection gene" refers to the use of a NOI which encodes a selectable marker which may have an enzymatic activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed.

10

## SELECTABLE MARKERS

Many different selectable markers have been used successfully in retroviral vectors. These are reviewed in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 444) and include, but are not limited to, the  
15 bacterial neomycin (neo) and hygromycin phosphotransferase genes which confer resistance to G418 and hygromycin respectively; a mutant mouse dihydrofolate reductase gene which confers resistance to methotrexate; the bacterial *gpt* gene which allows cells to grow in medium containing mycophenolic acid, xanthine and aminopterin; the bacterial  
20 *hisD* gene which allows cells to grow in medium without histidine but containing histidinol; the multidrug resistance gene (*mdr*) which confers resistance to a variety of drugs; and the bacterial genes which confer resistance to puromycin or phleomycin. All of these markers are dominant selectable and allow chemical selection of most cells expressing these genes. Other selectable markers are not dominant in that their use must  
25 be in conjunction with a cell line that lacks the relevant enzyme activity. Examples of non-dominant selectable markers include the thymidine kinase (*tk*) gene which is used in conjunction with *tk* cell lines.

Particularly preferred markers are blasticidin and neomycin, optionally operably linked to  
30 a thymidine kinase coding sequence typically under the transcriptional control of a strong viral promoter such the SV40 promoter.

-30-

## NOIs WITH THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS

In accordance with the present invention, suitable NOI sequences include those that are of therapeutic and/or diagnostic application such as, but are not limited to: sequences  
5 encoding cytokines, chemokines, hormones, antibodies, engineered immunoglobulin-like molecules, a single chain antibody, fusion proteins, enzymes, immune co-stimulatory molecules, immunomodulatory molecules, anti-sense RNA, a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen, a tumour suppressor protein and growth factors, membrane proteins, vasoactive proteins and peptides, anti-  
10 viral proteins and ribozymes, and derivatives thereof (such as with an associated reporter group). When included, such coding sequences may be typically operatively linked to a suitable promoter, which may be a promoter driving expression of a ribozyme(s), or a different promoter or promoters, such as in one or more specific cell types.

## 15 NOIs FOR TREATING CANCER

Suitable NOIs for use in the invention in the treatment or prophylaxis of cancer include NOIs encoding proteins which: destroy the target cell (for example a ribosomal toxin), act  
as: tumour suppressors (such as wild-type p53); activators of anti-tumour immune  
20 mechanisms (such as cytokines, co-stimulatory molecules and immunoglobulins); inhibitors of angiogenesis; or which provide enhanced drug sensitivity (such as pro-drug activation enzymes); indirectly stimulate destruction of target cell by natural effector cells (for example, strong antigen to stimulate the immune system or convert a precursor substance to a toxic substance which destroys the target cell (for example a prodrug  
25 activating enzyme).

## PRO-DRUG ACTIVATING ENZYMES

Examples of prodrugs include but are not limited to etoposide phosphate (used with  
30 alkaline phosphatase; 5-fluorocytosine (with cytosine deaminase); Doxorubin-N-p-hydroxyphenoxyacetamide (with Penicillin-V-Amidase); Para-N-bis (2-chloroethyl)aminobenzoyl glutamate (with Carboxypeptidase G2); Cephalosporin nitrogen mustard carbamates (with B-lactamase); SR4233 (with p450 reductase);

-31-

Ganciclovir (with HSV thymidine kinase); mustard pro-drugs with nitroreductase and cyclophosphamide or ifosfamide (with cytochrome p450).

#### NOIs FOR TREATING HEART DISEASE

5

Suitable NOIs for use in the treatment or prevention of ischaemic heart disease include NOIs encoding plasminogen activators. Suitable NOIs for the treatment or prevention of rheumatoid arthritis or cerebral malaria include genes encoding anti-inflammatory proteins, antibodies directed against tumour necrosis factor (TNF) alpha, and anti-  
10 adhesion molecules (such as antibody molecules or receptors specific for adhesion molecules).

#### BYSTANDER EFFECT

15 The expression products encoded by the NOIs may be proteins which are secreted from the cell. Alternatively the NOI expression products are not secreted and are active within the cell. In either event, it is preferred for the NOI expression product to demonstrate a bystander effector or a distant bystander effect; that is the production of the expression product in one cell leading to the killing of additional, related cells, either neighbouring or  
20 distant (e.g. metastatic), which possess a common phenotype. Encoded proteins could also destroy bystander tumour cells (for example with secreted antitumour antibody-ribosomal toxin fusion protein), indirectly stimulated destruction of bystander tumour cells (for example cytokines to stimulate the immune system or procoagulant proteins causing local vascular occlusion) or convert a precursor substance to a toxic substance  
25 which destroys bystander tumour cells (eg an enzyme which activates a prodrug to a diffusible drug). Also, the delivery of NOI(s) encoding antisense transcripts or ribozymes which interfere with expression of cellular genes for tumour persistence (for example against aberrant *myc* transcripts in Burkitts lymphoma or against *bcr-abl* transcripts in chronic myeloid leukemia. The use of combinations of such NOIs is also envisaged.

30



## CYTOKINES

The NOI or NOIs of the present invention may also comprise one or more cytokine-encoding NOIs. Suitable cytokines and growth factors include but are not limited to:

5 ApoE, Apo-SAA, BDNF, Cardiotrophin-1, EGF, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, FGF-acidic, FGF-basic, fibroblast growth factor-10 (Marshall 1998 Nature Biotechnology 16: 129). FLT3 ligand (Kimura *et al* (1997), Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF- $\beta$ 1, insulin, IFN- $\gamma$ , IGF-I, IGF-II, IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18 (IGIF), Inhibin  $\alpha$ , Inhibin  $\beta$ , IP-10, keratinocyte growth factor-2 (KGF-2), KGF,

10 Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein (Marshall 1998 *ibid*), M-CSF, MDC (67 a.a.), MDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-1 $\alpha$ , MIP-1 $\beta$ , MIP-3 $\alpha$ , MIP-3 $\beta$ , MIP-4, myeloid progenitor inhibitor factor-1

15 (MPIF-1), NAP-2, Neurturin, Nerve growth factor,  $\beta$ -NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDF1 $\alpha$ , SDF1 $\beta$ , SCF, SCGF, stem cell factor (SCF), TARC, TGF- $\alpha$ , TGF- $\beta$ , TGF- $\beta$ 2, TGF- $\beta$ 3, tumour necrosis factor (TNF), TNF- $\alpha$ , TNF- $\beta$ , TNIL-1, TPO, VEGF, GCP-2, GRO/MGSA, GRO- $\beta$ , GRO- $\gamma$ , HCC1, 1-309.

20

The NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and/or a promoter enhancer as known as “responsive elements” in the present invention.

## 25 VIRAL DELIVERY SYSTEMS

When the regulated retroviral vector particles are used to transfer NOIs into cells which they transduce, such vector particles also designated “viral delivery systems” or “retroviral delivery systems”. Viral vectors, including retroviral vectors, have been used

30 to transfer NOIs efficiently by exploiting the viral transduction process. NOIs cloned into the retroviral genome can be delivered efficiently to cells susceptible to transduction by a retrovirus. Through other genetic manipulations, the replicative capacity of the retroviral

-33-

genome can be destroyed. The vectors introduce new genetic material into a cell but are unable to replicate.

5 The regulated retroviral vector of the present invention can be delivered by viral or non-viral techniques. Non-viral delivery systems include but are not limited to DNA transfection methods. Here, transfection includes a process using a non-viral vector to deliver a gene to a target mammalian cell.

10 Typical transfection methods include electroporation, DNA biolistics, lipid-mediated transfection, compacted DNA-mediated transfection, liposomes, immunoliposomes, lipofectin, cationic agent-mediated, cationic facial amphiphiles (CFAs) (Nature Biotechnology 1996 14: 556), multivalent cations such as spermine, cationic lipids or polylysine, 1, 2,-bis (oleoyloxy)-3-(trimethylammonio) propane (DOTAP)-cholesterol complexes (Wolff and Trubetskoy 1998 Nature Biotechnology 16: 421) and combinations  
15 thereof.

Viral delivery systems include but are not limited to adenovirus vector, an adeno-associated viral (AAV) vector, a herpes viral vector, a retroviral vector, a lentiviral vector, or a baculoviral vector. These viral delivery systems may be configured as a split-intron  
20 vector. A split intron vector is described in WO 99/15683.

Other examples of vectors include *ex vivo* delivery systems, which include but are not limited to DNA transfection methods such as electroporation, DNA biolistics, lipid-mediated transfection, compacted DNA-mediated transfection.

25

The vector may be a plasmid DNA vector. Alternatively, the vector may be a recombinant viral vector. Suitable recombinant viral vectors include adenovirus vectors, adeno-associated viral (AAV) vectors, Herpes-virus vectors, or retroviral vectors, lentiviral vectors or a combination of adenoviral and lentiviral vectors. In the case of  
30 viral vectors, gene delivery is mediated by viral infection of a target cell.

-34-

If the features of adenoviruses are combined with the genetic stability of retro/lentiviruses then essentially the adenovirus can be used to transduce target cells to become transient retroviral producer cells that could stably infect neighbouring cells.

## 5 PHARMACEUTICAL COMPOSITION

The present invention also provides a pharmaceutical composition for treating an individual by gene therapy, wherein the composition comprises a therapeutically effective amount of a regulated retroviral vector according to the present invention. The  
10 pharmaceutical composition may be for human or animal usage. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.

The composition may optionally comprise a pharmaceutically acceptable carrier, diluent,  
15 excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase  
20 the viral entry into the target site (such as for example a lipid delivery system).

Where appropriate, the pharmaceutical compositions can be administered by any one or more of: minipumps, inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch,  
25 orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the  
30 form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

## DISORDERS

The present invention is believed to have a wide therapeutic applicability - depending on *inter alia* the selection of the one or more NOIs.

5

For example, the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute  
10 infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease,  
15 atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

20

In addition, or in the alternative, the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune deficiency, including infection with  
25 human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration;  
30 inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as

-36-

antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

- 5 In addition, or in the alternative, the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation;
- 10 inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases,
- 15 inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other
- 20 glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididymo-orchitis, infertility, orchidial trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or
- 25 inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fundus disease, inflammatory components of ocular trauma, ocular inflammation caused by
- 30 infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders

-37-

where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other  
5 degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillain-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome,  
10 Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side  
15 effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of  
20 monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.

## INTRODUCTION TO THE EXAMPLES SECTION AND THE FIGURES

25

The present invention will now be described only by way of example in which reference is made to the following Figures:

Figure 1 shows an MLV-based transduction method using a Cre/LoxP system as  
30 described by Vanin *et al* *ibid* (1997);

Figure 2 shows an EIAV-based transduction method using a Cre/Lox system;

-38-

Figure 3 shows an MLV SIN vector construct transduction method with an EIAV/HIV genome insertion using a Cre/Lox system;

5 Figure 4 shows an MLV-based transduction method with HRE 3'LTR using a Cre/Lox P system;

Figure 5 shows an MLV-based transduction method for MLV SIN vector production using a Cre/Lox P system;

10 Figure 6 shows an MLV-based transduction method with integration of a complete second genome construct using a Cre/LoxP system;

Figure 7 shows the basis molecular organisation of an RNA genome and a proviral DNA genome;

15 Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP plasmids;

Figure 9 shows an overall summary of the recombinase method;

20 Figure 10a shows a FACS analysis of EV1 packaging cells prior to transduction with Trap2 vector;

Figure 10b shows FACS analysis of EV1 packaging cell line transduced with Trap2 at an MOI of 0.3. A 5% top slice of the highest expressers was carried out;

25 Figure 11 shows a validation of the method for quantitation of GFP mRNA, relative to  $\beta$ -actin. A titration of the total RNA from EV1 clone A was used. The difference in Ct values between the two assays is shown on the y axis. The magnitude of the gradient must be  $<0.1$  for the method to be valid. The gradient is 0.077, so the method is suitable;

30 Figure 12 shows the quantitation of GFP mRNA relative to control  $\beta$ -actin mRNA. EV2 TD cells are transduced with Trap2 at an MOI of 0.3 and are the calibrator sample with the ratio designated 1.0;

-39-

Figure 13 shows FACS analysis of EV1 clone A:

Figure 13A shows original GFP expression of the clone;

- 5     Figure 13B shows GFP expression 7 days after transfection with Cre recombinase (pBS185). Excision frequency is 64%;

Figure 13C shows recombined clone 4 identified as being negative for GFP:

- 10    Figure 14 shows lacZ expression of transfected cells with and without the addition of the Cre recombinase (pBS185). Figure 14 shows EV1A4 and EV2D4 clones with and without the addition of Cre recombinase (pBS185). The efficiency of the insertion event was estimated to be about 12% by computer image analysis;

- 15    Figure 15 shows the structure of pONY8.1Z MLVHyb;

- Figure 16 shows the alignment of leader and gag regions present in vectors pONY4Z, 8Z and ATG mutated 8Z vector. The latter is referred to as pONY8ZA. The sequences aligned are from the NarI site in the leader to the XbaI site between the EIAV gag sequence and the CMV promoter. Sequences in the leader are shown in italic and a space is present upstream of the position of the gag ATG; and
- 20

Figure 17 shows a schematic representation of the structure of pONY 8.3G +/- vector genome plasmids.

25

## EXAMPLES

### EXAMPLE 1

- 30    Vanin *et al (ibid)* describe a recombinase system whereby an initial retroviral transduction event introduces retroviral LTRs and expressed gene/s flanked by two recombinase target sites (exemplified by loxP) into a cell line. Stable transduced cell lines are selected by resistance to the antibiotic neomycin and screened for high expression of



-40-

the expressed gene(s) (see Figure 1). Such cell lines (Cell Line 1) contain retroviral insertions in integration sites that support high level expression from the retroviral genome.

5 The next step involves the transfection of the relevant recombinase expression construct (exemplified here by Cre recombinase) into the identified high expressing cell line. The expressed gene(s) is/are excised and a single loxP site is retained in the construct (Cell Line 2). In this instance, thymidine kinase gene (tk) is used as a negative selectable marker in combination with the drug, gancyclovir. The final step involves the re-  
10 insertion of a therapeutic or marker gene of choice into the single loxP site via a Cre-assisted mechanism. Cell lines are identified that have been successfully recombined (Cell Line 3) and they will produce retroviruses at the same titre as the parental Cell Line 1.

## 15 **EXAMPLE 2**

Figure 2 and Figure 3 describe the production of EIAV or HIV high titre transduced producer cell lines.

20 Figure 2 shows a minimal EIAV genome construct with the 3' U3 sequences replaced by a strong constitutive promoter, CMV. A reporter gene such as blasticidin resistance gene (*bsr*) is flanked by loxP sites. Virus is made in a transient system and is transduced into an EIAV producer cell line and clones identified that maximally express the blast marker gene. A line is chosen (termed Cell Line 1) and the marker gene is excised by a Cre  
25 recombinase-assisted excision event, generating Cell Line 2.

Construct B comprises two loxP sites which flank an internal expression cassette and also the native EIAV 3' LTR. Therefore, this construct is recombined into the cell line such that the 5' R and U5 sequences are inherited from the packaging cell line, whereas the 3'  
30 LTR sequences are wholly derived from the recombined construct. The 3' LTR from Cell Line 2 is present downstream of the functional EIAV genome expression construct. This CMV-R-U5 module is still transcriptionally active but expression is directed away from the EIAV genome.

-41-

Figure 3 shows a further aspect of the invention. Construct C is based on an MLV SIN vector, with a deletion in the 3' U3 sequences. The cassette includes an internal CMV promoter linked to EIAV R and U5 sequences. This is followed by a blasticidin resistance gene (*bsr*) flanked by two loxP sites. Virus is made in a transient transfection system and the genome is transduced into a packaging line. Blast-resistant clones are identified and the highest expressing line is chosen for further analysis. This line is transfected with Cre recombinase and the blast gene is excised. The last step involves the insertion of construct B into the single loxP site. Once again, a complete EIAV 3' LTR is introduced into the producer cell line. This leads to a CMV-driven EIAV genome expression cassette with the EIAV 3' LTR still located at the 3' end of the genome. Transcriptionally quiescent MLV SIN LTRs flanks these EIAV sequences.

### EXAMPLE 3

Figure 4 shows an additional aspect of the invention. Construct D is an MLV-based vector with a CMV promoter in the 3' LTR in place of the U3 sequences. Virus is made in a transient system and is transduced into a packaging cell line as described previously. The neo and TK genes are excised by the action of Cre recombinase and construct E is recombined into the single loxP target sequence. The modified MLV 3' LTR including the HRE or similarly regulated system is transferred into the packaging cell line by the recombinase mechanism. Therefore, the 5' R and U5 sequences are inherited from the producer cell line whereas the therapeutic and marker gene/s and regulated 3' LTR is inherited from construct E. The final producer cell line is constitutively driven by the 5' CMV promoter and will produce high titre retroviral vectors which are regulated in the transduced target cells. This approach avoids the derivation of low titre transfected producer cell lines or the use of hypoxic conditions or chemical mimics for production from traditionally derived transduced producer lines.

### EXAMPLE 4

Figure 5 shows yet another aspect of the invention. Construct D is an MLV-based vector with a CMV promoter in the 3' LTR as previously described. The same process is carried

-42-

out as shown in Figure 4 until the final recombination is performed. Construct F contains a deletion in U3 sequences in the 3' LTR and an internal expression cassette comprising a promoter and gene sequences. The final cell line containing the Cre-mediated recombination will be CMV-driven and will constitutively produce high titre MLV SIN  
5 vectors. Previously, SIN vectors have not been amenable to production by stable cell line producer technology. Instead they have been prepared using transfection-based transient expression systems.

## EXAMPLE 5

10

Figure 6 shows an MLV-based transduction method with integration of complete second genome construct by Cre/LoxP system. In this approach, construct 1 is called TRAP1) is an MLV vector construct containing an internal CMV promoter operably linked to a marker gene (a truncated form of the human low affinity nerve growth factor receptor,  
15 called LNGFR). The enhancer elements in the 3' U3 sequence have been excised and replaced by a 34bp loxP site. Virus stocks are prepared in a transient system and the TRAP1 genome is stably transduced into packaging cell lines.

The modified 3'U3 sequences, including the lox P sequence, is copied from the 3'LTR  
20 position to the 5'LTR, such that there is little 5' promoter activity. Cell lines are screened for high levels of expression of LNGFR protein by fluorescent activated cell sorter (FACS) analysis and clonal lines are derived by standard techniques. A Cre recombinase expression plasmid is transfected into the derived cell line to excise all sequences between the two loxP sites. Next, cells are negatively selected by FACS for absence of  
25 LNGFR expression and clonal lines are derived by standard techniques. Construct 2 in this example comprises a complete HIV or EIAV or also MLV retroviral genome, which is flanked by two minimal 34bp loxP recombinase sites. A strong constitutive promoter such as CMV directs transcription of the genome. On transfection of plasmid 2 and Cre expression plasmid, the complete lentivirus vector or MLV vector genome is inserted in  
30 the producer cell line. These sequences are flanked to the 5' by a small portion of MLV U3 sequence and a loxP site and to the 3' by the second loxP site, enhancerless-U3 sequences, R and U5 derived from the MLV construct 1.

**Derivation of Plasmid TRAP1 (Figure 6 - Construct 1)**

Oligonucleotides VSAT129 and VSAT130 were synthesised which correspond to the minimal 34bp loxP sites and contain a 5' overhang for NheI and a 3' overhang for XbaI. The sequences 5' to 3' are as follows: VSAT129 (CTAGCATAACTTCGTATA ATGTATGCTATACGAAGTTATT) (SEQ ID No 49) and VSAT130 (CTAGAATAACTTCGTATAGC ATACATTATACGAAGTTATG) (SEQ ID No 50). The two oligonucleotides were treated with T4 polynucleotide kinase and were heated to 95°C for 5 minutes, before gradual cooling to room temperature. The annealed and kinased oligos were ligated to a 2,830 bp NheI/XbaI fragment from LTR plasmid (SEQ ID No 59). Fragments were ligated and correct clones of LTRloxP were identified by sequence analysis. Plasmid LTRloxP was then digested with NheI and ScaI and a 2,185bp fragment was prepared for following cloning steps.

Plasmids TRAP1 and TRAP1G were derived from LTRloxP and the MLV genome CGCLNGFR (encodes GFP and LNGFR from an internal CMV promoter – see SEQ ID No 57). However, the GFP gene was excised by EcoRI/BsmI digestion and the 6,796bp fragment was filled in by T4 DNA polymerase and re-ligated, in order to generate plasmid CXCLNGFR. Plasmid TRAP1 was generated by ligation of a 2,185bp NheI/ScaI fragment from LTRloxP (see SEQ ID No 58) to a 4,426bp NheI/ScaI fragment from CXCLNGFR. Plasmid TRAP1G was generated by ligation of a 2,185bp NheI/ScaI fragment from LTRloxP to a 5,179bp NheI/ScaI fragment from CGCLNGFR.

**Derivation of Plasmid pONY8z-lox (Figure 6 - Construct 2)**

In this example, the retroviral genome inserted into the loxP site in Figure 6 was based on the EIAV vector genome, pONY8z (for preparation see pONY8.0Z construction below). pONY8z was cut with SnaBI and NruI, and the 4358bp fragment purified and self-ligated to form pONY8z-shuttle. This plasmid has unique 5' sites (DraIII and BglII) and unique 3' sites (PvuII and BspLUII). Oligonucleotides encoding the 34bp loxP sites were inserted with suitable base pair overhangs at the unique 5' DraIII site and then the unique 3' BspLUII, to generate plasmid pONY-8z-shuttleloxP.

-44-

Plasmid pONY8z-loxP was made as follows. Plasmid pONY-8z-shuttleloxP was digested with BsrG I and NspV, and the 3670bp fragment was purified as the vector fragment. The insert for ligation to this fragment was derived from pONY8z by partial digestion with BsrGI (two sites) followed by digestion with NspV. A 7,328bp fragment was purified and ligated to the 3670bp fragment described above.

The Cre recombinase plasmid as used in this system is pBS185 (Gibco).

## 10 EXAMPLE 6

We constructed an MLV self-inactivating (SIN) vector called pTrap2 (see SEQ ID No 56) by replacing the 3' U3 NheI-XbaI fragment with a 34-bp loxP sequence. The vector transcribes the marker gene GFP from an internal CMV promoter. Trap2 vector was used to transduce EIAV packaging cell lines EV1 and EV2. The EV cell lines are based on human TE671 cells and express EIAV gag/pol proteins and VSV-G envelope, regulated by a temperature-sensitive switch. High expressing clones of transduced EV1 and EV2 cells were identified by FACS analysis for GFP. Individual clones expressing high levels of GFP were then selected. The GFP expression cassette was excised following transient transfection with a Cre recombinase expression plasmid. The derived cell line, EV-loxP, contains a single loxP site and minimal sequences derived from the MLV construct pTrap2. An EIAV genome was engineered to contain loxP sites flanking the entire vector genome.

This genome construct and Cre recombinase were co-transfected into EV-loxP. Stable cell lines expressing lacZ were selected by FACS and cell lines were cloned by limiting dilution. Therefore, we have introduced an entire EIAV genome expression cassette into a single loxP site. This site was previously identified by MLV transduction as highly permissive for transgene expression. A 5' CMV promoter transcribes the lentiviral genome in the producer cell line but the expression site was originally identified by MLV transduction. This method is adaptable to the generation of transduced producer cell lines for other lentiviral vector systems.

## Materials and Methods

**Vector construction:** Plasmid pTrap2 was made as follows: A plasmid containing a single MLV LTR plasmid (LTRplasmid – SEQ ID No 59) was digested with *NheI* and *XbaI* and a 34 bp minimal loxP site was introduced with relevant sticky ends. This insertion step removes the MLV U3 enhancer elements which lie within the excised *NheI*-*XbaI* fragment. The LTR-loxP plasmid was linearised by digestion with *NheI* and was ligated to a 6.8kb *NheI* fragment from the MLV construct CZCG (See SEQ ID No 55). This construct expresses lacZ from the 5' U3 promoter and GFP from an internal CMV promoter. The resulting pTrap2 construct is shown in Figure 8.

The EIAV genome construct pONY8.0Z and pONY8.1Z were prepared as follows:

### pONY8.0Z construction

pONY8.0Z was derived from pONY4.0Z (see WO 99/32646) by introducing mutations which 1) prevented expression of TAT by an 83nt deletion in the exon 2 of tat ) prevented S2 ORF expression by a 51nt deletion 3) prevented REV expression by deletion of a single base within exon 1 of rev and 4) prevented expression of the N-terminal portion of gag by insertion of T in ATG start codons, thereby changing the sequence to ATTG from ATG. With respect to the wild type EIAV sequence Acc. No. U01866 these correspond to deletion of nt 5234-5316 inclusive, nt 5346-5396 inclusive and nt 5538. The insertion of T residues was after nt 526 and 543.

### pONY8.1Z construction

pONY8.1Z was obtained directly from pONY8.0Z by digestion with *SalI* and partial digestion with *SapI*. Following restriction the overhanging termini of the DNA were made blunt ended by treatment with T4 DNA polymerase. The resulting DNA was then religated. This manipulation results in a deletion of sequence between the LacZ reporter gene and just upstream of the 3'PPT. The 3' border of the deletion is nt 7895 with respect to wild type EIAV, Acc. No. U01866. Thus pONY8.1Z does not contain sequences corresponding to the EIAV RREs.

Plasmid pONY8z was linearised by *Bgl*II, and a single loxP site was cloned into *Bgl*II, immediately upstream of the 5' CMV promoter, to produce pONY8z-loxP. Plasmids pONY3.2iresHYG and pHCMV-VSVG were used in the derivation of cell lines EV1 and  
5 EV2. The plasmid pONY3.2iresHYG was constructed as follows:

#### **pONY3.2IREShyg**

pONY3.IREShyg was derived from pONY3.2. pONY3.2 is a derivative of pONY3.1 in  
10 which expression of TAT and S2 are ablated by an 83nt deletion in the exon 2 of tat a 51nt deletion in S2 ORF. With respect to the wild type EIAV sequence Acc. No. U01866 these correspond to deletion of nt 5234-5316 inclusive and nt 5346-5396 inclusive. This fragment was introduced into the expression vector pHORSE IRES hyg which was made as follows. pHORSE (see WO 99/32646) was cut with *Sna*BI and *Not*I which excises a  
15 fragment running from the CMV promoter through EIAV gag/pol and introduced into pIRES1hyg (Clontech) digested with the same enzymes. This plasmid was then cut with *Sse*8387I and *Bst*EII and then ligated with the *Sse*8387I to *Bst*EII fragment from pONY3.2. The sequence of the plasmid is set out in SEQ ID No 51.

#### **20 Virus Production**

Transient MLV vector preparations pseudotyped with RD114 cat endogenous envelope were made as described previously (Soneoka et al., 1995). EIAV vector was harvested from confluent monolayers following 3 days induction of VSV-G expression at 32°C.  
25 MLV vector preparations were titred in triplicate on HT1080 fibrosarcoma cells. EIAV vector preparations were titred by GFP and lacZ on D17 dog osteosarcoma cells.

#### **Flow cytometry of b-galactosidase and GFP activity:**

30  $1.5 \times 10^5$  cells from a 12-well plate were analysed for lacZ expression using the FluoReporter lacZ Flow Cytometry kit (Molecular Probes). GFP expression was also directly assessed using the FACSCalibur flow cytometer (Beckton Dickinson).

#### **Transfection methods**

Calcium phosphate transfections were carried out using the Profection kit (Promega) according to manufacturer's instructions.

## 5     **Results**

Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP, plasmids used in this study.

## 10    **Introduction of Trap2 genome into EV1 and EV2**

An overall summary of the process described here is given in Figure 9. Trap2 MLV vector was made in a transient system with the amphotropic 4070A envelope. It gave a GFP titre of  $1.7 \times 10^6$  T.U. per ml. Trap2 vector however also gave a lacZ titre of  $9.4 \times 10^5$  T.U. per ml. This shows that replacement of the *NheI-XbaI* fragment from the MLV U3 region with loxP does not completely inactivate the MLV U3 promoter. Therefore Trap2, as constructed, is a partial SIN vector.

EV1 and EV2 cells were transduced with Trap2 vector at a multiplicity of infection (MOI) of 0.3. This was done to insert single copies of the MLV genome into the packaging lines.

## **Derivation of high expressers of GFP marker gene**

25    Transduced EV1 and EV2 cells were analysed by FACS (see Figure 10) and the top 5% of GFP expressing cells were sorted and expanded. Clonal lines were derived by limiting dilution and four clones of EV1 and EV2 were chosen by visual inspection.

30    A quantitative TaqMan RT-PCR reaction was established in order to identify which of the four clones of EV1 and EV2 were the highest expressors of GFP mRNA. Total RNA was analysed by RT-PCR for GFP and  $\beta$ -actin. Quantitation was calculated by direct comparison of the Ct values (Cycle threshold). This was possible as it was proved that the two individual RT-PCR reactions are of similar efficiency (see Figure 11). By identifying an



-48-

optimal chromosomal location for GFP transgene expression. we can ensure that the inserted loxP site will be highly permissive for expression of an inserted lentiviral genome construct.

5 Figure 5 shows the n-fold difference in GFP :  $\beta$ -actin ratio for clones EV1 A to D and EV2 A to D. All ratios are defined relative to a calibrator sample, defined as a ratio of 1.0. The calibrator sample used was RNA from EV2 cells transduced with Trap2 at an MOI of 0.3.

10 This identified the best expressing lines as:

- EV1 clone A - GFP :  $\beta$ -actin ratio is 22.8
- EV2 clone D - GFP :  $\beta$ -actin ratio is 18.6

These two lines were carried forward for further study.

15

#### **Excision of internal expression cassette by Cre recombinase**

The process of retroviral integration copies the loxP-containing modified 3' U3 to the 5' position. Therefore, one can excise the majority of the MLV Trap2 integration by the  
20 action of Cre recombinase. This will leave a single modified LTR, suitable for lentiviral genome integration.

EV1 clone A and EV2 clone D were transfected by the Cre expression plasmid pBS185 (Life Technologies). After one week, the cells were analysed for GFP by FACS (see  
25 Figure 13) to determine the excision frequency. This was measured at 20-70% in all lines.

Recombined clones were identified by limit dilute cloning cells and checking by microscope and FACS for loss of GFP expression.

30

#### **Insertion of EIAV genome into loxP site**

-49-

Plasmid pONY8x-loxP and pBS185 were co-transfected using Fugene into EV1 clone A (excised) and EV2 clone D (excised). A control transfection of pONY8z-loxP in the absence of pBS185 was also carried out.

5 Figure 14 shows lacZ expression of transfected cells with and without the addition of Cre recombinase (pBS185). The efficiency of the insertion event was estimated to be ~12% by computer image analysis.

10 We analysed cells for lacZ expression by FACS using the FluoReporter lacZ Flow Cytometry kit. The top 5% of lacZ positive cells were sorted by FACS and clones were derived by limiting dilution. In total, 12 clones of EV1/A/pONY8z-loxP were derived and 13 clones of EV2/D/pONY8z-loxP.

## 15 EXAMPLE 7

### Construction of EIAV vectors with LTR driven open reading frames

20 The EIAV vector configurations described previously utilise a single promoter - transgene cassette located internally in the vector. For example in pONY8Z the promoter-transgene cassette is CMV-LacZ. However for some uses it would be advantageous to have the option of expressing a gene from the 5'LTR promoter as well. For example a marker gene such as green fluorescent protein (GFP), a resistance marker such as neomycin phosphotransferase (neo) or another protein or a biologically active  
25 entity such as a ribozyme. Previous experiments have shown that the EIAV LTR is weakly active in human cells in the absence of EIAV tat. However the transcriptional activity of the LTR can be increased by replacement of the EIAV U3 region with the MLV U3 region or the CMV promoter. This is achieved by introducing these alterations in the 3'LTRs of the vector plasmids. As a result of the replicative strategy of  
30 retroviruses the modified 3'LTR becomes positioned at the 5'end of the integrated vector and can thus drive expression of a gene placed downstream of the gag region. To ensure optimal levels of expression there should preferably be no ATG start codons prior to the start codon of the gene to be expressed. In pONY8Z the ATG start codon of gag and the next ATG downstream were mutated to ATTG in order to ablate expression of the

-50-

aminoterminal portion of gag present in the vectors, however there are 7 other ATG codons further downstream of these, within gag, from which translation might be initiated.

- 5 Described below are the replacement of the U3 region of EIAV with MLV or CMV promoters and the mutation of ATG codons in the gag region

**Replacement of the EIAV U3 region with MLV U3 or CMV promoters**

- 10 The MLV U3 region was introduced into pONY8Z vector by replacement of the 3'LTR with a synthetic MLV/EIAV LTR made by the overlapping PCR technique, using the following primers and templates.

The EIAV PPT/U3 sequence was amplified from pONY8.1Z using primers:

- 15 KM001: CAAAGCATGCCTGCAGGAATTCG (SEQ ID No 1)

and

KM003:

- 20 GCCAAACCTACAGGTGGGGTCTTTCATTATAAAACCCCTCATAAAAACCCAC  
AG (SEQ ID No 2)

to give the following product:

- 25 CAAAGCATGCCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGAATTG  
GAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTAG  
AAAAACAAGGGGGGAAGTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGA  
CCCCACCTGTAGGTTTGGC (SEQ ID No 3)

- 30 The MLV U3 region was amplified from pHIT111 (Soneoka et al., (1995) Nucleic Acids Res. **23**, 628-633) using KM004:

-51-

CTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTG  
GC (SEQ ID No 4)

and

5 KM005:

GAAGGGACTCAGACCGCAGAATCTGAGTGCCCCCGAGTGAGGGGTTGTGGG  
CTCT (SEQ ID No 5) to give the following product:

10 CTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCT  
TAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATC  
AAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTT  
CCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCT  
GTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGC  
15 CCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCC  
TGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCG  
AGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCC  
CTTC (SEQ ID No 6)

20 The MLV U3/EIAV R/U5 was amplified from pONY8.1Z using primers

KM002: GAGCGCAGCGAGTCAGTGAGCGAG (SEQ ID No 7) and

KM006:

25

AGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCC  
CTTC (SEQ ID No 8)

to give the following product:

30

AGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTG  
GGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTT  
CGAGATCCTACAGAGCTCATGCCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTG  
TTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTG  
35 CTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCAGTCGGGAAAC

-52-

CTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGG  
CGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTC (SEQ ID No 9)

The PCR products described above were purified and then used as templates in new PCR  
5 reactions to link them together to obtain a 992bp product. The final product contains two  
SapI sites which flank the hybrid LTR. These allow introduction of the PCR product into  
the corresponding SapI sites present in the pONY8Z or pONY8.1Z vector plasmid,  
thereby creating pONY8Z MLVHyb and pONY8.1 MLVHyb. The sequence of the  
hybrid LTR in these plasmids was confirmed by sequencing. The titres obtained from the  
10 vectos in transient transfection assays are shown in Table 1. The titres were very similar  
to the titres from the parental construct pONY8Z and pONY8.1Z indicating that  
replacement of the EIAV U3 region with that of MLV had little or no detrimental effect  
on the infectious cycle of the vectors.

15 **Table 1. Titres obtained from MLV hybrid LTR vector plasmids**

vector plasmid	#titre (l.f.u./ml)
pONY8Z	$3 \times 10^5$
pONY8Z MLVHyb	$1 \times 10^5$
pONY8.1Z	$6 \times 10^4$
pONY8.1Z MLVHyb	$2 \times 10^4$

# Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml).  
Transfections were carried out in 293T cells using the vector plasmid shown and pRV67  
20 (VSV-G expression plasmid), and pONY3.1 (EIAV gag/pol expression plasmid).

The structure of pONY8.1Z MLVHyb is shown in Figure 15 and the sequence of this  
plasmid is shown as SEQ ID No 10.

25 The EIAV promoter was also replaced by the human cytomegalovirus (CMV) promoter  
using a similar strategy. The primers and templates were the same except that KM003  
was replaced by KM008:

-53-

GGCCATCGTGCCTCCCCACTCCTGCAGTTATAAAACCCCTCATAAAAACCCCA  
CAG (SEQ ID No 11)

KM004 was replaced by KM009:

5

CTGTGGGGTTTTTATGAGGGGTTTTATAAACTGCAGGAGTGGGGAGGCACGA  
TGGCC (SEQ ID No 12)

KM005 was replaced by KM010:

10

GAAGGGACTCAGACCGCAGAATCTGAGTGCCCGGTTCCTAAACGAGCTCTG  
CTTATATAGACC (SEQ ID No 13) and

KM006 was replaced by KM011:

15

GGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGGCACTCAGATTCTGCG  
GTCTGAGTCCCTTC (SEQ ID No 14)

The template for the PCR reaction with primers KM009 and KM010 was pONY2.1LacZ.

20 This plasmid contains a single CMV promoter. The combined PCR product of 1319 bp was digested with SapI and introduced into the pONY8Z or pONY8.1Z backbone as described above for pONY8Z MLVHyb.

#### **Mutation of remaining ATG codons in the gag of pONY8Z to ATTG**

25

The alignment of the sequence of the leader and gag region present in vectors pONY4Z (an earlier generation EIAV vector), pONY8Z and a derivative of pONY8Z in which the 7 remaining ATG codons are mutated to ATTG is shown in Figure 16. These mutations were created by PCR mutagenesis as follows. The template for the PCR reactions was

30 pONY8Z and the primers were:

F1: CGAGATCCTACAGTTGGCGCCCGAACAG (SEQ ID No 15);

-54-

R1:GAGTTACAATCTTCCAGCAATGGAATGACAATCCCTCAGCTGCCAGTCCTT  
TTCTTTTACAAAGTTGGTATCAATGAAATAAGTCTACTAGACTTAGC (SEQ ID  
No 16);

5 F2:TTCCATTGCTGGAAGATTGTAACCTCAGACGCTGTCAGGACAAGAAAGAGA  
GGCCTTTGAAAGAACATTGGTGGGCAATTTCTGCTGTAAAGATTG (SEQ ID No  
17);

R2:CAATATTTGCTCTTAGGAGCTGGAATGATGCCTTTCCAATCTACTACAAT  
10 TATTAATCTGGAGGCCCAATCTTTACAGCAGAAATTGCCCACCAATG (SEQ ID  
No 18);

R3:CCACTAGTTCTAGAGATATTCTTCAGAGGGCTCAGACTGCTTTTTATTAGC  
AGTCTTCTTTTCAATATTTGCTCTTAGGAGC (SEQ ID No 19)

15

In the first stage of construction two PCR reactions were set up with primer pairs F1/R1  
and F2/R2, respectively. These were purified and then used in a second 'overlapping'  
reaction in which primers F1 and R3 were added after 10 cycles. This procedure results  
in a 552bp PCR product (SEQ ID No 20):

20

CGAGATCCTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAA  
CCTGGCTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGT  
TCCTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTACTGGTAACTGTAAT  
25 TGGGCGCTAAGTCTAGTAGACTTATTTCAATTGATACCAACTTTGTAAAAGAAAAGGACTGGCA  
GCTGAGGGATTGTCAATTCATTGCTGGAAGATTGTAACCTCAGACGCTGTCAGGACAAGAAAGA  
GAGGCCTTTGAAAGAACATTGGTGGGCAATTTCTGCTGTAAAGATTGGGCCTCCAGATTAATA  
ATTGTAGTAGATTGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATTGAAAAGAAGACTG  
CTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGG

30 This was digested with NarI and XbaI and ligated into pONY8Z. pONY8Z MLVHyb and  
pONY8Z CMVHyb. which had been prepared for ligation by digestion with the same  
enzymes. These plasmids were designated pONY8ZA or pONY8ZA MLVHyb and  
pONY8ZA CMVHyb. The sequence for pONY8ZA CMVHyb is provided in SEQ ID No  
52. These plasmids have a unique XbaI site into which can be inserted genes such as

-55-

GFP or neomycin phosphotransferase or other biologically active entity. This use of the site is demonstrated for GFP. The GFP ORF was obtained from pEGFP-1 (Clontech) by digestion with SmaI and XbaI, and then the ends filled in by treatment with T4 DNA polymerase. This fragment was then ligated into pONY8ZA or pONY8ZA MLVHyb and pONY8ZA CMVHyb prepared for ligation by digestion with XbaI and subsequent filling in with T4DNA polymerase. The resulting vector plasmids were called pONY8GZA or pONY8GZA MLVHyb and pONY8GZA CMVHyb. Other genes can be inserted at this site by manipulations apparent to those skilled in the art.

#### 10 **Creation of EIAV vector genomes containing loxP sites in their LTR's**

The time taken to construct producer cell lines for EIAV vectors would be greatly reduced if it was possible to 1) locate and 2) reutilise a site in the host cell chromosome which was particularly favourable for high levels of transcription of the vector genome. In outline, this can be achieved by engineering loxP sites in the 3'LTR of EIAV vectors, transduction of the packaging cell line with vectors which carry loxP and hybrid LTRs, selection of cells which express the highest levels of vector genome and exchange of the test EIAV vector genome for the vector genome of choice using the cre/loxP recombination system.

20

The proposed scheme was evaluated using a derivative of pONY8GZA CMVHyb in which a loxP site was introduced into the PstI site between the EIAV sequences (required for efficient integration) and the CMV promoter in the 3'LTR. After transduction the integrated vector will thus have a loxP-CMV cassette located in the 5'LTR and 3'LTR's and therefore full length transcripts of the vector genome will be driven by the CMV promoter, which is a powerful promoter. pONY8GZA CMVHyb contains many PstI sites hence it was modified to allow insertion of the loxP site by digestion with XbaI and NheI and religation to create the subclone, pONY CMVHyb. This plasmid has a unique PstI site in the hybrid LTR. The loxP site was inserted into this site using two complimentary oligonucleotides which when annealed formed PstI-compatible termini. These were termed loxP POS

30



-56-

PSTI [GATAAC TTCGTATAATGTATGCTATACGAAGTTATCTGCA] (SEQ ID No 21)] and

loxP NEG PstI [GATAACTTCGTATAGCATACATTATACGAAGTTATCTGCA]  
5 (SEQ ID No 22)

The sequence and orientation of the loxP site was confirmed by DNA sequencing and the plasmid called pONY CMVHyb loxP. The central part of the vector genome was then reintroduced into this subclone by transfer of the NotI-BstEII fragment from pONY8GZA  
10 CMVHyb into pONY CMVHyb cut the same way. The resulting vector was termed pONY8GZA CMVHyb loxP.

Two routes for construction of a producer cell line are available using pONY8GZA CMVHyb loxP. The plasmid can be introduced into a packaging cell line by transfection  
15 or vector particles can be made using the 293T and these used to transduce the packaging cell line. Since the vector is derived from EIAV, rather than MLV, it is able to transduce non-dividing cells or slowly dividing cells. In this situation it has been hypothesised that integrations occur at chromosomal sites that are constitutively open; that is, are likely to be sites at which high levels of transcription will be maintained for extended periods.  
20 This may be important for the long term usefulness of the producer cell line and thus represents an advantage of strategy using transduction.

Producer cell lines were made by transfection or transduction of a TE671-derived cell line (EV11E) which has stably integrated copies of VSV-G and the synthetic EIAV gag/pol  
25 under the control of CMV promoters. Prior to transfection with pONY8GZA CMVHyb loxP it was linearised by digestion with AhdI. Seven days following transfection or transduction cells expressing the highest levels of GFP were selected by FACS and then cloned by limiting dilution. A number of clones were analysed for levels of full length vector RNA using Taqman technology based assays in order to confirm the hypothesis  
30 that the highest level of GFP expression correlates with the highest levels of vector RNA.

The cell line which expressed the highest level of RNA was then tested for production of transducing vector particles 5 days after changing the temperature of incubation from 37C

-57-

to 32°C. At 32°C, VSV-G expression is induced however maximal levels of VSV-G are only obtained after 5 days at the permissive temperature (see WO 00/52188). The cell line producing the highest titre, EV11E CMV loxP was selected for further work.

5 In order to exchange the vector genome with for another EIAV vector genome with a more suitable configuration for use in the clinical setting EV11EloxP cells were transfected with cre recombinase expression plasmid, pBS185 (Gibco), which results in excision of the EIAV vector between the loxP sites. This leaves a loxP-CMV promoter R-U5 sequence in the cells. Cells from which the EIAV vector genome had been excised  
 10 were selected on the basis of low levels of GFP expression by FACS and assumed to be clonal on the basis of the clonality of EV11E CMV loxP. These were termed EV11EloxP $\Delta$  and used as targets for new EIAV vector genomes.

#### 15 **Construction of EIAV vector genomes with downstream REV expression cassettes and flanking loxP sites**

The production of vector particles from minimal EIAV vectors (those which do not express EIAV REV or any other EIAV proteins) is increased by about 10-fold in the presence of EIAV REV in our 293T transient production system when the codon-  
 20 optimised EIAV gag/pol expression construct is used to drive production of vector particles as set out in Table 2. This may be improved nuclear to cytoplasmic transport of the vector genome in the presence of REV protein. Packaging/producer cell lines for EIAV vectors may be engineered to express Rev protein. One approach would be to engineer cells to express EIAV REV from an independently transfected expression  
 25 cassette. However, the cassette and the vector genome may be subject to differential regulation, for example by methylation or chromosome remodelling. Such an effect may limit the useful life of such cell lines.

Table 2. Effect of REV expression on titres obtained from REV-expressing [REV+] and  
 30 non-expressing [REV-] vectors

vector plasmid	gag/pol	expression	#titre
----------------	---------	------------	--------

-58-

	plasmids	(l.f.u./ml)
pONY4Z [REV+]	pONY3.1	$2.0 \pm 0.4 \times 10^6$
pONY4Z [REV+]	pE SYN GP	$0.9 \pm 0.2 \times 10^6$
pONY8Z [REV-]	pONY3.1	$1.5 \pm 0.2 \times 10^6$
pONY8Z [REV-]	pE SYN GP	$1.9 \pm 0.6 \times 10^5$

\* Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml). Transfections were carried out in 293T cells using the vector plasmid and gag/pol expression plasmid shown and pRV67 (VSV-G expression plasmid) (See WO 00/52188).

5

REV+ and REV- reflect the rev expression status of the vectors. REV+ reflects vectors which express the REV protein. REV- reflects expression vectors which do not express the REV protein.

#### 10 **pESYNGP**

The gag/pol expression plasmid shown in Figure called called pESYNGP was constructed as follows: The codon-optimised EIAV gag/pol ORF was synthesised by Operon Technologies Inc., Alameda and supplied in a proprietary plasmid backbone, GeneOp.

15 The complete fragment synthesised included sequences flanking the EIAV gag/pol ORF: tctagaGAATTCGCCACCATG- **EIAV gag/pol**- UGAACCCGGGgcggccgc (SEQ ID No 44). The ATG start and UGA stop codons are shown in bold. XbaI and NotI sites are in lower case. These were used to transfer the gag/pol ORF from GeneOp into pCIneo (Promega) using the NheI and NotI sites in the latter.

20

#### **pESDSYNGP**

25 An alternative expression plasmid for expression of the synthetic EIAV gag/pol could also be used. It is called pESDSYNGP and its construction is described as follows:

ESDSYNGP was made from pESYNGP by exchange of the 306bp EcoRI-NheI fragment, from just upstream of the start codon for gag/pol to approximately 300 base pairs inside

-59-

the gag/pol ORF with a 308bp EcoRI-NheI fragment derived by digestion of a PCR made using pESYNGP as template and using the following primers: SD FOR [GGCTAGAGAATTCCAGGTAAGATGGGCGATCCCCTCACCTGG] (SEQ ID No 60) and SD REV [TTGGGTACTCCTCGCTAGGTTC] (SEQ ID No 61). This manipulation replaces the Kozak consensus sequence upstream of the ATG in pESYNGP with the splice donor found in EIAV. The sequence between the EcoRI site and the ATG of gag/pol is thus CAGGTAAG (SEQ ID No 62).

The sequences for pESYNGP (SEQ ID No 53) and pESDSYNGP (SEQ ID No 54) are provided.

Packaging/Producer cells may be engineered by physically linking the genome and EIAV REV expression cassettes. In this way stable transfectants may be generated which contain the vector genome and the EIAV REV expression cassette in the same chromatin environment. This manipulation may ensure that the relative levels of transcription of the vector genome and the REV expression cassette are maintained leading to an increased duration of vector production from the producer cells.

Previous work has suggested that optimisation of the level of REV may be required with respect to the level of vector genome (see WO 98/17815). We have examined the levels of vector production in a transient system in which several different promoters are used to drive REV expression in order to determine which vector genome-rev expression cassette is optimal for use in constructing producer cell lines. The highest titres were obtained with FB29 and PGK promoters driving REV expression.

The following describes the construction of EIAV vector genomes plasmids in which there is a downstream expression cassette for synthetic EIAV REV protein. The promoters tested were FB29, PGK, TK, CMV, SV40 and RSV. In addition the loxP sites were engineered into the vector plasmid backbone in such a way that the genome and introduced promoter-REV expression plasmid was flanked. In this way, the complete vector-REV cassette can be recombined into loxP sites in the target cell.

-60-

The complete construction of the FB29 and PGK containing plasmids is described here. The REV expression construct was inserted in the both orientations with respect to the EIAV vector genome. Plasmids in which the FB29 or PGK promoters drive REV expression are being utilised for construction of stable producer cell lines.

5

### Construction of plasmids

In the first step of construction an SfiI site was inserted downstream of the EIAV vector sequence. This site is the insertion site for the promoter REV cassettes. The construction was made as follows. pONY8Z was digested with EheI and NruI, the ends were blunted by treatment with T4 DNA polymerase and religated. The resulting plasmid, pONY8Z delta, is thus deleted with respect to the leader, gag, reporter cassette and most of the Rev/RRE regions.

15 pONY8Z delta was mutated to contain loxP sites inserted in the DraII site immediately to the 5' of the CMV promoter and in the BspLU11I site to the 3' of the vector genome. The loxP sites were inserted using complementary nucleotide pairs which when annealed had overhanging termini suitable for cloning into these sites and were inserted in two steps of cloning. The oligonucleotides for insertion into the DraIII site were

20

VSAT 158: [GTGATAACTTCGTATAATGTATGCTATACGAAGTTATCACTAC]  
(SEQ ID No 23)

and

25

VSAT 155 [GTGATAACTTCGTATAGCATACATTATACGAAGTTATCACGTA]  
(SEQ ID No 24)

For the BspLU11I they were:

30

VSAT 156 [CATGTATAACTTCGTATAATGTATGCTATACGAAGTTATA] (SEQ ID  
No 25) and

-61-

VSAT 157 [CATGTATAACTTCGTATAGCATACATTATACGAAGTTATA] (SEQ ID No 26)

Plasmids were selected in which the orientation of the loxP at both sites were the same and the same as the EIAV vector genome. The modified plasmid was called pONY8Z delta 2xloxP.

pONY8Z delta 2xloxP has a unique PvuII site downstream of the deleted EIAV vector genome into which annealed complementary oligonucleotides encoding SfiI sites were inserted. The oligonucleotides were:

SFI SRFPOS [AGTAGGCCCGCCTCGGCCGCCCCGGGCATCA] (SEQ ID No 27) and

SFI SRF NEG [TGATGCCCCGGGCGGCCGAGGCGGCCTACT] (SEQ ID No 28)

Clones which had the SfiI – SrfII sites in either orientation were selected for further work. These were called pONY8Z delta SfiI FOR and REV.

#### **Amplification and cloning of FB29 and PGK promoters**

The FB29 promoter was amplified from pRDF (Cosset FL, et al. *J Virol* 1995 Dec;69(12):7430-6) using primers:

FB29 POS [TAGCCGAGATCTCAAATTGCTTAGCCTGATAGCC] (SEQ ID No 29) and

FB29 NEG [TGCGTAGCTAGCCTCCCGGTGGTGGGTCGGTG] (SEQ ID No 30) which introduce

5'BglII and 3'NheI sites.

The PGK promoter was amplified from pPE327 using primers

PGK POS [AGCAGTAGATCTGGGGTTGGGGTTGCGCCTTT] (SEQ ID No 31) and

PGK NEG [CGTCATGCTAGCCTGGGGAGAGAGGTCGGTG] (SEQ ID No 32)

-62-

The PGK promoter sequence obtained from this plasmid was the same as the sequence of GenBank Acc. No. M11958 except that it has a single mutation: nucleotide 347 of M11958 is changed from G to A. The TK promoter and intron was amplified from pRL-TK (Promega) with:

- 5 TK POS [TACGGAAGATCTAAATGAGTCTTCGGACCT] (SEQ ID No 33) and  
TK NEG [CTCAACGCTAGCGTACTCTAGCCTTAAGAGCTG] (SEQ ID No 34)

The RSV promoter was amplified from pREP7 (Invitrogen) with

- 10 RSV POS [TACCAGAGATCTTCTAGAGTCGACCAATTCTCATG] (SEQ ID No 35)  
and

RSV NEG [CATCGAGCTAGCAGCTTGGAGGTGCACACCAATG] (SEQ ID No 36)  
and

15

The SV40 promoter was amplified from pCIneo (Promega) with:

SV40 POS [GATGGTAGATCTGCGCAGCACCATGGCCTGAA] (SEQ ID No 37) and

- 20 SV40 NEG [CTCGAAGCTAGCAGCTTTTTGCAAAAGCCTAGGC] (SEQ ID No 38)

- The PCR fragments were digested with BglII and NheI and ligated into pSL1180 (Pharmacia) which had been prepared by digestion using the same enzymes. Following transformation into E.coli DNA was prepared and the sequence of the promoters checked  
25 by DNA sequencing. Clones in which the correct promoter sequence was present were used for further work and were called pSL1180-FB29, pSL1180-PGK, pSL1180-RSV, pSL1180-SV40, pSL1180-TK.

- In the next step the promoter fragments were positioned to drive transcription of synthetic  
30 EIAV REV in pE syn REV. pE syn REV is a pCIneo based plasmid (Promega) which was made by introducing the EcoRI to SalI fragment from the synthetic EIAV REV plasmid into the polylinker region of the plasmid using the same sites. The synthetic

-63-

EIAV REV plasmid made by Operon contains a codon-optimised EIAV REV open reading frame flanked by EcoRI and SalI. The sequence of this fragment is shown as SEQ ID No 39.

- 5 Prior to replacement of the CMV promoter in pE syn REV it was modified as follows. The SV40 neo region was deleted by digestion with KpnI and BamHI, the ends blunted by treatment with T4 DNA polymerase and then religated. The plasmid was termed pE syn REV delta. Next SfiI sites were introduced into both the BglII site which is just 5' of the CMV promoter and DraIII site downstream of the polyA signal.

10

The oligonucleotides used for this were as follows:

SFI FOR BglII POS [GATCGGCCGCCTCGGCCA] (SEQ ID No 40) and

- 15 SFI FOR BglII NEG [ GATCTGGCCGAGGCGGCC] (SEQ ID No 41)and

SFI FOR DRA POS [ GGCCGCCTCGGCCGTA] (SEQ ID No 42) and

SFI FOR DRA NEG [GGCCGAGGCGGCCTAC] (SEQ ID No 43)

20

- Clones in which the SfiI was located 5' of the BglII site were selected were used for further work. The plasmid obtained after this two step manipulation was termed pE syn REV delta 2xSfiI. It has the following features: 5'SfiI sites – BglII site - CMV promoter and intron – NheI site – E syn REV - polyA site – 3'SfiI site. Hence the CMV promoter
- 25 can be excised by digestion with BglII and NheI and replaced with the promoter of choice obtained from the pSL1180 series of clones by digestion with the same enzymes. Construction details are included from this point for only the constructs which contained FB29 and PGK promoters, however a similar scheme was used for the other promoters, except that a partial SfiI digestion was required for transfer of the SV40-REV cassette.

30

Promoter fragment were obtained from pSL1180 – FB29 and pSL1180 – PGK by digestion with BglII and NheI and ligated into pE syn REV delta 2xSfiI digested with the



-64-

same enzymes. The resulting plasmids were called FB29 E SYN REV and PGK E SYN REV.

In the next stage the internal regions of pONY8G, pONY8.1G SIN MIN and pONY4G were obtained by digestion with SgfI (which has unique site in the CMV promoter driving the EIAV vector genome) and MunI (which cuts in the 3'LTR) and ligated in to pONY8Z delta SfiI FOR and REV prepared for ligation by digestion with the same enzymes. The resulting plasmids were called pONY8G SfiI FOR and REV, pONY8.1G SIN MIN SfiI FOR and REV and pONY4G SfiI FOR and REV.

In the final stage the promoter-REV cassettes were moved from FB29 E SYN REV and PGK E SYN REV into pONY8G SfiI FOR and REV, pONY8.1G SIN MIN SfiI FOR and REV and pONY4G SfiI FOR. This manipulation was achieved as follows. FB29 E syn REV, PGK E syn REV, and the vector plasmids described immediately above were digested with SfiI and ligations set up with appropriate fragments. The promoter-REV cassettes were orientated in the same or opposite orientations with respect to the EIAV vector genome in the 'FOR' and 'REV' plasmids. The resulting plasmids were called pONY8.3G FB29 + or - and pONY8.3G PGK+ and -. A schematic structure of the pONY 8.3 +/- plasmids is shown in Figure 17.

The performance of these constructs was tested in relation to pONY8G in 293T transient production assays and the results are shown in Table 3.

**The sequence of the *EcoRI* to *SalI* fragment representing the codon-optimised EIAV REV open reading frame obtained from the plasmid synthesised by Operon (SEQ ID No 39)**

*EcoRI* and *SalI* sites are in bold. The ATG start and UGA termination codons are underlined

**GAATTCGCCACCAATGGCTGAGAGCAAGGAGGCCAGGGATCAAGAGATG**

-65-

ACCTCAAGGAA  
 GAGAGCAAAGAGGAGAAGCGCCGCAACGACTGGTGGGAAGATCGACCCA  
 AAGGCCCCCTG  
 GAGGGGGACCAAGTGGTGCCGCGTGCTGAGACAGTCCCTGCCCCGAGGAGAAGATTCCT  
 5 AGC  
 CAGACCTGCATCGCCAGAAGACACCTCGGCCCCGGTCCCACCCAGCACACACCCTCC  
 AGA  
 AGGGATAGGTGGATTAGGGGCCAGATTTTGCAAGCCGAGGTCCTCCAAGAAAGGCTG  
 GAA  
 10 TGGAGAATTAGGGGCGTGCAACAAGCCGCTAAAGAGCTGGGAGAGGTGAATCGCGG  
 CATC  
 TGGAGGGAGCTCTACTTCCGCGAGGACCAGAGGGGGCGATTTCTCCGCATGGGGAGGC  
 TAC  
 CAGAGGGCACAAGAAAGGCTGTGGGGCGAGCAGAGCAGCCCCCGCGTCTTGAGGCC  
 15 CGGA  
 GACTCCAAAAGACGCCGCAAACACCTGTGAAGTCGAC

Table 3

- 20 Titres obtained from a representative experiment in which the vector-REV constructs were tested by transient 293T production assay. The vector constructs were cotransfected with pE synGP, the synthetic EIAV gag/pol expression plasmid, and pRV67, VSV-G expression plasmid. Titres were measured in D17 cells.

Plasmid	Titre (g.f.u./ml)
pONY8G SfiI FOR	$1.6 \times 10^4$
#pONY8G SfiI FOR PLUS pE syn REV	$5.2 \times 10^5$
pONY8.3G FB29 +	$8.8 \times 10^5$
pONY8.3G FB29 -	$7.8 \times 10^5$
pONY8.3G PGK +	$1.2 \times 10^6$
pONY8.3G PGK -	$1.2 \times 10^6$
pONY8G	$9.4 \times 10^5$

-66-

Titre was assessed on D17 cells and is expressed as green fluorescent protein cell units/ml (g.f.u./ml). Transfections were carried out with pE syn GP KOZAK and pRV67 as described previously.

- 5 \* pONY8G SfiI FOR is identical to the pONY8.3 derivatives except that there is no promoter-REV expression cassette is inserted in the SfiI site

# pE syn REV plasmid was also included in this transfection

- 10 pONY8G is a standard EIAV vector genome used for comparative purposes

pONY8.3G FB29 – is shown as SEQ ID No 45

pONY8.3G FB29 + is shown as SEQ ID No 46

- 15 pONY8.3GPGK – is shown as SEQ ID No 47

pONY8.3G PGK + is shown as SEQ ID No 48.

## SUMMARY

20

Thus, in summation, the present invention provides high titer regulated retroviral vectors. These regulated retroviral vectors include lentivectors, HRE-regulated vectors and functional SIN vectors which can be produced at high titres from derived producer cell lines.

25

The present invention also provides a method other than retroviral transduction for the transfer of a regulated retroviral vector into a derived producer cell line. This method comprises a recombinase assisted method which allows for the production of high titer regulated retroviral vectors.

30

In one broad aspect, the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the

-67-

vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system. Thus, the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

5

In another broad aspect, the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system and a retroviral vector  
10 production system which incorporates a REV protein production system. Thus, the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

All publications mentioned in the above specification are herein incorporated by  
15 reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various  
20 modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

-68-

CLAIMS

1. A method of modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase  
5 recognition sequences within or upstream of its 3' LTR, the method comprising:  
introducing into the cell a construct comprising a 5' recombinase recognition sequence,  
an LTR and a 3' recombinase recognition sequence in that order, in the presence of a  
recombinase which is capable of acting on the recombinase recognition site(s) such that  
the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the  
10 construct is introduced into the provirus.
2. A method according to claim 1 wherein the construct further comprises at least  
one nucleotide sequence of interest (NOI) between the 5' recombinase recognition  
sequence and the LTR, which NOI is operably linked to a transcriptional regulatory  
15 sequence.
3. A method according to claim 1 or claim 2 wherein the construct further comprises  
a 5'LTR and/or a packaging signal.
- 20 4. A method according to any one of claims 1 to 3 wherein the LTR is a  
heterologous regulatable LTR.
5. A method according to claim 4 wherein the regulatable LTR comprises an  
ischaemic like response element (ILRE).  
25
6. A method according to any one of claims 1 to 3 wherein the LTR is inactive.
7. A method according to any one of the preceding claims wherein the provirus  
comprises an NOI encoding a selectable marker, which NOI is flanked by recombinase  
30 recognition sites
8. A method according to any one of the precedings claims wherein the provirus  
comprises an internal 5' LTR upstream of the recombinase site or the 5' recombinase site

-69-

where there is more than one site.

9. A method according to any one of the preceding claims wherein the U3 region of the 5' LTR is inactive.

5

10. A method according to any one of the preceding claims wherein the U3 region of the 5' LTR and/or the U3 region of the second internal 5'LTR comprises a heterologous promoter.

10

11. A method according to any one of the preceding claims wherein the provirus comprises two recombinase recognition sites and as a preliminary step, the recombinase is expressed in a host cell such that the nucleotide sequence present between the two sites is excised.

15

12. A method according to any one of the preceding claims wherein the producer cell is a high titre producer cell.

13. A method according to any one of the preceding claims wherein the provirus is a lentivirus.

20

14. A method according to claim 13 wherein the lentivirus is HIV or EIAV.

15. A method according to any one of claims 2-14 wherein the provirus further comprises a second NOI.

25

16. A producer cell obtainable by the method of any one of claims 1 to 15.

17. An infectious retroviral particle obtainable from the producer cell of claim 16.

30

18. A derived producer cell comprising integrated into its genome a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR;

-70-

wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the producer cell.

19. A producer cell according to claim 18 wherein the first 5' LTR comprising 5'R and 5' U5 sequences is derivable from a first vector; the second NOI operably linked to a second regulatable 3' LTR is derivable from a second vector; and the third 3'LTR is derivable from the first vector.

20. A producer cell according to claim 18 or claim 19 wherein the first vector comprises a retroviral vector wherein the retroviral vector comprises a first NOI flanked by recombinase recognition sequences.

21. A producer cell according to claim 19 or claim 20 wherein the retroviral vector further comprises an internal LTR located upstream of the first NOI and downstream of a packaging signal wherein the internal LTR comprises a heterologous U3 sequence linked to heterologous R and U5 sequences.

22. A producer cell according to any one of claims 18 to 21 wherein the third 3'LTR is transcriptionally quiescent.

23. A producer cell according to claim 22 wherein the third 3' LTR comprises a deletion in the U3 sequence.

24. A producer cell according to any one of claims 18 to 23 wherein the first NOI is a selectable marker.

25. A producer cell according to claim 19 wherein the second vector comprises a second NOI operably linked to a second regulatable 3'LTR comprising at least one recombinase recognition sequence.

26. A producer cell according to 25 wherein the second regulatable 3'LTR comprises a deletion in the U3 sequences in the 3'LTR.

-71-

27. A producer cell according to claim 25 or claim 26 wherein the second NOI comprises a coding sequence operably linked to a promoter.
28. A producer cell according to claim 27 wherein the second NOI comprises a  
5 discistronic construct.
29. A producer cell according to claim 28 wherein the discistronic construct comprises a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.
- 10 30. A method for producing a high titre regulatable retroviral vector, the method comprising the steps of:
- (i) providing a derived producer cell comprising integrated into its genome a first vector;
- 15 (ii) introducing a second vector into the derived producer cell using a recombinase assisted method;
- wherein the derived producer cell comprises a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR;  
20 and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the derived producer cell.
31. A method according to claim 30 wherein the third 3' LTR is transcriptionally active but expression is directed away from the second regulatable 3'LTR.
- 25 32. A method for introducing a second regulatable 3'LTR into a derived producer cell wherein the method comprises a recombinase assisted method.
33. A method according to claim 32 wherein the recombinase assisted method is a  
30 Cre/lox recombinase method.



-72-

34. A process for preparing a regulated retroviral vector as defined in claim 17 comprising performing the method according to any one of claims 30 to 33 and preparing a quantity of the regulated retroviral vector.
- 5 35. A regulated retroviral vector produced by the process according to claim 34.
36. A regulated retroviral vector according to claim 35 wherein the retroviral vector is capable of transducing a target site.
- 10 37. A regulated retroviral vector according to claim 36 wherein the retroviral vector is produced in sufficient amounts to effectively transduce a target site.
38. A regulated retroviral vector according to claim 36 or claim 37 wherein the target site is a cell.
- 15 39. A cell transduced with a regulated retroviral vector according to claim 38.
40. Use of a regulated retroviral vector according to any one of claims 35 to 38 in the manufacture of a pharmaceutical composition to deliver an NOI to a target site.
- 20 41. Use of a regulated retroviral vector according to any one of claims 35 to 38 in the manufacture of a medicament for diagnostic and/or therapeutic and/or medical applications.
- 25 42. Use of a recombinase assisted mechanism to introduce a regulated 3'LTR into a derived producer cell line to produce a high titre regulated retroviral vector.
43. A derived stable producer cell capable of expressing regulated retroviral vectors according to claims 35 to 38.
- 30 44. A derived stable producer cell according to claim 43 wherein the regulated retroviral vector is a high titre regulated retroviral vector.

-73-

49. A nucleic acid molecule according to any one of claims 46 to 48 wherein the LTR is a heterologous regulatable LTR.

50. A nucleic acid molecule according to any one of claims 46 to 48 wherein the LTR  
5 is transcriptionally quiescent.

51. A method and/or a producer cell substantially as described herein and with reference to the accompanying Figures.

10

15

20

25

30

35

40


45

50

1 / 16

**FIG. 1**


MLV-based transduction using Cre/loxP system as previously described



2 / 16

**FIG. 2**


EIAV-based transduction Cre/loxP system



3 / 16


**FIG. 3**

MLV SIN vector approach, with EIAV components in blue



## FIG. 4


MLV-based transduction with HRE 3' LTR using Cre/loxP system



5 / 16

## FIG. 5


MLV-based transduction for SIN vector production using Cre/loxP system



6 / 16

**FIG. 6**


MLV SIN-vector based transduction system. This general approach can be used with EIAV, HIV or MLV genomes





7 / 16

FIG. 7



8 / 16

FIG. 8







FIG. 9



9 / 16

**FIG. 10a**

FACS analysis of EV1 packaging cells prior to transduction with Trap2 vector

**FIG. 10b**


FACS analysis of EV1 packaging cell line transduced with Trap2 at an MOI of 0.3. A 5% top-slice of the highest expressers was carried out

10 / 16

## FIG. 11

Validation of the  $\Delta\Delta C_t$  method for quantitation of GFP mRNA, relative to  $\beta$ -actin.

A titration of total RNA from EV1 clone A was used. The difference in  $C_t$  values between the two assays is shown on the y-axis. The magnitude of the gradient must be  $<0.1$  for the method to be valid. The gradient is 0.077, so the method is suitable.



## FIG. 12

Quantitation of GFP mRNA relative to control  $\beta$ -actin mRNA. EV2 TD cells are transduced with Trap2 at an MOI of 0.3 and are the calibrator sample with the ratio designated 1.0.

Comparison of GFP expression levels in recombinase cell lines





FIG. 13




12 / 16



EV1 A4 cre/pONY8Z



EV2 D4 cre/pONY8Z



EV1 A4 pONY8Z



EV2 D4 pONY8Z

FIG. 14

13 / 16




FIG. 15

## FIG. 16

Alignment of leader and gag regions present in vectors pONY4Z, 8Z and ATG mutated 8Z vector. The later is referred to as pONY8ZA. The sequence aligned are from the NarI site in the leader to the XbaI site between the EIAV gag sequence and the CMV promoter. Sequences in the leader are shown in *italic* and a space is present upstream of the position of the gag ATG.

4Z	1	<i>cgcccgaacagggacctgagaggggcgcagaccctacctgttgaacctgg</i>
8Z	1	<i>cgcccgaacagggacctgagaggggcgcagaccctacctgttgaacctgg</i>
mutated 8Z	1	<i>cgcccgaacagggacctgagaggggcgcagaccctacctgttgaacctgg</i>
4Z	51	<i>ctgacgtaggatccccgggacagcagaggagaacttacagaagtcttct</i>
8Z	51	<i>ctgacgtaggatccccgggacagcagaggagaacttacagaagtcttct</i>
mutated 8Z	51	<i>ctgacgtaggatccccgggacagcagaggagaacttacagaagtcttct</i>
4Z	101	<i>ggaggtgttcctggccagaacacaggaggacaggtaag.at-gggagaccc</i>
8Z	101	<i>ggaggtgttcctggccagaacacaggaggacaggtaag.attgggagaccc</i>
mutated 8Z	101	<i>ggaggtgttcctggccagaacacaggaggacaggtaag.attgggagaccc</i>
4Z	150	<i>tttgacat-ggagcaaggcgctcaagaagttagagaaggtgacggtacaa</i>
8Z	151	<i>tttgacattggagcaaggcgctcaagaagttagagaaggtgacggtacaa</i>
mutated 8Z	151	<i>tttgacattggagcaaggcgctcaagaagttagagaaggtgacggtacaa</i>
4Z	199	<i>gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt</i>
8Z	201	<i>gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt</i>
mutated 8Z	201	<i>gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt</i>
4Z	249	<i>agacttatttcattgataccaactttgtaaaagaaaaggactggcagctg</i>
8Z	251	<i>agacttatttcattgataccaactttgtaaaagaaaaggactggcagctg</i>
mutated 8Z	251	<i>agacttatttcattgataccaactttgtaaaagaaaaggactggcagctg</i>




15 / 16

4Z	298	agggat-gtcattccattgctggaagat-gtaactcagacgctgcagga
8Z	300	agggat-gtcattccattgctggaagat-gtaactcagacgctgcagga
mutated 8Z	301	agggattgtcattccattgctggaagattgtaactcagacgctgcagga
4Z	346	caagaaagagaggcctttgaaagaacat-ggtgggcaatttctgctgtaa
8Z	348	caagaaagagaggcctttgaaagaacat-ggtgggcaatttctgctgtaa
mutated 8Z	351	caagaaagagaggcctttgaaagaacattggtgggcaatttctgctgtaa
4Z	395	agat-gggcctccagattaataat-gtagtagat-ggaaaggcatcattc
8Z	397	agat-gggcctccagattaataat-gtagtagat-ggaaaggcatcattc
mutated 8Z	401	agattgggcctccagattaataattgtagtagattggaaaggcatcattc
4Z	442	cagctcctaagagcgaaatat-gaaaagaagactgctaataaaaagcagt
8Z	444	cagctcctaagagcgaaatat-gaaaagaagactgctaataaaaagcagt
mutated 8Z	451	cagctcctaagagcgaaatattgaaaagaagactgctaataaaaagcagt
4Z	491	ctgagccctctgaagaatatct
8Z	493	ctgagccctctgaagaatatct
mutated 8Z	501	ctgagccctctgaagaatatct

FIG. 16 CONT'D

FIG. 17

Schematic representation of the structure of pONY 8.3G +/- vector genome plasmids



## SEQUENCE LISTING PART OF THE DESCRIPTION

## pONY8.1Z MLVHyb (SEQ ID NO 10)

5 AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTTCTGTGCGCGACTAAATTCATGTGCGCGC  
ATAGTGGTGTTTATCGCCGATAGAGATGGCGATATTGGAAAAATTGATATTTGAAAATATGGCATATTGAAAATGTCCG  
CGATGTGAGTTTCTGTGTAACGTATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGC  
TTATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTGCGCAAAATATCGCAGTTTCGA  
TATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGGCGACATCAAGCTGGCACATGGCCAATGCATATCGATC  
10 TATACATTGAATCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATT  
GCATACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATT  
GACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG  
TAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCC  
AATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCAT  
15 ATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGG  
ACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGG  
CGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTTTTGGCACCAAA  
ATCAACGGGACTTTCCAAAATGTCGTAACAACCTGCGATCGCCCGCCCCGTTGACGCAAAATGGGCGGTAGGCGTGTACGG  
TGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTGTCTGGGCT  
20 GAAAAGGCCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGTTGGCGC  
CCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGGCTGATCGTAGGATCCCCGGGACAGCAGAGGA  
GAACTTACAGAAGTCTTCTGGAGGTGTTCTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATT  
GGAGCAAGGCGCTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTGTTAATGTAAATTGGG  
CGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAAAGAAAAGGACTGGCAGCTGAGGGATGTCATTCCATT  
25 GCTGGAAGATGTAACCTCAGACGCTGTCAGGACAAGAAAAGAGAGGCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGT  
AAAGATGGGCCTCCAGATTAATAATGTAGTAGATGGAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAGAA  
GACTGCTAATAAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATCCCCGGGCTGCAGGAGTGGG  
GAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATA  
TTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
30 GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGTCCGC  
GTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATG  
TTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAG  
TACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTG  
35 GCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATTTGACGTCAATGGGAGT  
TTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTT  
TGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTCAGCTGCTCGAGGATCTGCGGATCCGG  
GGAATTCCCCAGTCTCAGGATCCACCATGGGGGATCCCGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTAC  
40 CCAACTTAATCGCCTTGACGACATCCCCCTTTCCGAGCTGGCGTAATAGCGAAGAGGCCCGACCGATCGCCCTTCC  
CAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAGCTGGCTG  
GAGTGCGATCTTCTGAGGCCGATACTGTCGTCGTCCTCCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCCATCTACA  
CCAACGTAACCTATCCATTACGGTCAATCCGCCGTTTGTTCACGAGAGAATCCGACGGGTTGTTACTCGCTCACATTT  
AATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGT  
45 GCAACGGGCGCTGGGTGCGTTACGGCCAGGACAGTCGTTTGCCGCTGTAATTTGACCTGAGCGCATTTTTACGCGCCGG  
AGAAAACCGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGATGAG  
CGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCATGTTGCCACTCGCTTTAATG  
ATGATTTACGCCGCGCTGACTGGAGGCTGAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAAACAGTTTC  
TTTATGGCAGGGTGAAACGCAGGTGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTGTTAT

GCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGG  
TGGTTGAACTGCACACCGCCGACGGCAGCGTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGA  
AAATGGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTGAGGCGTTAACCGTCACGAGCATCATCTCTGCATGGT  
CAGGTCATGGATGAGCAGACGATGGTGACAGGATATCCTGCTGATGAAGCAGAACAACCTTAACGCCGTGCGCTGTTCCG  
5 ATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAAC  
CCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGCGCATGAGCGAACGCGTAACGCGAAT  
GGTGCAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTTCGCTGGGGAATGAATCAGGCCACGGCGCTAATCACGA  
CGCGCTGTATCGCTGGATCAAACTGTGCGATCCTTCCCGCCCGGTGCAGTATGAAGGCGCGGAGCCGACACCACGGCC  
ACCGATATTATTTGCCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAA  
10 AATGGCTTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCCACGCGATGGGTAAACAGTCTTGCGCG  
TTTCGCTAAATACTGGCAGGCGTTTCGTGAGTATCCCCGTTTACAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGC  
TGATTAAATATGATGAAAACGGCAACCCGTTGGTGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTT  
CTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGATCCAGCGCTGACGGAAGCAAAAACACCAGCAGCAGTTTTTC  
CAGTTCGGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACT  
15 GGATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCTCTGGATGTCGCTCCACAAGGTAACAGTTGA  
TTGAACTGCCTGAACACCGCAGCCGGAGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAACCGAACGCGA  
CCGCATGGTCAGAAGCCGGGACATCAGCGCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCG  
CCGCGTCCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATT  
TAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAACCTGCTGACGCCGCTGCGCGATCAGTTC  
20 ACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGATTGACCCTAACGCTGGGTGCAACGCTGG  
AAGGCGGCGGGCCATTACCAGGCCGAAGCAGCGTTGTTGACGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATT  
ACGACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGGAAAACCTACCGGATTGATGGTAGTGGTC  
AAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATTGGCTGAACTGCCAGCTGGC  
GCAGGTAGCAGAGCGGGTAACTGGCTCGGATTAGGGCCGCAAGAAAACCTATCCCGACCGCCTTACTGCCGCTGTTTTT  
25 GACCGCTGGGATCTGCCATTGTCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGC  
GCGAATTGAATTATGGCCACACCAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGAT  
GGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACATGGCTGAATATCGACGGTTTCCATATGGGGATTGG  
TGGCGACGACTCCTGGAGCCCGTCAGTATCGCGGAATTCCAGCTGAGCGCCGGTCTGCTACCATTACCAGTTGGTCTGG  
TGTCAAAAATAATAAACCAGGCGAGGGGGGATCCGCAGATCCGGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAG  
30 TCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGAA  
TTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTAGAAAAACAAGGGGGGAAGTGTGGG  
GTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGAAGG  
CATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCA  
AACAGGATATCTGTGGTAAGCAGTTCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGC  
35 AGGATATCTGTGGTAAGCAGTTCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGC  
AGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAA  
TCAGTTCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCAACCCCTCACTCGGGGGG  
CACTCAGATTCTGCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGGCCCTTTGTAATAAATAAATCTCTACTCAGTCC  
CTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAA  
40 ATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAG  
CTAACTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCG  
GCCAACGCGCGGGGAGAGGCGGTTTGGCTATTGGGCGCTTTCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTGCGTT  
CGGTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAG  
AACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGGTGGCGTTTTTCCATAGGCTCCGC  
45 CCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAAACCCGACAGGACTATAAAGATACCAGGCG  
TTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCG  
GGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGT  
GCACGAACCCCCGTTACGCCGACCGCTGCGCTTATCCGGTAACATCGTCTTGAGTCCAACCCGGTAAGACACGAC  
TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT

GGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG  
 AGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTGTTTGAAGCAGCAGATTACGCGC  
 AGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACACGTTAAG  
 5 GGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAA  
 AGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCG  
 TTCATCCATAGTTGCGCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCA  
 ATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCCAGCCAGCCGGAAGGGCCGAGCGCAGA  
 AGTGGTCCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA  
 TAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCG  
 10 GTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGTTAGCTCCTTCGGTCTCTCCGATCGTT  
 GTCAGAAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGT  
 AAGATGCTTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATCGGGCGACCGAGTTGCTCTTGCC  
 CGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACCTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCG  
 AAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTT  
 15 TTACTTTACCAAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAGGGGCGACACGGA  
 AATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT  
 TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGCACATTTCCCGAAAAGTGCCACCTAAATTGTAAGCGTT  
 AATATTTTGTAAAAATTCGCGTTAAATTTTTGTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCC  
 TTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTGTTTCCAGTTTGGAAACAAGAGTCCACTATTAAGAACGTG  
 20 GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAGTTTTT  
 TGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAGCCAA  
 CCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCGGC

### pONY8.3G FB29 – (SEQ ID No 45)

25

AGATCTTGAATAATAAAATGTGTGTTGTCCGAAATACGCGTTTTGAGATTTCTGTGCGC  
 GACTAAATTCATGTGCGCGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGAA  
 AAATTGATATTTGAAAATATGGCATATTGAAAATGTCGCCGATGTGAGTTTCTGTGTAAC  
 TGATATCGCCATTTTTCCAAAAGTGATTTTTGGGCATACGCGATATCTGGCGATAGCGCT  
 TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
 GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
 CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
 ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATAATTGGCTATTGGCCATTGCA  
 TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
 ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
 TAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
 GCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
 AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT  
 ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
 CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
 CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
 ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
 GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGTAACAACCTGCGATCGCCCGCC  
 CCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
 TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
 CCTTTGTAATAAATAAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
 CTACAGTTGGCGCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
 CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAAGTTACAGAAGTCTTCTGGAGGTGTC

CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTACTGGTAAGTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAAAGAAAAGGAC  
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAATCAGACGCTGTCAGGACAA  
GAAAGAGAGGGCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCAAGCTTGTGGGATCCACCGGTCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGGCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTCATCTGCACCACCGCAAGCTGCCCCTGCCCTGGCCACCCTCGTGACCAC  
CCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGGACTT  
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAGCGCATCAAGGT  
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT  
CGTGACCGCCCGCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAAATTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGCTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAACCAGGACTA  
AGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAGGGGGAATC  
TCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGATGAACCTGAAAGAAGAATCTAAAGAAGAAAAAAGAAATGACTGGTGGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAATT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT

AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTAAACAAAATAATGGA  
AGTACAAAATCATACTTTTGAGGTAGAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCACTACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGATTCTTGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTGCTTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGAACAATCCTCA  
CCAAGGGTCCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTTCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAAGTGTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCAACTAAACCGCAATAACCGCATTGTGACGCGAGTTCCCCATTGGTGACGCGTT  
AACTTCTGTTTTTACAGTATATAAGTGCTTGATTTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATAAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAAATCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCGCTTTCAGTCGGGAAACCTGTCGTGCCAGTGATGCCCC  
GGCGGCCGAGGCGGCCTACGTGAACCATCACCCAAATCAAGTTTTTGGCGTCGAGGTGC  
CGTAAAGCTCTAAATCGGAACCCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAG  
CCGGCGAACGTGGCGAGAAAGGAAGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTG  
GCAAGTGTAGCGGTACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTA  
CAGGGCGCGTCCATTGCGCATTAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGG  
CCTCTTCGCTATTACGCCAGCCCGGATCGATCCTTATCGGATTTTACCACATTTGTAGAG  
GTTTTACTTGCTTTAAAAAACCTCCCACATCTCCCCCTGAACCTGAAACATAAAATGAAT  
GCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGC  
ATCACAAATTTACAAATAAAGCATTTTTTTTCACTGCATTCTAGTTGTGGTTGTCCAAA  
CTCATCAATGTATCTTATCATGTCTGCTCGAAGCATTAACCCCTACTAAAGGGAAGCGGC  
CGCCCCGGTTCGACTTCACAGGTGTTTGGCGGCTCTTTTGGAGTCTCCGGGCCTCAAGACG  
CGGGGGCTGCTCTGCTCGCCCCACAGCCTTTCTTGTCCTCTGGTAGCCTCCCCATGCG  
GAGAAATCGCCCCCTCTGGTCTCGCGGAAGTAGAGCTCCCTCCAGATGCCGCGATTACCC  
TCTCCAGCTCTTTAGCGGCTTGTTGCACGCCCCTAATTCTCCATTCCAGCCTTTCTTGG  
AGGACCTCGGCTTGCAAAATCTGGCCCCTAATCCACCTATCCCTTCTGGAGGGTGTGTGC  
TGGGTGGGACCGGGGCGAGGTGTCTTCTGGCGATGCAGGTCTGGCTAGGAATCTTCTCC  
TCGGGCAGGGACTGTCTCAGCACGCGGCACCACTGGTCCCCCTCCAGGGGGCCTTGTGGG  
TCGATCTTCCACCAGTCGTTGCGGCGCTTCTCTCTTTGCTCTCTCTTCTGAGGTTTCATC

TCTTGATCCCTGGCCTCCTTGCTCTCAGCCATGGTGGCGAATTCTCGAGGCTAGCCTCCC  
GGTGGTGGGTGGTGGTCCCTGGGCAGGGGTCTCCAGATCCCGGACGAGCCCCAAATGA  
AAGACCCCCGAGACGGGTAGTCAATCACTCTGAGGAGACCCTCCCAAGGAACAGCGAGAC  
CACGAGTCGGATGCAACAGCAAGAGGATTTATTGGATACACGGGTACCCGGGCGACTCAG  
TCTATCGGAGGACTGGCGCGCCGAGTGAGGGGTGTGAGCTCTTTATAGAGCTCGGGAA  
GCAGAAGCGCGCGAACAGAAGCGAGAAGCAGGCTGATTGGTTAATTCAAATAAGGCACAG  
GGTCATTTCAAGGTCCTTGGGGGAGCCTGGAAACATCTGATGGGTCTTAAGAACTGCTGA  
GGGTTGGGGCCATATCTGGGGACCATCTGTTCTTGGCCCCGGGCGGGGCCGAACCGCGGT  
GACCATCTGTTCTTGGCCCCGGGCGGGGCCGAAACTGCTCACCGCAGATATCCTGTTTG  
GCCAACGTTAGCTGTTTTCTGTGTACCCGCCCTTGATCTGAACCTCTCTATTCTTGGTTT  
GGTATTTTTCCATGCCTTGCAAAATGGCGTTACTGCGGCTATCAGGCTAAGCAATTTGAG  
ATCTGGCCGAGGCGGCTACTCTGCATTAATGAATCGGCCAACGCGGGGAGAGGCGGT  
TTGCGTATTGGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGTCGG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTATAACTTCGTATAATGTATGCTATACGAAGTTATACAT  
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTC  
TCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGT  
GGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCTCGTCCAA  
GCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCAGCGCTGCGCCTTATCCGGTAACTA  
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA  
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTCTTGAAGTGGTGGCCTAA  
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTTCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGAT  
CTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACTCACGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAAATGAAGTTTTAAATC  
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTTCTGTTTATCCATAGTTGCCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA  
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCTCGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGC  
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTAGCTCCGGTTCCCAACGATCAAG  
GCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCTCGAT  
CGTTGTCAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA  
GTCACTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGCGTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAAAGTGCTCATCATTGGAAAACGTTCTTCGGG  
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGTGC  
ACCCAACTGATCTTCAGCATCTTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGG  
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACT  
CTTCTTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTTGTAAAAATTCGCGTTAAATTTTTGTAAATC  
AGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAG  
ACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGAACAAGAGTCCACTATTAAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGCGGATGGCCCACTACGTGATAAC



TTCGTATAATGTATGCTATACGAAGTTATCACTACGTGAACCATCACCTAATCAAGTTT  
TTTGGGGTCGAGGTGCCGTAAGCACTAAATCGGAACCTAAAGGGAGCCCCGATTAG  
AGCTTGACGGGGAAAGCCAACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC  
CGGC

**pONY8.3G FB29 + (SEQ ID No 46)**

AGATCTTGAATAATAAAATGTGTGTTGTCCGAAATACGCGTTTTGAGATTTCTGTGCGC  
GACTAAATTCATGTGCGCGGATAGTGGTGTATATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTTGAAAATATGGCATATTGAAAATGTGCGCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGCCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
GCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACAAAATCAACGGGACTTTCCAAAATGTCGTAACAACATGCGATCGCCCGCC  
CCGTTGACGCAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAATAAATAAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAATTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCC  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAACACTGGTAACTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTGTAAAAGAAAAGGAC  
TGGCAGCTGAGGGATGTCAATTCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAA  
GAAAGAGAGGCCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACCAAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGC

AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCAAGCTTGTGGGATCCACCGGTGCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTTATCTGCAACCACCGGAAGCTGCCCCTGCCCTGGCCCCACCTCGTGACCAC  
CCTGACCTACGGCGTGCAGTGCTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTT  
CTTCAAGTCCGCCATGCCCCAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT  
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCCACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT  
CGTGACCGCCGCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAAATTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGCTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAAACCAGGACTA  
AGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAGGGGGAATC  
TCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAGAATCTAAAGAAGAAAAAGAAGAAATGACTGGTGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAAAT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTAAACAAAATAATGGA  
AGTACAAAATCATACTTTTGAGGTAGAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCACTAGTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGCTTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCCTTAGACCTGGAGATTCTGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAAGAACTCTCGCTATCCCTTGCTGTGGATTCCCTTATGGCTATTTTG

GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAACGTGTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCAACTAAACCGCAATAACCGCATTTGTGACGCGAGTTCCTCCATTGGTGACGCGTT  
AACTTCCTGTTTTTACAGTATATAAGTGCTTGTATTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCCGCTTTCAGTCGGGAAACCTGTCTGCCAGAGTAGGCCG  
CCTCGGCCAGATCTCAAATTGCTTAGCCTGATAGCCGCAGTAACGCCATTTTGCAAGGCA  
TGGAATAATACCAAACCAAGAATAGAGAAGTTCAGATCAAGGGCGGTACACGAAAACAG  
CTAACGTTGGGCCAAACAGGATATCTGCGGTGAGCAGTTTCGGCCCCGGCCGGGGCCAA  
GAACAGATGGTCACCGCGGTTCCGGCCCCGGCCGGGGCCAAGAACAGATGGTCCCCAGAT  
ATGGCCCCAACCTCAGCAGTTTCTTAAGACCCATCAGATGTTTCCAGGCTCCCCAAGGA  
CCTGAAATGACCCTGTGCCTATTTGAATTAACCAATCAGCCTGCTTCTCGTTCTGTTT  
GCGCGCTTCTGCTTCCCGAGCTCTATAAAGAGCTCACAACCCCTCACTCGGCGCGCCAG  
TCCTCCGATAGACTGAGTCGCCCCGGTACCCGTGTATCCAATAAATCCTCTTGCTGTTGC  
ATCCGACTCGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTCAGAGTGATTGACTACCCGT  
CTCGGGGGTCTTTCAATTTGGGGGCTCGTCCGGGATCTGGAGACCCCTGCCCAGGGACCAC  
CGACCCACCACCGGGAGGCTAGCCTCGAGAATTCGCCACCATGGCTGAGAGCAAGGAGGC  
CAGGGATCAAGAGATGAACCTCAAGGAAGAGAGCAAAGAGGAGAAGCGCCGCAACGACTG  
GTGGAAGATCGACCCACAAGGCCCCCTGGAGGGGGACCAGTGGTGCCGCGTGCTGAGACA  
GTCCCTGCCCCGAGGAGAAGATTCTAGCCAGACCTGCATCGCCAGAAGACACCTCGGCCC  
CGGTCCCACCCAGCACACACCCTCCAGAAGGGATAGGTGGATTAGGGGCCAGATTTTGCA  
AGCCGAGGTCTCCAAGAAAAGGCTGGAATGGAGAATTAGGGGCGTGCAACAAGCCGCTAA  
AGAGCTGGGAGAGGTGAATCGCGGCATCTGGAGGGAGCTCTACTTCCGCGAGGACCAGAG  
GGGCGATTTCTCCGCATGGGGAGGCTACCAGAGGGCACAAGAAAGGCTGTGGGGCGAGCA  
GAGCAGCCCCCGCGTCTTGAGGCCCGGAGACTCCAAAAGACGCCGCAACACCTGTGAAG  
TCGACCCGGGCGGCCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGA  
TACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGT  
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAC  
AACAACAATTGCATTCTTTATGTTTCAGGTTTCAGGGGGAGATGTGGGAGGTTTTTTAA  
AGCAAGTAAACCTCTACAAATGTGGTAAAAATCCGATAAGGATCGATCCGGGCTGGCGTA  
ATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAAT  
GGACGCGCCCTGTAGCGGCGCATTAAGCGCGGGCGGGTGTGGTGTTACGCGCAGCGTGAC  
CGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTCTTCCCTTCTTCTCGC  
CACGTTGCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT  
TAGAGCTTTACGGCACCTCGACCGCAAAAACTTGATTTGGGTGATGGTTCACGTAGGCC  
GCCTCGGCCCGCCGGGCATCACTGCATTAATGAATCGGCCAACGCGGGGAGAGGCGGT  
TTGCGTATTGGGCGCTTCTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGTTCCG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTATAACTTCGTATAATGTATGCTATACGAAGTTATACAT  
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCACAATAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTC  
TCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTCTCCCTTCGGGAAGCGT

GGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAA  
GCTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACTA  
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA  
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAAGTGGTGGCCTAA  
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGAT  
CTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACCTACGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTAAATC  
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA  
CCCACGCTCACC GGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC  
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGGCAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCTAACGATCAAG  
GCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGAT  
CGTTGTCAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCA  
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGCGCTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATATTGGAACCGTTCTTCGGG  
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC  
ACCCAAGTATCTTCAGCATCTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAACAGG  
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACT  
CTTCCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTTGTAAAAATTCGCGTTAAATTTTGTAAATC  
AGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAAGATAG  
ACCGAGATAGGGTTGAGTGTTGTCCAGTTTGAACAAGAGTCCACTATTAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGATAAC  
TTCGTATAATGTATGCTATACGAAGTTATCACTACGTGAACCATCACCTAATCAAGTTT  
TTTGGGGTGCAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCGATTTAG  
AGCTTGACGGGAAAGCCAACCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC  
CGGC

### pONY8.3GPGK – (SEQ ID No 47)

AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTCTGTGCGC  
GACTAAATTCATGTCGCGCGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTGAAAAATATGGCATATTGAAAATGTGCGCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
GCCCAACGACCCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT

AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCCTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCTTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTG  
ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTGCGATCGCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
T TAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAAATAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTCT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTACTGGTAACTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAAAGAAAAGGAC  
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAA  
GAAAGAGAGGCCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCAATTAGTTCATA  
GCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCTTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCCAAGCTTGTGGGATCCACCGGTGCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCCTGCCCACCCCTCGTGACCAC  
CCTGACCTACGGCGTGCACTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTT  
CTTCAAGTCCGCCATGCCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTCAAGGACGA  
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT  
GAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCATCGGGCAGGGCCCCGTGCTGCTGCCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT  
CGTGACCGCCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCGCGGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTCCCTTTAGTGAGGGTTAATTGCGCGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAAATTTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGCTGTGAAGGGTGATG

GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAACCAGGACTA  
AGTTACTAATAAAAAACCAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAGGGGGAATC  
TCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAAGAAGAAATCTAAAGAAGAAAAAGAAGAAATGACTGGTGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACACTGAGGAATACTTTGGTGGTATGAAG  
GACTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAATT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTTAACAAAATAATGGA  
AGTACAAAATCATACTTTTGGAGGTAGAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCTACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGATTCTCGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGCTTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGAACTGTGGGGTTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCAACTAAACCGCAATAACCGCATTGTGACGCGAGTTCCCATTTGGTGACGCGTT  
AACTTCCTGTTTTTACAGTATATAAGTGCTTGATTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCCGCTTTCCAGTCGGGAAACCTGTCTGCCAGTGATGCCCCG  
GGCGGCCGAGGCGGCCTACGTGAACCATCACCCAAATCAAGTTTTTTCGGTTCGAGGTGC  
CGTAAAGCTCTAAATCGGAACCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAG  
CCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTG  
GCAAGTGTAGCGGTACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTA  
CAGGGCGCGTCCATTGCCCCATTAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGG  
CCTCTTCGCTATTACGCCAGCCCGGATCGATCCTTATCGGATTTTACCACATTTGTAGAG  
GTTTTACTTGCTTTAAAAAACCTCCCACATCTCCCCTGAACCTGAAACATAAAATGAAT

GCAATTGTTGTTGTTAACTTGTATTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGC  
ATCACAAATTTACAAATAAAGCATTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAA  
CTCATCAATGTATCTTATCATGTCTGCTCGAAGCATTAAACCTCACTAAAGGGAAAGCGGC  
CGCCCGGGTCGACTTCACAGGTGTTTGC GGCGTCTTTTGGAGTCTCCGGGCCTCAAGACG  
CGGGGGCTGCTCTGCTCGCCCCACAGCCTTTCTTGTGCCCTCTGGTAGCCTCCCCATGCG  
GAGAAATCGCCCCCTCTGGTCCTCGCGGAAGTAGAGCTCCCTCCAGATGCCGCGATTACAC  
TCTCCCAGCTCTTTAGCGGCTTGTGACGCCCCCTAATTCTCCATTCCAGCCTTTCTTGG  
AGGACCTCGGCTTGCAAAATCTGGCCCCCTAATCCACCTATCCCTTCTGGAGGGTGTGTGC  
TGGGTGGGACCGGGGCGGAGGTGTCTTCTGGCGATGCAGGTCTGGCTAGGAATCTTCTCC  
TCGGGCAGGGACTGTCTCAGCACGCGGCACCACTGGTCCCCCTCCAGGGGGCCTTGTGGG  
TCGATCTTCCACAGTCGTTGCGGCGCTTCTCCTCTTGTCTCTTCTTCTGAGGTTTCATC  
TCTTGATCCCTGGCCTCCTTGCTCTCAGCCATGGTGGCGAATTCTCGAGGCTAGCCTGGG  
GAGAGAGGTGGTGATTCTGGTCAACGAGGGAGCCGACTGCCGACGTGCGCTCCGGAGGCT  
TGCAGAAATCGGAACACCGCGCGGGCAGGAACAGGGCCACACTACCGCCCCACACCCCG  
CCTCCCGCACCGCCCCCTCCCGGCGCTGCTCTCGGCGCGCCCCGCTGAGCAGCCGCTAT  
TGGCCACAGCCCATCGCGGTGCGGCGCTGCCATTGCTCCCTGGCGCTGTCCGTCTGCGA  
GGGTACTAGTGAGACGTGCGGCTTCCGTTTGTACGTCCGGCACGCGCGAACC GCAAGG  
AACCTTCCCGACTTAGGGGCGGAGCAGGAAGCGTCGCCGGGGGGGCCACAAGGGTAGCGG  
CGAAGATCCGGGTGACGCTGCGAACGGACGTGAAGAATGTGCGAGACCCAGGGTCGGCGC  
CGCTGCGTTTCCCGGAACACGCCCCAGAGCAGCCGCGTCCCTGCGCAAACCCAGGGCTGC  
CTTGGA AAAAGGCGCAACCCCAACCCAGATCTGGCCGAGGCGGCCTACTCTGCATTAATG  
AATCGGCCAACGCGCGGGGAGAGGCGGTTTGGCTATTGGGCGCTTCTCCGCTTCTCTGCT  
CACTGACTCGCTGCGCTCGGTCGTTGCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC  
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTATAACTTCGT  
ATAATGTATGCTATACGAAGTTATACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACC  
GTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATACA  
AAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGT  
TTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC  
TGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTACGCTGTAGGTATC  
TCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC  
CCGACCGCTGCGCCTTATCCGGTAACATCGTCTTGAGTCCAACCCGGTAAGACACGACT  
TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTA  
TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCA  
AACAAACACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAA  
AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGAACG  
AAAACCTCAGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCC  
TTTTAAATTA AAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTG  
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTAT  
CCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTG  
GCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA  
TAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAAGTGGTCTTGCAACTTTATCCGCCTCCA  
TCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGC  
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTT  
CATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAA  
AAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGCAAGTAAGTTGGCCGAGTGTTAT  
CACTCATGGTTATGGCAGCACTGCATAATTCTTCTTACTGTCATGCCATCCGTAAGATGCT  
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGA  
GTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAG

TGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGA  
GATCCAGTTCGATGTAACCCACTCGTGCACCCAAGTATCTTCAGCATCTTTACTTTCA  
CCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGG  
CGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTATC  
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAG  
GGGTTCCGCGCACATTTCCCGAAAAGTGCCACCTAAAATTGTAAGCGTTAATATTTTGT  
AAAAATCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGG  
CAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTCCAGTTTG  
GAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTA  
TCAGGGCGATGGCCCACTACGTGATAACTTCGTATAATGTATGCTATACGAAGTTATCAC  
TACGTGAACCATCACCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATC  
GGAACCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAGCCAACCTGGCTTATCG  
AAATTAATACGACTCACTATAGGGAGACCGGC



**pONY8.3G PGK + (SEQ ID No 48)**

AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTCTGTGCGC  
GACTAAATTCATGTCGCGGATAGTGGTGTTCATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTGAAAAATATGGCATATTGAAAAATGTCGCCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
GCCCCACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGT  
ACATCAAGTGATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCGCATCGCCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TtagTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAATAAATAAATCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAACCTACTGGTAACGTG  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAGAAAGAAAGGAC  
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAA  
GAAAGAGAGGCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGCGCCAT  
TAGCCATATTATTATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTAC  
ATCAAGTGATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTGTACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCAAGCTTGTGGGATCCACCGGTCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTACGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC

CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCCACCCTCGTGACCAC  
CCTGACCTACGGCGTGAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTT  
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT  
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT  
CGTGACCGCCGCGGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTCCCTTTAGTGAGGGTTAATTGCGCGGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAACTCTCCAAAAAATTTGTTTTT  
ACAAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAACCAGGACTA  
AGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCAACTACCATTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCAGGGGGAATC  
TCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACAATGTTTCAA  
CCTTATTGTTATAAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAGAATCTAAAGAAGAAAAAAGAAGAAATGACTGGTGGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAAT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTAAACAAAATAATGGA  
AGTACAAAATCATACTTTTGGGTAGAAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGAAAAAGACCTTTGGAGTCATATTGGAATTTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGTCTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAAGACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCCAAGAAGGAACCTCTCGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAACGTGTTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTGTATAACCCAAAGGACTAGCTCATGTTG

CTAGGCAACTAAACCGCAATAAACCGCATTGTGTACGCGAGTTCCCCATTGGTGACGCGTT  
AACTTCCTGTTTTACAGTATATAAGTGCTTGTATTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCCGTTTCCAGTCGGGAAACCTGTCTGTCCAGAGTAGGCCG  
CCTCGGCCAGATCTGGGGTTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAG  
GGACGCGGCTGCTCTGGGCGTGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGC  
ACATTCTTACGTCCGTTTCGACGCTACCCGGATCTTCGCCGCTACCCTTGTGGGCCCC  
CCGGCGACGCTTCTGCTCCGCCCTAAGTCGGGAAGGTTCTTGGGTTTCGCGCGTGC  
CGGACGTGACAAACGGAAGCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAG  
GGAGCAATGGCAGCGCGCCGACCAGTGGGCTGTGGCCAATAGCGGCTGCTCAGCGGGG  
CGCGCCGAGAGCAGCGGCCGGGAAGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTG  
TGGGCCCTGTTCTGCCCCGCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCTG  
CGAGTCGGCTCCCTCGTTGACCGAATCACCAGCTCTCTCCCCAGGCTAGCCTCGAGAAT  
TCGCCACCATGGCTGAGAGCAAGGAGGCCAGGGATCAAGAGATGAACCTCAAGGAAGAGA  
GCAAAGAGGAGAAGCGCCGCAACGACTGGTGGAAGATCGACCCACAAGGCCCCCTGGAGG  
GGGACCACTGGTGCCGCTGCTGAGACAGTCCCTGCCCGAGGAGAAGATTCTAGCCAGA  
CCTGCATCGCCAGAAGACACCTCGGCCCGGTCCACCCAGCACACACCCTCCAGAAGGG  
ATAGGTGGATTAGGGGCCAGATTTTGAAGCCGAGGTCTCCAAGAAAGGCTGGAATTGGA  
GAATTAGGGGCGTGCAACAAGCCGCTAAAGAGCTGGGAGAGGTGAATCGCGGCATCTGGA  
GGGAGCTCTACTTCCGCGAGGACCAGAGGGGCGATTCTCCGCATGGGGAGGCTACCAGA  
GGGCACAAGAAAGGCTGTGGGGCGAGCAGAGCAGCCCCGCGTCTTGAGGCCCGGAGACT  
CCAAAAGACGCCGCAAAACCTGTGAAGTCGACCCGGGCGGCCGCTTCCCTTTAGTGAGG  
GTTAATGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAG  
AATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC  
CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCAATTTATGTTTCAGGT  
TCAGGGGGAGATGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAAATGTGGTAAAAT  
CCGATAAGGATCGATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCC  
CAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAAGCGCGG  
CGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCCGCTC  
CTTTCGCTTTCTCCCTTCTTCTCGCCACGTTGCGCGGCTTCCCCGTCAGGCTCTAA  
ATCGGGGGCTCCCTTTAGGGTTCCGATTTAGAGCTTTACGGCACCTCGACCGCAAAAAAC  
TTGATTTGGGTGATGGTTCACGTAGGCCGCTCGGCCGCCCCGGGCATCACTGCATTAATG  
AATCGGCCAACGCGCGGGGAGAGGCGGTTTGGCTATTGGGCGCTCTTCCGCTTCTCGCT  
CACTGACTCGCTGCGCTCGGTCTGCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC  
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTATAACTTCGT  
ATAATGTATGCTATACGAAGTTATACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACC  
GTAAAAAGGCCGCTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACA  
AAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGT  
TTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC  
TGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCAGCTGTAGGTATC  
TCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGC  
CCGACCGCTGCGCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGTAAGACACGACT  
TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTA  
TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGCCA  
AACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAA

AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG  
AAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCC  
TTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATAGTAAACTTGGTCTG  
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCTGTTCT  
CCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTG  
GCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA  
TAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCA  
TCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGC  
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGTTGGTATGGCTT  
CATTACGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAA  
AAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTAT  
CACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGTAAGATGCT  
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGA  
GTTGCTCTTGCCCGCGCTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAG  
TGCTCATCATTGGAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGA  
GATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCA  
CCAGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGG  
CGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTTATC  
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAG  
GGGTCCGCGCACATTTCCCGAAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGT  
AAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTAAACCAATAGGCCGAAATCGG  
CAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTGTTCCAGTTTG  
GAACAAGAGTCCACTATTAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTA  
TCAGGGCGATGGCCCACTACGTGATAACTTCGTATAATGTATGCTATACGAAGTTATCAC  
TACGTGAACCATCACCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATC  
GGAACCCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAGCCAACCTGGCTTATCG  
AAATTAATACGACTCACTATAGGGAGACCGGC

SEQ ID No 51

**pONY3.2IRESHyg**

AGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA  
AGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATT  
5 TAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGG  
CGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACT  
AGTTATTAAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCG  
GTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTG  
ACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGACGTCAA  
10 TGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCA  
AGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC  
ATGACCTTATGGGACTTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACC  
ATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTACTCACGGGGA  
TTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGG  
15 GACTTTCCAAAATGTCGTAACAACCTGCGATCGCCCGCCCGTTGACGCAAAATGGGCGGTA  
GGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTGAAACCGTCAGATCACTA  
GAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACA  
CAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCG  
TGAGGCACTGGGAGGTAAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAA  
20 CTGGGCTTGTGAGACAGAGAAGACTCTTGGCTTCTGATAGGCACCTATTGGTCTTACT  
GACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAA  
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGCCTCGAGGTGACGGTATCGCCCGA  
ACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACTGGCTGATCGTAGGATCCCC  
GGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTCTGGCCAGAACACAGGA  
25 GGACAGGTAAAGATGGGAGACCCCTTGGACATGGAGCAAGGCGCTCAAGAAGTTAGAGAAG  
TGACGGTACAAGGGTCTCAGAAATTAACACTACTGGTAACTGTAATTGGGCGCTAAGTCTAG  
TAGACTTATTCATGATACCAACTTTGTAAAAGAAAAGGACTGGCAGCTGAGGGATGTCA  
TTCCATTGCTGGAAGATGTAACCTCAGACGCTGTGAGGACAAGAAAGAGAGGCCCTTTGAAA  
GAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCTCCAGATTAATAATGTAGTAGATG  
30 GAAAGGCATCATCTCCAGCTCCTAAGAGCGAAATATGAAAAGAAAGACTGCTAATAAAAAGC  
AGTCTGAGCCCTCTGAAGAATATCCAATCATGATAGATGGGGCTGGAAACAGAAATTTTA  
GACCTCTAACACCTAGAGGATATACTACTTGGGTGAATACCATACAGACAAATGGTCTAT  
TAAATGAAGCTAGTCAAAACTTATTGGGATATTATCAGTAGACTGTACTTCTGAAGAAA  
TGAAATGCATTTTGGATGTGGTACCTGGCCAGGCAGGACAAAAGCAGATATTACTTGATG  
35 CAATTGATAAGATAGCAGATGATTGGGATAATAGACATCCATTACCGAATGCTCCACTGG  
TGGCACCACCACAAGGGCCTATTCCCATGACAGCAAGGTTTATTAGAGGTTTAGGAGTAC  
CTAGAGAAAAGACAGATGGAGCCTGCTTTGATCAGTTTAGGCAGACATATAGACAATGGA  
TAATAGAAGCCATGTGAGAAGGCATCAAAGTGATGATTGGAACCTAAAGCTCAAAATA  
TTAGGCAAGGAGCTAAGGAACCTTACCCAGAATTTGTAGACAGACTATTATCCCAATAA  
40 AAGTGAGGGACATCCACAAGAGATTTCAAAATCTTGACTGATACACTGACTATTGAGA  
ACGCAAAATGAGGAATGTAGAAATGCTATGAGACATTTAAGACCAGAGGATACATTAGAAG  
AGAAAATGTATGCTTGCAGAGACATTGGAACACAAAACAAAAGATGATGTTATTGGCAA  
AAGCACTTCAGACTGGTCTTGGCGGCCCATTTAAAGGTGGAGCCTTGAAGGAGGGCCAC  
TAAAGGCAGCACAAACATGTTATAAAGTGTGGGAAGCCAGGACATTTATCTAGTCAATGTA  
45 GAGCACCTAAAGTCTGTTTTAAATGTAAACAGCCTGGACATTTCTCAAAGCAATGCAGAA  
GTGTTCCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGCCCCAGAAAACAACTTTCCCGA  
TACAACAGAAGAGTCAGCACAAACAACTGTTGTACAAGAGACTCCTCAGACTCAAAATC  
TGTACCCAGATCTGAGCGAAATAAAAAAGGGAATACAATGTCAAGGAGAAGGATCAAGTAG  
AGGATCTCAACCTGGACAGTTTGTGGGAGTAACATATAATCTAGAGAAAAGGCCTACTAC  
50 AATAGTATTAATTAATGATACTCCCTTAAATGTACTGTTAGACACAGGAGCAGATACTTC  
AGTGTGACTACTGCACATTATAATAGGTTAAATATAGAGGGAGAAAATATCAAGGGAC  
GGGAATAATAGGAGTGGGAGGAAATGTGGAACATTTTCTACGCCTGTGACTATAAAGAA  
AAAGGGTAGACACATTAAGACAAGAATGCTAGTGGCAGATATTCCAGTGACTATTTTGGG  
ACGAGATATTCTTCAGGACTTAGGTGCAAAATTTGGTTTTGGCACAGCTCTCCAAGGAAAT  
55 AAAATTTAGAAAATAGAGTTAAAAGAGGGCACAATGGGGCCAAAATTCCTCAATGGCC  
ACTCACTAAGGAGAACTAGAAGGGGCCAAAGAGATAGTCCAAAGACTATTGTGAGAGGG  
AAAAATATCAGAAGCTAGTGACAATAATCCTTATAATTCACCCATATTTGTAATAAAAAA  
GAGGTCTGGCAATGGAGGTTATTACAAGATCTGAGAGAATTAACAAAACAGTACAAAGT  
AGGAACGGAAATATCCAGAGGATTGCCTACCCGGGAGGATTAATTAATGTAAACACAT  
60 GACTGTATTAGATATTGGAGATGCATATTTCACTATACCTTAGATCCAGAGTTTAGACC  
ATATACAGCTTTCACTATTTCCCTCCATTAATCATCAAGAACCAGATAAAAGATATGTGTG  
GAAATGTTTACCACAAGGATTCGTGTTGAGCCCATATATATATCAGAAAACATTACAGGA  
AATTTTACAACCTTTTAGGGAAAGATATCCTGAAGTACAATTGTATCAATATATGGATGA

TTTGTTCATGGGAAGTAATGGTTCTAAAAACAACACAAAAGAGTTAATCATAGAATTAAG  
GGCGATCTTACTGGAAAAAGGTTTTGAGACACCAGATGATAAATTACAAGAAAGTGCCACC  
TTATAGCTGGCTAGGTTATCAACTTTGTCTGAAAAATTGGAAAGTACAAAAAATGCAATT  
5 AGACATGGTAAAGAATCCAACCCTTAATGATGTGCAAAAAATTAATGGGGAATATAACATG  
GATGAGCTCAGGGATCCAGGGTTGACAGTAAACACATTGCAGCTACTACTAAGGGATG  
TTTAGAGTTGAATCAAAAAAGTAATTTGGACGGAAGAGGCACAAAAAGAGTTAGAAGAAAA  
10 ATGTGAGAGATTAATAATGCTCAAGGGTTACAATATTATAATCCAGAAGAAGAAATGTT  
ATGTGAGGTTGAAATTACAAAAAATTATGAGGCAACTTATGTTATAAAACAATCACAAGG  
AATCCTATGGGCAGGTAAAAAGATTATGAAGGCTAATAAGGGATGGTCAACAGTAAAAAA  
TTTAATGTTATTGTTGCAACATGTGGCAACAGAAAGTATTACTAGAGTAGGAAAAATGTCC  
15 AACGTTTAAGGTACCATTACCAAAGAGCAAGTAATGTGGGAAATGCAAAAAGGATGGTA  
TTATCTTGGCTCCAGAAAATAGTATATACACATCAAGTAGTTCATGATGATTGGAGAAT  
GAAATTGGTAGAAGAACCTACATCAGGAATAACAATATACACTGATGGGGGAAAAACAAAA  
TGGAGAAGGAATAGCAGCTTATGTGACCAGTAATGGGAGAACTAAACAGAAAAGGTTAGG  
20 ACCTGTCACCTCAAGTTGCTGAAAGAATGGCAATACAAATGGCATTAGAGGATACCAAG  
AGATAAAACAAGTAAATATAGTAACTGATAGTTATTATTGTTGGAAAAATATTACAGAAGG  
ATTAGGTTTAGAAGGACCACAAAGTCCTTGGTGGCTATAATACAAAATATACGAGAAAA  
AGAGATAGTTTATTTGCTTGGGTACCTGGTCACAAAGGGATATATGTAATCAATTGGC  
AGATGAAGCCGCAAAAAATAAAGAAGAAATCATGCTAGCATACCAAGGCACACAAATTA  
25 AGAGAAAAGAGATGAAGATGCAGGGTTTGACTTATGTGTTCTTATGACATCATGATACC  
TGTATCTGACACAAAAATCATACCCACAGATGTAAAAATTCAAGTTCCTCCTAATAGCTT  
TGGATGGGTCACTGGGAAATCATCAATGGCAAAACAGGGGTTATTAATTAATGGAGGAAT  
AATTGATGAAGGATATACAGGAGAAATACAAGTGATATGTACTAATATTGGAAAAAGTAA  
TATTAATTAATAGAGGGACAAAAATTTGCACAATTAATTATACTACAGCATCACTCAA  
30 TTCCAGACAGCTTTGGGATGAAAAATAATCTCAGAGAGGGGATAAAGGATTTGGAAAG  
TACAGGATTAATCTGGGTAGAAAAATTTAGGAAGCACAAGATGAACATGAGAATTGGCA  
TACATCACCAAGATATTGGCAAGAAATTATAAGATACCATTGACTGTAGCAAAACAGAT  
AACTCAAGAAATGTCTCATTGCACTAAGCAAGGATCAGGACCTGCAGGTTGTGTCATGAG  
ATCTCCTAATCAATTGGCAGGCAGATTGCACACATTGGACAATAAGATAATATTGACTTT  
35 TGTAGAGTCAAAATCAGGATACATACATGCTACATTATTGTCAAAAGAAAATGCATTATG  
TACTTCATTGGCTATTTAGAAATGGGCAAGATTGTTTTACCAAAAGTCCTTACACACAGA  
TAACGGCACTAATTTGTGGCAGAACCAGTTGTAAATTTGTTGAAGTTCCTAAAGATAGC  
ACATACCACAGGAATACCATATCATCCAGAAAGTCAGGGTATTGTAGAAAAGGGCAATAG  
GACCTTGAAAGAGAAGATTCAAAGTCATAGAGACAACACTCAAACACTGGAGGCAGCTTT  
40 ACAACTTGCTCTCATTACTTGTAAACAAAGGGAGGGAAAGTATGGGAGGACAGACCCATG  
GGAAGTATTTATCACTAATCAAGCACAAGTAATACATGAGAAACTTTTACTACAGCAAGC  
ACAATCCCTCCAAAAAATTTTGTTTTACAAAATCCCTGGTGAACATGATTGGAAGGGACC  
TACTAGGTTGCTGTGGAAGGGTGATGGTGCAGTAGTAGTTAATGATGAAGGAAAGGGAAT  
AATTGCTGTACCATTAAACCAGGACTAAGTTACTAATAAAACCAATAGATTGTTGCA  
45 GGAAGCAAGACCCAACTACCATGTCTAGCTGTGTTTCTGACCTCAATATTGTTATAAG  
GTTTGATATGAATCCAGGGGGAATCTCAACCCCTATTACCAACAGTCAGAAAAATCTA  
AGTGTGAGGAGAACACAATGTTTCAACCTTATTGTTATAATAATGACAGTAAGAACAGCA  
TGGCAGAATCGAAGGAAGCAAGAGACCAAGAAATGAACCTGAAAGAAGAAATCTAAAGAAG  
50 AAAAAAGAAGAAATGACTGGTGGAAAAATAGGTATGTTCTGTTATGCTTAGCAGGAATA  
CTGGAGGAATACTTTGGTGGTATGAAGGACTCCACAGCAACATTATATAGGGTTGGTGG  
CGATAGGGGGAAGATTAAACGGATCTGGCCAATCAAATGCTATAGAATGCTGGGGTTCCT  
TCCCGGGGTGTAGACCATTTCAAAATTACTTCAGTTATGAGACCAATAGAAGCATGCATA  
TGGATAATAATACTGCTACATTATTAGAAGCTTTAACCAATATAACTGCTCTATAAATAA  
55 CAAAACAGAAATTAGAAACATGGAAGTTAGTAAAGACTTCTGGCATAACTCCTTTACCTAT  
TTCTTCTGAAGCTAACACTGGACTAATTAGACATAAGAGAGATTGTTGTTAAGTGCAAT  
AGTGGCAGTATTGTAGCCGCTACTGCTATTGCTGCTAGCGCTACTATGCTTATGTTGC  
TCTAACTGAGGTTAACAAAATAATGGAAGTACAAAATCATACTTTGAGGTAGAAAATAG  
TACTCTAAATGGTATGGATTAAATAGAACGACAAAATAAAGATATTATGCTATGATTCT  
TCAAACACATGCAGATGTTCAACTGTTAAAGGAAAGACAACAGGTAGAGGAGACATTTAA  
60 TTTAATTGGATGTATAGAAAGAACAACATGTATTTTGTACACTGGTCAATCCCTGGAATAT  
GTCATGGGGACATTTAAATGAGTCAACACAATGGGATGACTGGGTAAAGCAAAATGGAAGA  
TTTAAATCAAGAGATACTAATACACTTCATGGAGCCAGGAACAATTTGGCACAATCCAT  
GATAACATTCAATACACCAGATAGTATAGCTCAATTTGGAAAAGACCTTTGGAGTCATAT  
TGGAAATTGGATTCTCGGATTGGGAGCTTCCATTATAAAATATATAGTGATGTTTTGCT  
65 TATTTATTGTTACTAACCTCTTCGCCTAAGATCCTCAGGGCCCTCTGGAAGGTGACCAG  
TGGTGCAGGGTCTCCGGCAGTCGTTACCTGAAGAAAAAATTCATCACAACATGCATC  
GCGAGAAGACACCTGGGACCAGGCCAACACAACATACCTAGCAGGCGTGACCGGTGG  
ATCAGGGGACAAATACTACAAGCAGAAGTACTCCAGGAACGACTGGAATGGAGAATCAGA  
GGAGTACAACAGGGCGGCCAAAGAGCTGGGTGAAGTCAATCGAGGCATTGGAGAGAGCTA  
70 TATTTCCGAGAAGACCAAGGGGAGATTTCTCAGCCTGGGGCGGCTATCAACGAGCACAA  
GAACCGCTCTGGGGGAACAATCCTCACCAAGGGTCTTAGACCTGGAGATTGGAAGCGA  
AGGAGGAAACATTTATGACTGTTGCATTAAAGCCCAAGAAAGAACTCTCGCTATCCCTTG  
CTGTGGATTTCCCTTATGGCTATTTTGGGGTTCGACCGGGCGGCGCTAGAGGAAT  
CGCCCTCTCCCTCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGAATAAGGCCGG  
TGTGTGTTTGTCTATATGTGATTTCCACCATTGCGCTCTTTGGCAATGTGAGGGCC  
CGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCTCTCGCCAAA  
GGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCTCTGGAAGCTTCTGAAGA  
CAAAACAAGTCTGTAGCGACCTTTGCAAGGACGGAACCCCCACCTGGCGACAGGTGC  
CTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAGGGCGGCACAACCCAGTGC

CACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTAGTCAAC  
 AAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTTGTATGGGAATCTGATCTGGGGCCTCG  
 GTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAGCTCTAGCCCCCGAACCAC  
 5 GTGGATAGATCCGGAAGCCTGAACCTACCGCGACGTCTGTGAGAAAGTTTCTGATCGAA  
 AAGTTGACAGCGTCTCCGACCTGATGCAGCTCTCGGAGGGCGAAGAATCTCGTGCTTTC  
 AGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTC  
 TACAAAGATCGTTATGTTTATCGGCACCTTGCATCGGCCGCGCTCCCGATTCCGGAAGTG  
 CTTGACATTGGGGAATTCAGCGAGAGCCTGACCTATTGCATCTCCCGCGTGACACAGGGT  
 10 GTCACGTTGCAAGACCTGCCTGAAACCGAAGTGCCTGTTCTGACAGCCGTCGCGGAG  
 GCCATGGATGCGATCGCTGCGGCCGATCTTAGCCAGACGAGCGGGTTCGGCCCATTCGGA  
 CCGCAAGGAATCGGTCAATACTACATGCGCTGATTTCATATGCGCGATTGCTGATCCC  
 CATGTGTATCACTGGCAAACCTGTGATGGACGACACCGTCAGTGCGTCCGTCGCGCAGGCT  
 CTCGATGAGCTGATGCTTTGGGCGGAGGACTGCCCGAAGTCCGGCACCTCGTGACGCG  
 15 GATTTGCGCTCCAACAATGTCCTGACGGACAATGGCCGATAACAGCGGTCAITGACTGG  
 AGCGAGGCGATGTTTCGGGGATTCCCAATACGAGGTGCGCAACATCTTCTTCTGGAGCCG  
 TGGTTGGCTTGTATGGAGCAGCAGACGCGCTACTTCGAGCGGAGGCATCCGGAGCTTGCA  
 GGATCGCCGCGGCTCCGGGCGTATATGCTCCGCAATTGGTCTTGACCAACTCTATCAGAGC  
 TTGGTTGACGGCAATTCGATGATGCAGCTTGGGCGCAGGGTTCGATGCGACGCAATCGTC  
 20 CGATCCGGAGCCGGGACTGTGCGGCGTACACAAATCGCCCGCAGAAGCGCGGCGCTCTGG  
 ACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAACCGACGCCCCAGCACTCGTCCG  
 AGGGCAAAGGAATAGAGTAGATGCCGACCGAACAAGAGCTGATTTCGAGAACGCCCTCAGC  
 CAGCAACTCGCGCGAGCCTAGCAAGGCAATGCGAGAGAACCGGCTTACGCTTGGTGGA  
 CAGTTCTCGTCCACAGTTTCTGCTAAGCTCGCTCGGCTGGGTGCGGGAGGGGCCGCTCGCAG  
 25 TGATTACAGGCCCTTCTGGATTGTGTTGGTCCCCAGGGCACGATTGTCATGCCCCACGCACT  
 CGGGTGATCTGATGATCCCGCAGATTGGAGATCGCCGCCCGTGCCTGCCGATTGGGTGC  
 AGATCTAGAGCTCGCTGATCAGCCTCGACTGTGCTCTAGTTGCCAGCCATCTGTTGTTT  
 GCCCCCTCCCGCTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGCTTTCCTAAT  
 AAAATGAGGAAATTCATCGCATTGTCTGAGTAGGTGTCAATTCTATTCTGGGGGGTGGG  
 30 TGGGCGAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGG  
 TGGGCTCTATGGCTTCTGAGGCGGAAAGAACAGCTGGGGCTCGAGTGCATTCTAGTTGT  
 GGTGTGTCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAG  
 AGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATT  
 CCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCTAATGAGTGAGC  
 35 TAACTCACATTAATTGCGTTGCGTCACTGCCCGCTTTCAGTCGGGAAACCTGTGCTGC  
 CAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGCGCTCT  
 TCCGCTTCCCTCGCTCACTGACTCGCTGCGCTCGGTTCGCTCGGCTGCGGCGAGCGGTATCA  
 GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAAC  
 ATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTT  
 40 TTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGG  
 CGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGC  
 TCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGC  
 GTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTCGCTCC  
 AAGTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAAC  
 45 TATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGT  
 AACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCT  
 AACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACC  
 TTCGGAAGAAAGAGTTGGTAGCTCTTGATCCGGCAAAACACCGCTGGTAGCGGTGGT  
 TTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTG  
 50 ATCTTTTCTACGGGTCTGACGCTCAGTGGAAACGAAAACTACGTTAAGGGATTGTTGTC  
 ATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAATAAATGAAGTTTAA  
 TCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG  
 GCACCTATCTCAGCGATCTGTCTATTTCGTTTATCCATAGTTGCTGACTCCCCGCTCGT  
 TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGA  
 55 GACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACACAGCCAGCCGGAAGGGCCGAG  
 CGCAGAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAA  
 GCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCAGCAACGTTGTTGCCATTGCTACAGGC  
 ATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTATTACGCTCCGGTTCCCAACGATCA  
 AGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCG  
 60 ATCGTTGTGCAAGTAAGTTGGCCGCGAGTGTATCACTCATGGTTATGGCAGCACTGCAT  
 AATTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACC  
 AAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTTTCGCCGGCGTCAATACGG  
 GATAATACCGCGCCACATAGCAGAATTTAAAGTGCTCATATTGGAAAACGTTCTTCG  
 GGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGT  
 65 GCACCCAACTGATCTTCAGCATCTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACA  
 GGAAGGCAAAATGCCGCAAAAAAGGAATAAGGGCGACACGGAAATGTTGAATACTCATA  
 CTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATAC  
 ATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAA  
 70 GTGCCACCTGACGTGACGGATCGG

**pONY8ZA CMVHyb (SEQ ID No 52)**

AGATCTTGAATAATAAAATGTGTGTTGTCCGAAATACGCGTTTGGAGATTCTGTGCGC

5 GACTAAATTCATGTCGCGCGATAGTGGTGTATATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTTGAAAATATGGCATATTGAAAATGTGCGCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTTCCAAAAGTGATTTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
10 GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCTTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
15 TAGCCCATATATGGAGTTCGCGGTTACATAAATTACGGTAAATGGCCCCGCTGGCTGACC  
GCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGAATTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTA  
20 CGTATTAGTCATCGCTATTACCAATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGCGTAACAACTGCGATCGCCCCG  
CCGTTGACGCAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
25 CCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTGTCTGTTCGAGATC  
CTACAGTTGGCGCCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAAGTTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGGC  
CTCAAGAAGTTAGAGAAGGTGACGGTACAGGGTCTCAGAAATTAACACTGGTAACTGT  
30 AATTGGGCGCTAAGTCTAGTAGACTTATTTTATTGATACCAACTTTGTAAGAAAAGGA  
TTGGCAGCTGAGGGATTGTCAATTCATTGCTGGAAGATTGTAACCTCAGACGCTGTCAGGA  
CAAGAAAGAGAGGCCCTTTGAAAGAACATTGGTGGGCAATTTCTGCTGTAAGATTGGGCC  
TCCAGATTAATAATTGTAGTAGATTGGAAGGCATCATTCCAGCTCCTAAGAGCGAAATA  
TTGAAAAGAAAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGA  
35 AGTGGATCCCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGAT  
CCGGCCATTAGCCATATTATTCTTGGTTATATAGCATAAATCAATATTGGCTATTGGCC  
ATTGCATACGTTGTATCCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATT  
ACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT  
AGTTCATAGCCCATATATGGAGTTCGCGGTTACATAAATTACGGTAAATGGCCCCGCTGG  
40 CTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAAC  
GCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCACTT  
GGCAGTACATCAAGTGATCATAATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAA  
ATGGCCCGCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTA  
CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGG  
45 GCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGG  
GAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGCGTAACAACTCCGCCCC  
ATTGACGCAAAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTT  
AGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACA  
50 CCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTCAGCTGCTCGAGGATCTGCGGATCCG  
GGGAATTTCCAGTCTCAGGATCCACCATGGGGGATCCCGTCGTTTTACAACGTCGTGAC  
TGGGAAAACCTTGGCGTTACCCAATTAAATCGCCTTGCAGCACATCCCCCTTTGCCAGC  
TGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAAT  
GGCGAATGGCGCTTTGCTGCTGTTTCCGGCACAGAAAGCGGTGCCGAAAGCTGGCTGGAG  
55 TGCGATCTCTGAGGCGGATACTGTGCTGCTCCCTCAAACCTGGCAGATGCACGGTTAC  
GATGCGCCCATCTACACCAACGTAACCTATCCCATACGGTCAATCCGCGGTTTGTCCC  
ACGGAGAATCCGACGGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAG  
GAAGGCCAGACGCGAATTATTTTGTATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAAC  
GGGCGCTGGGTGGTTACGGCCAGGACAGTGGTTGCCGTCTGAATTTGACCTGAGCGCA  
60 TTTTTACGCGCCGGAGAAAACCGCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGT  
TATCTGGAAGATCAGGATATGTGGCGGATGAGCGGCATTTCCGTGACGTCTCGTTGCTG  
CATAAACCGACTACACAAATCAGCGATTTCATGTTGCCACTCGCTTTAATGATGATTTT  
AGCCGCGCTGTACTGGAGGCTGAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGG  
GTAACAGTTTCTTTATGGCAGGGTGAAACGCAAGGTGCGCAGCGGCACCGCGCTTTCCGGC  
65 GGTGAAATTATCGATGAGCGTGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTC  
GAAAACCCGAAACTGTGGAGCGCGGAAATCCCGAATCTCTATCGTGGGTGGTTGAACGT  
CACACCGCCGACGGCAGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTG  
CGGATTGAAAATGGTCTGCTGCTGCTGAACGGCAAGCGGTTGCTGATTGAGGCGTTAAC  
CGTCACGAGCATCATCTCTGATGGTCAAGTCAATGATGAGCAGACGATGGTGCAGGAT  
ATCCTGCTGATGAAGCAGAACAATTTAACGCGGTGCGCTGTTCCGATTATCCGAACCAT  
70 CCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTTGGTGGATGAAGCCAAAT  
GAAAACCCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCG  
ATGAGCGAACGCGTAACGCGAATGGTGACGCGGATCGTAATCACCCGAGTGTGATCATC  
TGGTCTGTGGGAATGAATCAGGCCACGGCGCTAATCAGCAGCGCTGTATCGCTGGATC  
AAATCTGTGCGATCCTTCCCGCCGGTGCAAGTATGAAGCGGGGAGCCGACACCGGCC  
ACCGATATTATTTGCCCGATGTACGCGCGCTGGATGAAGACCAGCCCTTCCCGGCTGTG  
CCGAAATGGTCCATCAAAAAATGGCTTTTCGCTACCTGGAGAGACGCGCCGCTGATCCTT  
TGCGAATACGCCACCGCATGGGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCG  
TTTCGTCAGTATCCCCGTTTACAGGGCGGCTTCTGCTGGGACTGGGTGGATCAGTCGCTG  
ATTAATATGATGAAAACGGCAACCCGTGGTTCGGCTTACGGCGGTGATTTTGGCGATACG



CCGAACGATCGCCAGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCA  
 GCGCTGACGGAAGCAAAACACCAGCAGCAGTCTTTCCAGTTCCGTTTATCCGGGCAAAACC  
 ATCGAAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATG  
 GTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAA  
 5 GGTAAACAGTTGATTGAACTGCCTGAACTACCGCAGCCGAGAGCGCCGGGCAACTCTGG  
 CTCACAGTACGCGTAGTGCAACCGAACCGCAGCCGATGGTCAGAAAGCCGGGCACATCAGC  
 GCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCTCCAC  
 GCCATCCCGCATCTGACCACCAGCGAAATGGATTTTGCATCGAGCTGGGTAATAAGCGT  
 10 TGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAA  
 CTGCTGACGCCGCTGCGCGATCAGTTTACCCGTCACCGCTGGATAACGACATTGGCGTA  
 AGTGAAGCGACCCGATTGACCCTAACGCCCTGGGTGCAACGCTGGAAAGCGCGCGGCCAT  
 TACCAGGCCGAAGCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTG  
 ATTACGACCGCTCAGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGGAACCC  
 TACCGGATTGATGGTAGTGGTCAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGAT  
 15 ACACCGCATCCGGCGCGGATTGGCCTGGAACCTGCCAGCTGGCGCAGGTAGCAGAGCGGGTA  
 AACTGGCTCGGATTAGGGCCGCAAGAAAATATCCCGACCGCCTACTGCCGCTGTTTT  
 GACCGCTGGGATCTGCCATTGTGACAGCATGTATACCCGTCAGTCTTCCCGAGCGAAAAC  
 GGTCTGCGCTGCGGGACGCGCAATTGAATTATGGCCACACCAAGTGGCGCGGCGACTTC  
 CAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTG  
 20 CTGCACGCGGAAGAAAGCACATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGC  
 GACGACTCCTGGAGCCCGTCAGTATCGGCGGAATTCAGCTGAGCGCCGGTCGCTACCAT  
 TACCAGTTGGTCTGGTGTCAAAAAATAATAAACCGGGCAGGGGGGATCCGCAGATCCGG  
 CTGTGGAATGTGTGTCAGTTAGGGTGTGGAAGTCCCCAGGCTCCCCAGCAGGCAGAAAT  
 ATGCAAGCATGCTGTCAGGAATTCGATATCAAGCTTATCGATACCGTTCGACCTCGAGGG  
 25 GGGGCCCCGTACCCAGCTTTTGTCTTCTAGTGAGGGTAAATTGCGCGGGAAGTATTTA  
 TCACTAATCAAGCACAAAGTAATACATGAGAACTTTTACTACAGCAAGCACATCTCCA  
 AAAAAATTTGTTTTTACAAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGC  
 TGTGGAAGGGTGATGGTGCAGTAGTAGTTAATGATGAAGGAAGGGAATAATTGCTGTAC  
 CATTAAACCGGACTAAGTTACTAATAAAACCAAATTGAGTATTGTTGCAAGGAAGCAAGAC  
 30 CCAACTACCATTGTGACGTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGA  
 ATCCCAGGGGGAATCTCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAG  
 AACACAATGTTTCAACCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCG  
 AAGGAAGCAAGAGACCAAGAATGAACCTGAAAGGAAGAATCTAAAGAAGAAAAAGAA  
 ATGACTGGTGGAAAAATAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATAC  
 35 TTTGGTGGTATGAAGGACTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGAA  
 GATTAAACCGGATTGGCCAATCAAAATGCTATAGAATGCTGGGGTTCTTCCCGGGGTGA  
 GACCAATTTCAAAATTACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATA  
 CTGCTACATTATTAGAAGCTTTAACCAATATAACTGCTCTATAAATAACAAAAACGAATT  
 AGAAACATGGAAGTTAGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTCTGAAGC  
 40 TAACCTGGACTAATTAGACATAAGAGAGATTTTGGTATAAGTGCATAGTGGCAGCTAT  
 TGTAGCCGCTACTGCTATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGT  
 TAACAAAAATATGGAAGTACAAAATCATACTTTTGGGTAGAAAAATAGTACTCTAAATGG  
 TATGGATTTAATAGAACGACAAATAAAGATATTATATGCTATGATTCTTCAACACATGC  
 AGATGTTCAACTGTTAAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATG  
 45 TATAGAAAGAACACATGTATTTGTCATACTGGTCATCCCTGGAATATGTCATGGGGACA  
 TTTAAATGAGTCAACACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGA  
 GATACTAATACTTTCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAA  
 TACACCAGATAGTATAGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGAT  
 TCCTGGATTGGGAGCTTCCATTATAAAATATATAGTGATGTTTTTGGCTATTTATTTGTT  
 50 ACTAACCTCTTCGCTAAGATCCTCAGGGCCCTCGGAAGGTACCAAGTGGTGCAGGGTC  
 CTCCGGCAGTCGTTACCTGAAGAAAAATCCATCACAACATGCATCGGAGAAGACAC  
 CTGGGACCAGGCCAACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAA  
 ATACTACAAGCAGAAGTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAG  
 GCGGCCAAAGAGCTGGGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAA  
 55 GACCAAAAGGGGAGATTTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGG  
 GGGGAACAACTCTCACCAAGGGTCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACAT  
 TTATGACTGTTGCATTAAGCCCCAAGAAGGAACCTCGCTATCCCTTGCTGTGGATTTCC  
 CTTATGGCTATTTTGGGACTAGTAATTATAGTAGGCTTAAATTTGATATTTGAAATAAT  
 TGGACTCGCTGTTATAATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAAT  
 60 CAGAAAAATGCTTTGATTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAAT  
 GCCTCAGTATGCTTTAGAAAAACAAGGGGGAACCTGTGGGGTTTTATGAGGGGTTTTATA  
 AACTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCATTAGCC  
 ATATTATTCAATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTG  
 TATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACGCCATGTTGA  
 65 CATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCAATTAGTTTATAGCCCA  
 TATATGGAGTTCGCGGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAAC  
 GACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACT  
 TTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAA  
 GTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGG  
 70 CATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTA  
 GTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGCGGTGGATAGCGG  
 TTTGACTACGGGGATTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTTTTGG  
 CACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCATTTGACGCAAAATG  
 GGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTGAACCGGGCA

CTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATA  
TAATTCCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTGAGATCCTACAGAGCTCATGC  
CTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCC  
5 ACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTA  
ACTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCA  
GCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGCGCTCTTC  
CGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTGGGCTGCGGCGAGCGGTATCAGC  
10 TCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT  
GTGAGCAAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTC  
15 TCCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCTTTTCTCCCTTCGGGAAGCGT  
GGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCTGTCGTCCAA  
GCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCGACCGCTGCGCCTTATCCGGTAAC  
TCGTCTTGAGTCCAACCCGGTAAGACAGACTTATCGCCACTGGCAGCAGCCACTGGTAA  
20 CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCTAA  
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTTGCAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGAT  
25 CTTTTCTACGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAATGAAGTTTAAATC  
AATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTTTCGTTTATCCATAGTTGCCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA  
30 CCCACGCTACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGAAGC  
TAGAGTAAAGTAGTTGCCAGTTAATAGTTTGGCGCAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCTGTTGGTATGGCTTCAATCAGCTCCGCTTCCCAACGATCAAG  
GCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGAT  
35 CGTTGTGAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA  
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAAACGTTCTTCGGG  
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC  
40 ACCCAACTGATCTTCAGCATCTTTTACTTTACCCAGCGTTTCTGGGTGAGCAAAAACAGG  
AAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACT  
CTTCCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTTGTAAAAATTCGCGTTAAATTTTGTAAATC  
45 AGCTCATTTTTAACCATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAG  
ACCGAGATAGGGTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCA  
TCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAGCACTAAATCGGAACCCTAAA  
GGGAGCCCCGATTTAGAGCTTGACGGGAAAGCCAACCTGGCTTATCGAAATTAATACG  
ACTCACTATAGG

5

**PEsynGP (SEQ ID No 53)**

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTA  
TTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCC  
AATATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG  
GTCATTAGTTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCC  
GCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCAT  
AGTAACGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC  
CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA  
CGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTG  
GCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAC  
CAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT  
CAATGGGAGTTTTGTTTTGGCACCAAAATCAACGGGACTTTCAAAATGTCGTAACAACCTG  
CGATCGCCCGCCCCGTTGACGCAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATA  
AGCAGAGCTCGTTTATGTAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCAT  
AGTTAAATTGCTAACGCAGTCAGTGTCTTGACACAACAGTCTCGAACTTAAGCTGCAGT  
GACTCTCTTAAGGTAGCCTTGACAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAA  
GGTTACAAGACAGGTTTAAGGAGACCAATAGAACTGGGCTTGTGAGACAGAGAAGACT  
CTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTCTCTCCAC  
AGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT  
ATAGGCTAGAGAATTTCGCCACCATGGGCGATCCCCCACCTGGTCCAAAGCCCTGAAGAA  
ACTGGAAAAAGTCACCGTTACGGGTAGCCAAAAGCTTACCACAGGCAATTGCAACTGGGC  
ATTGTCCCTGGTGGATCTTTTCCACGACACTAATTTCTGTTAAGGAGAAAAGATTGGCACT  
CAGAGACGTGATCCCCCTCTTGGAGGACGTGACCCAAACATTGTCTGGGCAGGAGCGCGA  
AGCTTTCGAGCGCACCTGGTGGGCCATCAGCGCAGTCAAAATGGGGCTGCAAAATCAACAA  
CGTGGTTGACGGTAAAGCTAGCTTTCAACTGCTCCGCGCTAAGTACGAGAAGAAAACCGC  
CAACAAGAAACAATCCGAACCTAGCGAGGAGTACCCAAATTATGATCGACGGCGCCGCA  
TAGGAACTTCCGCCCACTGACTCCAGGGGCTATACCACCTGGGTCAACACCATCCAGAC  
AAACGGACTTTTGAACGAAGCCTCCAGAACCTGTTCCGGCATCCTGTCTGTGGACTGCAC  
CTCCGAAGAAATGAATGCTTTTCTCGACGTGGTGCCAGGACAGGCTGGACAGAAACAGAT  
CCTGCTCGATGCCATTGACAAGATCGCCGACGACTGGGATAATCGCCACCCCTGCCAAA  
CGCCCCCTCTGGTGGCTCCCCACAGGGGCTATCCCTATGACCGCTAGGTTTATTAGGGG  
ACTGGGGGTGCCCCGCGAACGCCAGATGGAGCCAGCATTTGACCAATTTAGGCAGACCTA  
CAGACAGATGGATCATCGAAGCCATGAGCGAGGGGATTAAAGTCATGATCGGAAAGCCCAA  
GGCACAGAACATCAGGCAGGGGGCCAAGGAACCATACCCTGAGTTTGTGACAGGCTTCT  
GTCCAGATTAAATCCGAAGGCCACCCTCAGGAGATCTCCAAGTTCTTGACAGACACACT  
GACTATCCAAAATGCAAATGAAGAGTGCAGAAACGCCATGAGGCACCTCAGACCTGAAGA  
TACCCTGGAGGAGAAAAATGTACGCATGTGCGGACATTGGCACTACCAAGCAAAAGATGAT  
GCTGCTCGCCAAGGCTCTGCAAAACCGGCTGGCTGGTCCATTCAAAGGAGGAGCACTGAA  
GGGAGGTCCATTGAAAGCTGCACAAACATGTTATAATTGTGGGAAGCCAGGACATTTATC  
TAGTCAATGTAGAGCACCTAAAGTCTGTTTTAAATGTAAACAGCCTGGACATTTCTCAA  
GCAATGCAGAAGTGTTCCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGCCCCAGAAACA  
AACTTTCCCGATAACAACAGAAGAGTCAGGACACAACAAATCTGTTGTACAAGAGACTCTCA  
GACTCAAAATCTGTACCCAGATCTGAGCGAAATAAAAAAGGAATACAATGTCAAGGAGAA  
GGATCAAGTAGAGGATCTCAACCTGGACAGTTTGTGGGAGTAACATACAATCTCGAGAAG  
AGGCCCCTACCATCGTCTGATCAATGACACCCCTCTTAATGTGCTGCTGGACACCGGA  
GCCGACACCAGCGTTCTCACTACTGCTCACTAATAACAGACTGAAATACAGAGGAAGGAAA  
TACCAGGGCACAGGCATCATCGGCGTTGGAGGCAACGTGCAAAACCTTTTCCACTCCTGTC  
ACCATCAAAAAGAAAGGGGAGACACATTAAAAACCAGAATGCTGGTCCGCGACATCCCCGTC  
ACCATCCTTGGCAGAGACATTCTCCAGGACCTGGGCGCTAAACTCGTGTGCTGGCACAACCTG  
TCTAAGGAAATCAAGTTCCGCAAGATCGAGCTGAAAAGAGGGGCACAATGGGTCCAAAAATC  
CCCCAGTGGCCCCCTGACCAAGAGAAGCTTGAGGGCGCTAAGGAAATCGTGCAGCGCCTG  
CTTCTGAGGGCAAGATTAGCGAGGCCAGCGACAATAACCCTTACAACAGCCCCATCTTT

GTGATTAAGAAAAGGAGCGGCAAATGGAGACTCCTGCAGGACCTGAGGGAACCTCAACAAG  
ACCGTCCAGGTGCGAACTGAGATCTCTCGCGGACTGCCTACCCCGGCGGCCTGATTAAA  
TGCAAGCACATGACAGTCCTTGACATTGGAGACGCTTATTTTACCATCCCCCTCGATCCT  
5 GAATTCGCCCCCTATACTGCTTTTACCATCCCCAGCATCAATCACCAGGAGCCCCGATAAA  
CGCTATGTGTGGAAGTGCCTCCCCCAGGGATTTGTGCTTAGCCCCCTACATTACCAGAAG  
ACACTTCAAGAGATCCTCCAACCTTTCCGCGAAAGATACCCAGAGGTTCAACTCTACCAA  
TATATGGACGACCTGTTTCATGGGGTCCAACGGGTCTAAGAAGCAGCACAAGGAACCTATC  
ATCGAACTGAGGGCAATCCTCCTGGAGAAAAGGCTTCGAGACACCCGACGACAAGCTGCAA  
10 GAAGTTCCTCCATATAGCTGGCTGGGCTACCAGCTTTGCCCTGAAAACCTGGAAAGTCCAG  
AAGATGCAGTTGGATATGGTCAAGAACCCAACTGAACGACGTCCAGAAGCTCATGGGC  
AATATTACCTGGATGAGCTCCGGAATCCCTGGGCTTACCGTTAAGCACATTGCCGCAACT  
ACAAAAGGATGCCCTGGAGTTGAACCAGAAGGTCATTTGGACAGAGGAAGCTCAGAAGGAA  
CTGGAGGAGAATAATGAAAAGATTAAGAATGCTCAAGGGCTCCAATACTACAATCCCGAA  
GAAGAAATGTTGTGCGAGGTGCAAACTACTAAGAAGTACGAAGCCACCTATGTCATCAA  
15 CAGTCCCAAGGCATCTTGTGGGCGGAAAGAAAATCATGAAGGCCAACAAAGGCTGGTCC  
ACCGTTAAAAATCTGATGCTCCTGCTCCAGCAGTCCGCCACCGAGTCTATCACCCTGCTC  
GGCAAGTGCCCCACCTTCAAAGTTCCCTTCACTAAGGAGCAGGTGATGTGGGAGATGCAA  
AAAGGCTGGTACTACTCTTGGCTTCCCGAGATCGTCTACACCCACCAAGTGGTGCACGAC  
GACTGGAGAATGAAGCTTGTGAGGAGGCCACTAGCGGAATTACAATCTATACCGACGGC  
20 GGAAAGCAAAACGGAGAGGGAATCGCTGCATACGTCACATCTAACGGCCGACCAAGCAA  
AAGAGGCTCGGCCCTGTCACTCACCAGGTGGCTGAGAGGATGGCTATCCAGATGGCCCTT  
GAGGACAGTAGAGACAAGCAGGTGAACATTGTGACTGACAGCTACTACTGCTGAAAAAAC  
ATCACAGAGGGCCTTGGCCTGGAGGGACCCAGTCTCCCTGGTGGCCTATCATCCAGAAT  
ATCCGCGAAAAGGAAATTGTCTATTTTCGCTGGGTGCCTGGACACAAAGGAATTTACGGC  
25 AACCAACTCGCCGATGAAGCCGCCAAAATTAAGAGGAAATCATGCTTGCCTACCAGGGC  
ACACAGATTAAGGAGAAGAGAGACGAGGACGCTGGCTTTGACCTGTGTGTGCCATACGAC  
ATCATGATTCCCGTTAGCGACACAAAGATCATTTCCAACCGATGTCAAGATCCAGGTGCCA  
CCCAATTCATTTGGTTGGGTGACCGGAAAAGTCCAGCATGGCTAAGCAGGGTCTTCTGATT  
AACGGGGGAATCATTGATGAAGGATACACCGGCGAAATCCAGGTGATCTGCACAAATATC  
30 GGCAAAAGCAATATTAAGCTTATCGAAGGGCAGAAAGTTCGCTCAACTCATCTCTCCAG  
CACCACAGCAATTCAAGACAACCTTGGGACGAAAAACAAGATTAGCCAGAGAGGTGACAAAG  
GGCTTCGGCAGCACAGGTGTGTTCTGGGTGGAGAACATCCAGGAAGCACAGGACGAGCAC  
GAGAAATTGGCACACCTCCCTTAAGATTTTGGCCCGCAATTACAAGATCCCACTGACTGTG  
GCTAAGCAGATCACACAGGAATGCCCCCACTGCACCAACAAGGTTCTGGCCCCGCGGGC  
35 TGCGTGATGAGGTCCCCAATCACTGGCAGGACAGATTGCACCCACCTCGACAACAAAATT  
ATCCTGACCTTCGTGGAGAGCAATTCGGGTACATCCACGCAACACTCCTCTCCAAGGAA  
AATGCATTGTGCACCTCCCTCGCAATTCTGGAATGGGCCAGGCTGTTCTCTCCAAGTCC  
CTGCACACCGACAACGGCACCAACTTTGTGGCTGAACCTGTGGTGAATCTGCTGAAGTTC  
CTGAAAATCGCCACACCACTGGCATTCCCTATCACCTGAAAGCCAGGGCATTGTGAG  
40 AGGGCCAACAGAACTCTGAAAGAAAAGATCCAATCTCACAGAGACAATACACAGACATTG  
GAGGCCGCACTTCAGCTCGCCCTTATCACCTGCAACAAAGGAAGAGAAAGCATGGGCGGC  
CAGACCCCTGGGAGGTCTTCATCACTAACAGGCCAGGTATCCATGAAAAGCTGCTC  
TTGCAGCAGGCCAGTCTCCCAAAAGTCTGCTTTTATAAGATCCCCGGTGAGCACGAC  
TGGAAAAGGTCTACAAGAGTTTTGTGGAAGGAGACGGCGCAGTTGTGGTGAACGATGAG  
45 GGCAAGGGGATCATCGCTGTGCCCTGACACGCACCAAGCTTCTCATCAAGCCAACTGA  
ACCCGGGGCGGCCGCTTCCCTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGATA  
CATTGATGAGTTTGGACAAACCACAATAAGATGCAGTGAAGAAAAATGCTTTATTGTGA  
AATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAATAAACAAGTTAACA  
CAACAATTGCATTATTTTATGTTTCAGGTTTCAGGGGGAGATGTGGGAGGTTTTTTAAAG  
50 CAAGTAAAACCTCTACAAATGTGGTAAAATCCGATAAGGATCGATCCGGGTGGCGTAAT  
AGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGG  
ACGCGCCCTGTAGCGGCGCATTAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCG  
CTACACTTGCCAGCGCCCTAGCGCCGCTCCTTTTCGCTTTCTCCCTTCTTCTCGCCA  
CGTTTCGCCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTA  
55 GAGCTTTACGGCACCTCGACCGCAAAAACTTGATTGGGTGATGGTTCACGTAGTGGGC  
CATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTG  
GACTCTTGTTCCAACTGGAACAACACTCAACCTATCTCGGTCTATTCTTTGATTAT  
AAGGGATTTTGGCGATTTCGGCTATTGGTTAAAAAATGAGCTGATTTAACAAATATTTA  
ACGCGAATTTTAACAAATATTAACGTTTACAATTTTCGCTGATGCGGTATTTTCTCCTT  
60 ACGCATCTGTGCGGTATTTACACCCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAA  
TAACCTCTGAAAGAGGAACCTTGGTTAGGTACCTTCTGAGGCGGAAAGAACAGCTGTGGA  
ATGTGTGTCAGTTAGGGTGTGGAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAA  
GCATGCATCTCAATTAGTCAGCAACCAAGTGTGGAAGTCCCCAGGCTCCCCAGCAGCA  
GAAGTATGCAAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGC  
65 CCATCCCGCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTT  
TTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAG

GAGGCTTTTTTGGAGGCCTAGGCTTTTGC AAAAGCTTGATTCTTCTGACACAACAGTCT  
 CGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGC  
 CGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGA  
 TGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGTTCTTTTGTCAAGACCGACCT  
 5 GTCCGGTGGCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGAC  
 GGGCGTTCCTTGGCGAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCT  
 ATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTATCTCACCTTGCTCCTGCCGAGAAAAT  
 ATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATT  
 CGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGT  
 10 CGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTGTTCGCCAG  
 GCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCTGTGACCCATGGCGATGCCTGCTT  
 GCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCGACTGTGGCCGGCTGGG  
 TGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGG  
 CGGCGAATGGGCTGACCGCTTCTCGTGCTTTACGGTATCGCCGCTCCCGATTCCGACGC  
 15 CATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATG  
 ACCGACCAAGCGACGCCCAACCTGCCATCAGCATGGCCGCAATAAAATATCTTTATTTTC  
 ATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGATAGCGATAAGGATCCGCGTATGGTG  
 CACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAAC  
 ACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGT  
 20 GACCGTCTCCGGGAGCTGCATGTGTGACAGGTTTTACCGTCATCACCGAAACGCGGAG  
 ACGAAAGGGCCTCGTGATACGCCTATTTTATAGGTTAATGTCATGATAATAATGGTTTC  
 TTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTT  
 CTAATAACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATA  
 ATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCCGCTTATTCCCTTTTT  
 25 TGCGGCATTTTGCCCTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGC  
 TGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAGAT  
 CCTTGAGAGTTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCT  
 ATGTGGCGCGGTATTATCCCGTATTGACGCCGGGAAGAGCAACTCGGTGCGCCGATACA  
 CTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAAGCATCTTACGGATGG  
 30 CATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAA  
 CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATCGG  
 GGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA  
 CGAGCGTGACACCAACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGG  
 CGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGT  
 35 TGCAGGACCATTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
 AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTC  
 CCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA  
 GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTC  
 ATATATACTTTAGATTGATTTAAAACTTCATTTTAAATTTAAAGGATCTAGGTGAAGAT  
 40 CCTTTTGTATAATCTCATGACCAAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTC  
 AGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTG  
 CTGCTTGCAAAACAAAAAACACCCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAGCT  
 ACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCT  
 TCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT  
 45 CGCTCTGCTAATCCTGTTACCACTGGCTGCTGCCAGTGGCGATAAGTCTGTCTTACCGG  
 GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTC  
 GTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA  
 GCTATGAGAAAGCGCCACGCTTCCCGAAGGAGAAAAGGCGGACAGGTATCCGGTAAGCGG  
 CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTA  
 50 TAGTCTGTGGGTTTTGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGG  
 GGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG  
 CTGGCCTTTTGCTCACATGGCTCGACAGATCT

# **PESDSYNGP (SEQ ID No 54)**

55 TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTA  
 TTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCC  
 AATATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG  
 GTCATTAGTTCAAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC  
 60 GCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCAT  
 AGTAACGCCAATAGGGACTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC  
 CCATTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA  
 CGGTAAATGGCCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCCTACTTG  
 GCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAC  
 65 CAATGGGCGTGATAGCGGTTTGACTCACGGGGATTCCAAGTCTCCACCCCATGACGT

CAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTG  
 CGATCGCCCCGCCCCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATA  
 AGCAGAGCTCGTTTGTAGTAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCAC  
 AGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGT  
 5 GACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCTGAGGCACTGGGCAGGTAAGTATCAA  
 GGTTACAAGACAGGTTTAAAGAGACCAATAGAAACTGGGCTTGTGAGACAGAGAAGACT  
 CTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCAC  
 AGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT  
 ATAGGCTAGAGAATTCCAGGTAAAGATGGGCGATCCCCCTCACCTGGTCCAAAGCCCTGAAG  
 10 AAAGTGGAAAAAGTCACCGTTCAGGGTAGCCAAAAGCTTACCACAGGCAATTGCAACTGG  
 GCATTGTCCCTGGTGGATCTTTTCCACGACACTAATTTCGTTAAGGAGAAAAGATTGGCAA  
 CTCAGAGACGTGATCCCCCTCTTGGAGGACGTGACCCAAACATTGTCTGGGCAGGAGCGC  
 GAAGCTTTCGAGCGCACCTGGTGGGCCATCAGCGCAGTCAAATGGGGCTGCAAATCAAC  
 AACGTGGTTGACGGTAAAGCTAGCTTTCAACTGCTCCGCGCTAAGTACGAGAAGAAAACC  
 15 GCCAACAAGAAAACAATCCGAACCTAGCGAGGAGTACCCAATTATGATCGACGGCGCCGGC  
 AATAGGAACCTCCGCCCCACTGACTCCAGGGGCTATACCACTGGGTCAACACACTCCAG  
 ACAACGGACTTTTGAACGAAGCCTCCAGAACCTGTTCCGGCATCTGTCTGTGGACTGC  
 ACCTCCGAAGAAATGAATGCTTTTCTCGACGTGGTGCCAGGACAGGCTGGACAGAAACAG  
 ATCCTGCTCGATGCCATTGACAAGATCGCCGACGACTGGGATAATCGCCACCCCCCTGCCA  
 20 AACGCCCCCTCTGGTGGCTCCCCACAGGGGCTATCCCTATGACCGCTAGGTTTATTAGG  
 GGACTGGGGGTGCCCCGCGAACGCCAGATGGAGCCAGCATTGACCAATTTAGGCGAGCC  
 TACAGACAGTGATCATCGAAGCCATGAGCGAGGGGATTAAAGTCATGATCGGAAGGCC  
 AAGGCACAGAACATCAGGCAGGGGGCCAAGGAACCATACCCTGAGTTTGTGACAGGCTT  
 CTGTCCCAGATTAATCCGAAGGCCACCCTCAGGAGATCTCCAAGTTCTTGACAGACACA  
 25 CTGACTATCCAAAATGCAAATGAAGAGTGCAGAAACGCCATGAGGCACCTCAGACCTGAA  
 GATACCCTGGAGGAGAAAATGTACGCATGTGCGGACATTGGCACTACCAAGCAAAAAGATG  
 ATGCTGCTCGCCAAGGCTCTGCAAAACCGGCTGGCTGGTCCATTCAAAGGAGGAGCACTG  
 AAGGGAGGTCCATTGAAAGCTGCACAAACATGTTATAATTGTGGGAAGCCAGGACATTTA  
 TCTAGTCAATGTAGAGCACCTAAAGTCTGTTTTAAATGTAAACAGCCTGGACATTTCTCA  
 30 AAGCAATGCAGAAGTGTTCCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGGCCCCAGAAA  
 CAAACTTTCCCGATACAACAGAAGAGTGACGACACAACAAATCTGTTGTACAAGAGACTCT  
 CAGACTCAAAATCTGTACCCAGATCTGAGCGAAATAAAAAAGGAATACAATGTCAAGGAG  
 AAGGATCAAGTAGAGGATCTCAACCTGGACAGTTTGTGGGAGTAACATACAATCTCGAGA  
 AGAGGCCCACTACCATCGTCTGATCAATGACACCCCTCTTAATGTGCTGCTGGACACCG  
 35 GAGCCGACACCAGCGTTCTCACTACTGCTCACTATAACAGACTGAAATACAGAGGAAGGA  
 AATACCAGGGCACAGGCATCATCGGCGTTGGAGGCAACGTCGAAACCTTTTCCACTCTG  
 TCACCATCAAAAAGAAGGGGAGACACATTAACAGGAATGCTGGTCCGCGCATCCCCG  
 TCACCATCCTTGGCAGAGACATTCTCCAGGACTGGGCGCTAAACTCGTGCTGGCACAAC  
 TGTCTAAGGAAATCAAGTTCCGCAAGATCGAGCTGAAAGAGGGGCACAATGGGTCCAAAAA  
 40 TCCCCCAGTGGCCCCCTGACCAAGAGAAAGCTTGAGGGCGCTAAGGAAATCGTGACGCGC  
 TGCTTTCTGAGGGCAAGATTAGCGAGGCCAGCGACAATAACCCCTTACAACAGCCCCATCT  
 TTGTGATTAAGAAAAGGAGCGGCAATGGAGACTCCTGCAGGACCTGAGGGAACCTCAACA  
 AGACCGTCCAGGTGCGAACTGAGATCTCTCGCGGACTGCCTACCCCCGGCGGCTGATTA  
 AATGCAAGCACATGACAGTCTTGACATTGGAGACGCTTATTTTACCATCCCCCTCGATC  
 45 CTGAATTTGCCCCCTATACTGCTTTTACCATCCCCAGCATCAATCACCAGGAGCCCCGATA  
 AACGCTATGTGTGGAAGTGCTCCCCCAGGGATTTGTGCTTAGCCCCCTACATTTACCAGA  
 AGACACTTCAAGAGATCCTCAACCTTTCCGCGAAAGATACCCAGAGGTTCAACTCTACC  
 ATATATGGACGACCTGTTTATGGGGTCCAACCGGTCTAAGAAAGCAGCACAAGGAACCTCA  
 50 TCATCGAACTGAGGGCAATCCTCCTGGAGAAAGGCTTCGAGACACCCGACGACAAGCTGC  
 AAGAAGTTCCTCCATATAGCTGGCTGGGCTACCAGCTTTGCCCTGAAAAGTGGAAAGTCC  
 AGAAGATGCAGTTGGATATGGTCAAGAACCACCACTGAACGACGTCCAGAAGCTCATGG  
 GCAATATTACCTGGATGAGCTCCGGAATCCCTGGGCTTACCGTTAAGCACATTGCCGCAA  
 CTACAAAAGGATGCCTGGAGTTGAACCAAGGTCATTGAGACAGAGGAAGCTCAGAAGG  
 55 AACTGGAGGAGAATAATGAAAAGATTAAGAATGCTCAAGGGCTCCAATACTACAATCCCCG  
 AAGAAGAAATGTTGTGCGAGGTCGAAATCACTAAGAAGTACGAAGCCACCTATGTCATCA  
 AACAGTCCCAAGGCATCTTGTGGGCGGAAAGAAAATCATGAAGGCCAACAAAGGCTGGT  
 CCACCGTTAAAAATCTGATGCTCCTGCTCCAGCACGTCGCCACCGAGTCTATCACCAGCG  
 TCGGCAAGTGCCCCACCTTCAAAGTTCCCTTCACTAAGGAGCAGGTGATGTGGGAGATGC  
 60 AAAAAAGGCTGGTACTACTCTTGGCTTCCCGAGATCGTCTACACCCACCAAGTGGTGCACG  
 ACGACTGGAGAATGAAGCTTGTGCGAGGAGCCCACTAGCGGAATTACAATCTATACCGACG  
 GCGGAAAGCAAAACGGAGAGGGAATCGCTGCATACGTCACTAACGGCCGACCAAGC  
 AAAAGAGGCTCGGCCCTGTCACTCACCAGGTGGCTGAGAGGATGGCTATCCAGATGGCCC  
 TTGAGGACACTAGAGACAAGCAGGTGAACATTGTGACTGACAGCTACTACTGTGGA  
 65 ATATCCGCGAAAAGGAAATTTGTCTATTTGCGCTGGGTGGCTGGACACAAGGAATTTACG  
 GCAACCAACTCGCCGATGAAGCCGCCAAAATTAAGAGGAAATCATGCTTGCCTACCAGG

GCACACAGATTAAGGAGAAGAGAGACGAGGACGCTGGCTTTGACCTGTGTGTGCCATACG  
ACATCATGATTCCCGTTAGCGACACAAAAGATCATTCCAACCGATGTCAAGATCCAGGTGC  
CACCCAATTTCATTTGGTTGGGTGACCGGAAAGTCCAGCATGGCTAAGCAGGGTCTTCTGA  
5 TTAACGGGGGAATCATTGATGAAGGATACACCGGCGAAATCCAGGTGATCTGCACAAATA  
TCGGCAAAAGCAATATTAAGCTTATCGAAGGGCAGAAAGTTCGCTCAACTCATCATCTCTCC  
AGCACCACAGCAATTCAAGACAACCTTGGGACGAAAACAAGATTAGCCAGAGAGGTGACA  
AGGGCTTCGGCAGCACAGGTGTGTTCTGGGTGGAGAACATCCAGGAAGCACAGGACGAGC  
ACGAGAATTGGCACACCTCCCCTAAGATTTTGGCCCGCAATTACAAGATCCCCTGACTG  
10 TGGCTAAGCAGATCACACAGGAATGCCCCACTGCACCAAAACAAGGTTCTGGCCCCGCCG  
GCTGCGTGATGAGGTCCCCCAATCACTGGCAGGCAGATTGCACCCACCTCGACAACAAAA  
TTATCCTGACCTTCGTGGAGAGCAATTCCGGCTACATCCACGCAACACTCCTCTCCAAGG  
AAAATGCATTGTGACCTCCCTCGCAATTCTGGAATGGGCCAGGCTGTTCTCTCCAAAT  
CCCTGCACACCGACAACGGCACCAACTTTGTGGCTGAACCTGTGGTGAATCTGCTGAAGT  
15 TCCTGAAAATCGCCACACCACTGGCATTCCCTATCACCTGAAAAGCCAGGGCATTGTCTG  
AGAGGGCCAACAGAACTCTGAAAGAAAAGATCCAATCTCACAGAGACAATACACAGACAT  
TGGAGGGCCGCACTTCAGCTCGCCCTTATCACCTGCAACAAAGGAAGAGAAAGCATGGGCG  
GCCAGACCCCTGGGAGGTCTTCATCACTAACAGGCCAGGTCATCCATGAAAAGCTGC  
TCTTGCAGCAGGCCAGTCCCTCCAAGTTCTGCTTTTATAAGATCCCCGGTGAGCAG  
20 ACTGGAAGGTCCTACAAGAGTTTGTGGAAAGGAGACGGCGCAGTTGTGGTGAACGATG  
AGGGCAAGGGGATCATCGCTGTGCCCTGACACGCACCAAGCTTCTCATCAAGCCAACT  
GAACCCGGGGCGGCCGCTTCCCTTATGTAGGGGTTAATGCTTCGAGCAGACATGATAAG  
TACATTGTAGTGTGGACAAACCACAACCTAGAAATGCAGTGAAAAAATGCTTTATTTGT  
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAACAAGTTAAC  
25 AACAACAATTGCATTTCATTTATGTTTCAGGTTTCAGGGGGAGATGTGGGAGGTTTTTAA  
AGCAAGTAAAACCTCTACAAATGTGGTAAAATCCGATAAGGATCGATCCGGGCTGGCGTA  
ATAGCGAAGAGGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAAT  
GGACGCGCCCTGTAGCGGCGCATTAAAGCGCGGGGTGTGGTGGTTACGCGCAGCGTGAC  
CGCTACACTTGCAGCGCCCTAGCGCCCGCTCCTTTCTGCTTTCTTCCCTTCTTTCTCGC  
30 CACGTTTCGGCGCTTTCCCGCTCAAGCTCTAAATCGGGGGCTCCCTTAGGGTTCGGATT  
TAGAGCTTTACGGCACCTCGACCGCAAAAACTTGATTTGGGTGATGGTTCACGTAGTGG  
GCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAG  
TGGACTCTTGTTCAAACTGGAACAACACTCAACCTATCTCGTCTATTCTTTGATTT  
ATAAGGGATTTTGGCGATTTTCGGCTATTGGTTAAAAAATGAGCTGATTTAACAATATT  
35 TAACGCGAATTTTAAACAAAATATTAACGTTTACAATTTTCGCTGATGCGGTATTTTCTCC  
TTACGCATCTGTGCGGTATTTACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGA  
AATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTG  
GAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCA  
AAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGG  
CAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCC  
40 GCCCATCCCGCCCTAACTCCGCCAGTTCCGCCATTCTCCGCCCATGGCTGACTAAT  
TTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCCTGTAGCTATTCAGAAGTAGTG  
AGGAGGCTTTTTTGGAGGCCTAGGCTTTTGA AAAAGCTTGATTCTTCTGACACAACAGT  
CTCGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCG  
GCCGATTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCT  
45 GATGCCGCGGTGTTCCGGCTGTACGCGCAGGGGCGCCCGTTCTTTTGTCAAGACCGAC  
CTGTCCGGTGCCCTGAATGAAGTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACG  
ACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTG  
CTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCTATCTACCTTGCTCCTGCCGAGAAA  
GTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCA  
50 TTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTT  
GTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTTCGCC  
AGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCTGACCCATGGCGATGCCTGC  
TTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCGACTGTGGCCGGCTG  
GGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGCTGATATTGCTGAAGAGCTT  
55 GCGGCGAATGGGCTGACCGCTTCTCGTGTCTTACGGTATCGCCGCTCCCGATTTCGCAG  
CGCATCGCTTCTATCGCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTTCGAAA  
TGACCGACCAAGCGACGCCAACCTGCCATCACGATGGCCGCAATAAAAAATCTTTATTT  
TCATTACATCTGTGTGTTGGTTTTTGTGTGAATCGATAGCGATAAGGATCCGCGTATGG  
TGCATCTCAGTACAATCTGCTCTGATGCGCATAGTTAAGCCAGCCCCGACACCCGCCA  
60 ACACCCGCTGACGCGCCCTGACGGGCTTCTGCTCTCCCGGCATCCGCTTACAGACAAGCT  
GTGACCGTCTCCGGGAGCTGCATGTGTACAGAGTTTTCACCGTCATACCGAAACGCGCG  
AGACGAAAGGGCCTCGTGATACGCTATTTTTATAGGTTAATGTCATGATAATAATGGTT  
TCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTATTT  
TTCTAAATACATTCAAATATGTATCGCTCATGAGACAATAACCTGATAAATGCTTCAA  
65 TAATATTGAAAAAGGAAGAGTATGAGATTCAACATTTCCGTGTGCGCCCTTATTCCTTT  
TTTGGCGCATTTTGCCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGAT

GCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAG  
 ATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTG  
 CTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA  
 CACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTCACAGAAAAGCATCTTACGGAT  
 5 GGCATGACAGTAAGAGAATTATGCAAGTGTGCCATAACCATGAGTGATAAACTGCGGCC  
 AACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG  
 GGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAAC  
 GACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAC  
 GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAA  
 10 GTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTATTGCTGATAAATCT  
 GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC  
 TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA  
 CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTAC  
 TCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAAAGGATCTAGGTGAAG  
 15 ATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCG  
 TCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATC  
 TGCTGCTTGCAAAACAAAAAACACCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAG  
 CTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTC  
 CTTCTAGTGTAGCCGTAGTTAGGCCACCACTCAAGAACTCTGTAGCACCGCCTACATAC  
 20 CTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGCTTACC  
 GGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGT  
 TCGTGACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGT  
 GAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGC  
 GGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCTGGTATCTT  
 25 TATAGTCCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCA  
 GGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGCCCTTTTTACGGTTCCTGGCCTTT  
 TGCTGGCCTTTTGCTCACATGGCTCGACAGATCT

### MLV construct CZCG (SEQ ID No 55)

GTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTGCGATGGCCGCGAGACGGCACC  
 TTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTACCTGGCCCGCATGGA  
 CACCCAGACCAGGTCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCC  
 TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCTCCATCCGCCCCGTCT  
 CTCCCCCTTGAACCTCCTCGTTGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
 35 CCTTCTCTAGGCGCCGGAATTTCGTTAACTCGAGAGGCCTGCCACCATGGGGACTGCTCCA  
 AAGAAGAAGCGTAAGGTAGTCGTTTTACAACGTGCTGACTGGGAAAACCCCTGGCGTTACC  
 CAACTTAATCGCCTTGACGACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCC  
 CGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGG  
 TTTCCGGCACCAGAAGCGGTGCCGGAAGCTGGCTGGAGTGCGATCTTCTGAGGCCGAT  
 40 ACTGTCGTGCTCCCCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAAC  
 GTAACCTATCCCATTACGGTCAATCCGCCGTTTGTTCACGAGGAATCCGACGGGTTGT  
 TACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATT  
 TTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTGCGTTACGGC  
 CAGGACAGTCGTTTGGCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGAGAAAAC  
 45 CGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATG  
 TGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATC  
 AGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTACGCCGCGCTGTACTGGAGGCT  
 GAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAG  
 GGTGAAACGCGAGGTGCGCAGCGGCACCGCGCCTTTCGCGCGGTGAAATTATCGATGAGCGT  
 50 GGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTGAAAACCCGAACTGTGGAGC  
 GCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACGGCACGCTG  
 ATTGAAGCAGAAGCCTGCGATGTGCGTTTCCGCGAGGTGCGGATTGAAAATGGTCTGCTG  
 CTGCTGAACGGCAAGCCGTTGCTGATTTCGAGGCGTTAACCGTCACGAGCATCATCCTCTG  
 CATGGTCAGGTATGGATGAGCAGACGATGGTGACAGGATATCCTGCTGATGAAGCAGAAC  
 55 AACTTTAACGCCGTGCGCTGTTTCGCATTATCCGAACCATCCGCTGTGGTACACGCTGTGC  
 GACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCA  
 ATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGA  
 ATGGTGACGCGCATCGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATCA  
 GGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTGATCCTTCCCGC



CCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATTTGCCCGATG  
TACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAA  
TGGCTTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATG  
GGTAACAGTCTTGGCGGTTTTCGCTAAATACTGGCAGGCGTTTTCGTCAGTATCCCCGTTTA  
5 CAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGC  
AACCCGTGGTTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGT  
ATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACAC  
CAGCAGCAGTTTTTCCAGTTCGGTTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATAC  
10 CTGTTCCGTCATAGCGATAACGAGCTCCTGCCTGGATGGTGGCGCTGGATGGTAAGCCG  
CTGGCAAGCGGTGAAGTGCCCTCTGGATGTCGCTCCACAAGGTAACAGTTGATTGAACTG  
CCTGAACCTACCGCAGCCGGAGAGCGCCGGCAACTCTGGCTCACAGTACGCGTAGTGCAA  
CCGAACGCGACCGCATGGTCAAGAGCCGGGCACATCAGCGCTGGCAGCAGTGGCGTCTG  
GCGGAAAACCTCAGTGTGACGCTCCCCGCGCGTCCCACGCCATCCCGCATCTGACCACC  
AGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCA  
15 GGCTTTCTTTACAGATGTGGATTGGCGATAAAAAACAACCTGCTGACGCCGCTGCGCGAT  
CAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGAC  
CCTAACGCCTGGGTCAACGCTGGAAGGCGGCGGCCATTACCAGGCCGAAGCAGCGTTG  
TTGCAGTGCACGGCAGATACTTGTGTGATGCGGTGCTGATTACGACCGCTCAGCGTGG  
CAGCATCAGGGGAAAACCTTATTTATCAGCCCGGAAAACCTACCGGATTGATGGTAGTGGT  
20 CAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATT  
GGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAACTGGCTCGGATTAGGGCCG  
CAAGAAAATATCCCGACCGCCTTACTGCCGCTGTTTTGACCGCTGGGATCTGCCATTG  
TCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGC  
GAATTGAATTATGGCCACACCACTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTAC  
25 AGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACA  
TGGCTGAATATCGACGGTTTTCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCA  
GTATCGGCGGAATTCCAGCTGAGCGCCGGTTCGCTACCATTACCAGTTGGTCTGGTGTCAA  
AAATAATAATAACCGGGCAGGGGGGATCCGCGAGATCCGGCTGTGGAATGTGTGTGAGTTA  
GGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCCTGCAGGA  
30 GTGGGGAGGCACGATGGCCGCTTTGGTTCGAGGCGGATCCGGCCATTAGCCATATTATTC  
TTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATC  
ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTAT  
TGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGT  
TCCGCGTTACATAAATTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCC  
35 CATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC  
GTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATA  
TGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCC  
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA  
TTACCATGGTGTATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCAC  
40 GGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATC  
AACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTTAGTGAACCGTCAGATCGCCTGGA  
GACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCG  
GCCCCAAGCTTGTGGGATCCACCGGTGCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT  
45 CACCGGGGTGGTGGCCATCCTGGTTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTTCAG  
CGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCTGAAGTTCATCTG  
CACCACCGGCAAGCTGCCCGTGCCCTGGCCACCTCGTGACCACCTGACCTACGGCGT  
GCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTTCTCAAGTCCGCCAT  
GCCCCAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGAC  
50 CCGCGCCGAGGTGAAGTTGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCAT  
CGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACATAACAGCCA  
CAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACCTCAAGATCCG  
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCAT  
CGGCGACGGCCCCGTGCTGCTGCCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAG  
55 CAAAGACCCCAACGAGAAGCGGATACATGGTCTGCTGGAGTTCTGACCGCCGCGCGG  
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCGCGACTCTAGATCATAATC  
AGCCATAACCATTTGTAGAGTTTTACTTGCTTTAAAAAACCTCCACACCTCCCCCTG  
AACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACATCGATAAAATAAAGATTTT  
ATTTAGTCTCCAGAAAAGGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGC  
60 TTAAGTAACGCCATTTTGAAGGCATGGAAAAATACATAACTGAGAATAGAGAAGTTTCAG

ATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAG  
CAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAG  
GATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGAT  
GCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGA  
5 CCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTC  
GCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGCGCCAG  
TCCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAATAAACCCCTCTTGCAGTTGC  
ATCCGACTTGTGGTCTCGCTGTTCCCTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGT  
CAGCGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCAGGGACCA  
10 CCGACCCACCACCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTA  
GTGTCTATGACTGATTTTATGCGCCTGCGTCCGGTACTAGTTAGCTAACTAGCTCTGTATC  
TGGCGGACCCGTGGTGGAAGTACGAGTTCCGAACACCCGGCCGCAACCCCTGGGAGAGGA  
ATTCTCATGTTTGACAGCTTATCATCGATAAGCTTTTTGCAAAAGCCTAGGCCTCCAAAA  
AAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGGCCTCTGCATAA  
15 AAAAAAAAAATAGTCAGCCATGGGGCGGAGAATGGGCGGAAGTGGGCGGAGTTAGGGGC  
GGGATGGGCGGAGTTAGGGGCGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTGC  
ATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGA  
TGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGA  
CACACATTCCACAGCCGATCCTCTACGCCGACGCATCGTGGCCGGCATCACCGGCGCC  
20 ACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGC  
CACTTCGGGCTCATGAGCGCTTGTTCGCGCTGGGTATGGTGGCAGGCCCGCTGGCCGGG  
GGACTGTTGGGCGCCATCTCCTTGATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGC  
CTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCG  
ATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATC  
25 GTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCG  
CTCTGGGTATCTTTCCGCGAGGACCCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCTG  
CTTGCGGTATTCGGAATCTTGACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACC  
AAACGTTTCGCGCAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTAC  
GTCTTGCTGGCGTTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCT  
30 TCCGGCGGCATCGGGATGCCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGAC  
CATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGA  
CCGCTGATCGTCACGGCGATTTATGCCGCCCTCGGCGAGCACATGGAACGGGTTGGCATGG  
ATTGTAGGCGCGCCCTATACCTTGCTGCTCCCGCGGTTGCGTTCGCGTGCAGTGCATGGAGC  
CGGGCCACCTCGACCTGAATGGAAGCCGCGGCACCTCGCTAACGGATTCAACCACTCCAA  
35 GAATTGGAGCCAATCAATTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCCTTGGCAGA  
ACATATCCATCGCGTCCGCCATCTCCAGCAGCCGACGCGGCGCATCTCGGGCAGCGTTG  
GGTCTTGCCACGGGTGCGCATGATCGTGTCTCTGTGTTGAGGACCCGGCTAGGCTGGC  
GGGGTTGCCTTACTGGTTAGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACT  
GCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCCGGTTTCCGTGTTT  
40 CGTAAAGTCTGGAACCGGAAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCG  
CAGGATGCTGCTGGCTACCCGTGGAACACCTACATCTGTATTAACGAAGCGCTGGCATT  
GACCCTGAGTGATTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCAC  
AACGTTCCAGTAACCGGGCATGTTTCATCATCAGTAACCCGTATCGTGAGCATCCTCTCTC  
GTTTCATCGGTATCATTACCCCCATGAACAGAAATTCCCCCTTACACGGAGGCATCAAGT  
45 GACCAAACAGGAAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAAC  
GCTTCTGGAGAACTCAACGAGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCT  
TCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGA  
AAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGG  
GAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGGGGCGCAGCCAT  
50 GACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAG  
ATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAA  
TACCGCATCAGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTGCTTCGG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG  
55 GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGA  
CGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTTCCCCCT  
GGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCC  
TTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCG  
GTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCCGACCGC  
60 TGCGCCTTATCCGGTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCA

CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAG  
TTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAAGGACAGTATTTGGTATCTGCGCT  
CTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACC  
ACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGA  
5 TCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGAACGAAAACCTCA  
CGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAAT  
TAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTAC  
CAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCTGTTTCATCCATAGTT  
GCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGT  
10 GCTGCAATGATACCGCGAGACCCACGCTCACC GGCTCCAGATTTATCAGCAATAAACCAG  
CCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCCTCCATCCAGTCT  
ATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCCGCCAGTTAATAGTTTGGCGAACGTT  
GTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTACGC  
TCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTT  
15 AGCTCCTTCGGTCTCCGATCGTCTGTTGTGAGAAGTAAGTTGGCCGCGAGTGTATCACTC  
ATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGTAAGATGCTTTTCT  
GTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGC  
TCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTC  
ATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCAGTGTGAGATCC  
20 AGTTTCGATGTAAACCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTTACCAGC  
GTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA  
CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTATCAGGGT  
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAATAGGGGTT  
CCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTTATTCATGACA  
25 TTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGAC  
GGTGAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGAT  
GCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGCGGGCTGG  
CTTAATCTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATCGACGCTCTCCCT  
TATGCGACTCCTGCATTAGGAAGCAGCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCG  
30 CCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTG  
CCACCATACCACGCGCAACAAGCGCTCATGAGCCCAAGTGGCGAGCCCGATCTTCCC  
CATCGGTGATGTGCGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGG  
CCACGATGCGTCCGGCGTAGAGGATCTGGCTAGCGATGACCCGTGCTGATTGGTTCGCTGA  
CCATTTCCGGGGTGCGGAACGGCGTTACCAGAACTCAGAAGGTTTCGTCCAACCAACCG  
35 ACTCTGACGGCAGTTTACGAGAGAGATGATAGGGTCTGCTTCAGTAAGCCAGATGCTACA  
CAATTAGGCTTGTACATATTGTCTGTAGAACGCGGCTACAATTAATACATAACCTTATGT  
ATCATACACATACGATTTAGGTGACACTATAGAATACAAGCTGGAAGATCTTCCAGCTTG  
GGCTGCAGGTGACTCTAGAGTCCGTTACATAAATACGTTAAATGGCCCGCTGGCTGA  
CCGCCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA  
40 ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCCTTGCCA  
GTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG  
CCCGCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTACATC  
TACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGT  
GGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGT  
45 TTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTG  
ACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTG  
AACCGCGCAGTCTTCCGATAGACTGCGTCGCCCGGGTACCCGTATTCCCAATAAAGCCT  
CTTGCTGTTTGCATCCGAATCGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTCTGAGTGA  
TTGACTACCCACGACGGGGTCTTTTCAATTTGGGGGCTCGTCCGGGATTTGGAGACCCCTG  
50 CCCAGGGACCACCGACCCACCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGT  
CCGATTGTCTAGTGTCTATGTTTGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACT  
AGCTCTGTATCTGGCGGACCCGTGGTGGAAGTACGAGTTCTGAACACCCGGCCGCAACC  
CTGGGAGACGTCCCAGGGACTTTGGGGGGCGTTTTTGTGGCCCGACCTGAGGAAGGGAGT  
CGATGTGGAATCCGACCCCGTCAGGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAAC  
55 AGTTCCCGCCTCCGTCTGAATTTTGTCTTTCGGTTTGGAAACCGAAGCCGCGCTCTGTG  
TGCTGCAGCGCTGCAGCATCGTCTGTGTTGTCTCTGTCTGACTGTGTTTCTGTATTTGT  
CTGAAAATTAGGGCCAGACTGTTACCACTCCCTTAAGTTTGACCTTAGGTCACTGGAAAG  
ATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGG

GTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCGCGAGACGGCACC  
TTTAACCGAGACCTCATCACCCAGGTAAAGATCAAGGTCTTTTCACCTGGCCCCGATGGA  
CACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCC  
5 TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCCCTCCATCCGCCCCGTCT  
CTCCCCCTTGAACCTCCTCGTTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
CCTTCTCTAGGCGCCGGAATTCGTTAACTCGAGAGGCCTGCCACCATGGGGACTGCTCCA  
AAGAAGAAGCGTAAGGTAGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACC  
CAACTTAATCGCCTTGCAGCACATCCCCCTTTCCGCCAGCTGGCGTAATAGCGAAGAGGCC  
10 CGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGG  
TTTCCGGCACCGAAGCGGTGCCGGAAGCTGGCTGGAGTGCGATCTTCTGAGGCCGAT  
ACTGTGCTCGTCCCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAAC  
GTAACCTATCCCATTACGGTCAATCCGCCGTTTGTTCACGGAGAATCCGACGGGTGTGT  
TACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATT  
15 TTTGATGGCGTTAACTCGGCGTTTTCATCTGTGGTGCAACGGGCGCTGGGTTCGGTTACGGC  
CAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTACGCGCCGGAGAAAAC  
CGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATG  
TGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATC  
AGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTTACGCCGCGCTGTACTGGAGGCT  
20 GAAGTTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAG  
GGTGAAACGCAGGTCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGT  
GGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGC  
GCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACGGCACGCTG  
ATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGAAAATGGTCTGCTG  
25 CTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCATCATCCTCTG  
CATGGTCAGGTCATGGATGAGCAGACGATGGTGCAAGGATATCCTGCTGATGAAGCAGAAC  
AACTTTAACGCCGTGCGCTGTTTCGCATTATCCGAACCATCCGCTGTGGTACACGCTGTGC  
GACCGCTACGGCTGTATGTGGTGATGAAGCCAATATTGAAACCCACGGCATGGTGCCA  
ATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGA  
30 ATGGTGCAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATCA  
GGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTGATCCTTCCCGC  
CCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATTTGCCCGATG  
TACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAA  
TGGCTTTTCGCTACCTGGAGAGACCGCCCCGCTGATCCTTTGCGAATACGCCCCACGGCATG  
35 GGTAACAGTCTTGGCGGTTTTCGCTAAATACTGGCAGGCGTTTTCGTAGTATCCCCGTTTA  
CAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGC  
AACCCTGGTTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGT  
ATGAACGGTCTGGTCTTTGCCGACCGCACGCCGATCCAGCGCTGACGGAAGCAAAACAC  
CAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATAC  
40 CTGTTCCGTATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCG  
CTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTAAACAGTTGATTGAACTG  
CCTGAACTACCGCAGCCGAGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAA  
CCGAACGCGACCGCATGGTTCAGAAGCCGGGCACATCAGCGCCTGGCAGCAGTGGCGTCTG  
GCGGAAAACCTCAGTGTGACGCTCCCCGCGCGTCCCACGCCATCCCGCATCTGACCACC  
45 AGCGAAATGGATTTTTCATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCA  
GGCTTTCTTTACAGATGTGGATTGGCGATAAAAAACAACCTGCTGACGCCGCTGCGCGAT  
CAGTTTACCCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGAC  
CCTAACGCTGGGTGCAACGCTGGAAGGCGGCGGCCATTACCAGGCCGAAGCAGCGTTG  
TTGCAGTGCACGGCAGATACACTTGTGATGCGGTGCTGATTACGACCGCTCACGCGTGG  
50 CAGCATCAGGGGAAAACCTTATTTATCAGCCGGAAAACCTACCGGATTGATGGTAGTGGT  
CAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATT  
GGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCG  
CAAGAAAATATCCCCGACCGCTTACTGCCGCTGTTTTGACCGCTGGGATCTGCCATTG  
TCAGACATGTATACCCCGTACGTCTTCCGAGCGAAAACGGTCTGCGCTGCGGACGCGC  
55 GAATTGAATTATGGCCACACCACTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTAC  
AGTCAACAGCAACTGATGGAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACA  
TGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCA  
GTATCGGCGGAATTCCAGCTGAGCGCCGGTCTGCTACCATACCAGTTGGTCTGGTGTCAA  
AAATAATAATAACCGGGCAGGGGGGATCCGAGATCCGGCTGTGGAATGTGTGTCAGTTA  
60 GGGTGTGGAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCCTGCAGGA

GTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCATTAGCCATATTATTCA  
TTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATC  
ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTAT  
TGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGT  
5 TCCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCC  
CATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC  
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCCTTGGCAGTACATCAAGTGTATCATA  
TGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCC  
AGTACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA  
10 TTACCATGGTGTATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTTGACTCAC  
GGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATC  
AACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGA  
GACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCG  
15 GCCCCAAGCTTGTGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT  
CACCGGGGTGGTGCCCATCCTGGTTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAG  
CGTGTCGGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTG  
CACCACCGGCAAGCTGCCCGTGCCCTGGCCACCCTCGTGACCACCCTGACCTACGGCGT  
GCAGTGCTTCAGCCGCTACCCCGACCATGAAGCAGCAGACTTCTTCAAGTCCGCCAT  
20 GCCCGAAGGTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGAC  
CCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCAT  
CGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACACAAGCCA  
CAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACCTCAAGATCCG  
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCCTACCAGCAGAACACCCCCAT  
25 CGGCGACGGCCCCGTGCTGCTGCCCGACAACCCTACCTGAGCACCCAGTCCGCCCTGAG  
CAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCTGTGACCGCCCGCG  
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGCCGCGACTCTAGATCATAATC  
AGCCATACCACATTTGTAGAGGTTTTACTTGTCTTAAAAAACCTCCCACACCTCCCCCTG  
AACCTGAAACATAAAAATGAATGCAATTGTTGTTGTTAACATCGATAAAAATAAAGATTTT  
30 ATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGC  
ATAACTTCGTATAATGTATGCTATACGAAGTTATTCTAGAGAACCATCAGATGTTTCCAG  
GGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTT  
CTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCA  
CTCGGGGCGCCAGTCCCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAATAAAC  
35 CTCTTGCAAGTTGCATCCGACTTGTGGTCTCGCTGTTTCTTGGGAGGGTCTCCTCTGAGTG  
ATTGACTACCCGTACGCGGGGTCTTTTCAATTTGGGGGCTCGTCCGGGATCGGGAGACCCC  
TGCCAGGGACCACCGACCCACCGGGAGGTAAGCTGGCTGCCTCGCGCGTTTTCGGTG  
ATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAG  
CGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTCCGG  
40 GCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACCTATGCGGC  
ATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGT  
AAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCTCTCGCTCACTGACTCGCTGCGCTC  
GGTCGTTTCGGTGCAGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCAC  
AGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAA  
45 CCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCA  
CAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCGACAGGACTATAAAGATACCAGGC  
GTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATA  
CCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCAGCTGTAGGTA  
TCTCAGTTCCGTGTAGGTGTTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCA  
50 GCCCGACCGCTGCGCCTTATCCGGTAACCTATCGTCTTGAGTCCAACCCGGTAAGACACGA  
CTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGG  
TGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTGG  
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGG  
CAACAAACCACCGCTGGTAGCGGTGGTTTTTTGTTTGGCAAGCAGAGATTACGCGCAG  
55 AAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAA  
CGAAAACCTCAGTTAAGGGATTTTGGTTCATGAGATTATCAAAAAGGATCTTACCTAGAT  
CCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTC  
TGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTT  
ATCCATAGTTGCCTGACTCCCCGTGCTGTAGATAACTACGATACGGGAGGGCTTACCATC  
60 TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGC

5 AATAAACCCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTC  
CATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTT  
GCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGC  
TTCATTACAGCTCCGGTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAA  
10 AAAAGCGGTTAGCTCCTTCGGTCCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTT  
ATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGTAAGATG  
CTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACC  
GAGTTGCTCTTGCCCGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAA  
AGTGCTCATCATTGGAACGTTCTTCGGGGCGAAACTCTCAAGGATCTTACCGCTGTT  
15 GAGATCCAGTTCGATGTAACCCACTCGTGACCCCACTGATCTTCAGCATCTTTTACTTT  
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAG  
GGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTTA  
TCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAAT  
AGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTTATTAT  
20 CATGACATTAACTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTCAT  
ACCAGATCACCGAAAACGTCTCTCCAAATGTGTCCCCCTCACACTCCCAAATTCGCGGGC  
TTCTGCCTCTTAGACCACTCTACCCTATTCCCCACACTCACCGGAGCCAAAGCCGCGGCC  
CTTCCGTTTCTTTGCTTTTGAAGACCCACCCGTAGGTGGCAAGCTAGCGATGACCCTG  
CTGATTGGTTCGCTGACATTTCCGGGGTGCGGAACGGCGTTACCAGAACTCAGAAGGT  
25 TCGTCCAACCAAACCGACTCTGACGGCAGTTTACGAGAGAGATGATAGGGTCTGCTTCAG  
TAAGCCAGATGCTACACAATTAGGCTTGTACATATTGTCTGTAGAACGCGGCTACAATTA  
ATACATAACCTTATGTATCATACACATACGATTTAGGTGACACTATAGAATACAAGCTGG  
AAGATCTTCCAGCTTGGGCTGCAGGTCGACTCTAGAGTCCGTTACATAACTTACGGTAAA  
TGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGT  
30 TCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTA  
AACTGCCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGT  
CAATGACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCC  
TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCA  
GTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCAT  
35 TGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCTGTAA  
CAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAG  
CAGAGCTCGTTTAGTGAACCGCGCCAGTCTTCCGATAGACTGCGTCGCCCCGGGTACCCGT  
ATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGTCTCGCTGTTCTTTGGGAG  
GGTCTCCTCTGAGTGATTGACTACCCACGACGGGGGTCTTTCATTTGGGGGCTCGTCCGG  
40 GATTTGGAGACCCCTGCCCAGGGACCACCGACCCACCACCGGGAGGTAAGCTGGCCAGCA  
ACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGTTTGTATGTTATGCGCCTGCGCTGT  
TACTAGTTAGCTAAGTCTGTATCTGGCGGACCCGTGGTGGAAGTACGAGTTCTGA  
ACACCCGGCCGCAACCCTGGGAGACGTCCCAGGGACTTTGGGGGCGGTTTTTGTGGCCCCG  
ACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTCAGGATATGTGGTTCTGGTAGGA  
45 GACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGCTTTTCGGTTTGGAAACCGA  
AGCCGCGCGTCTTGTCTGCTGCAGCGCTGCAGCATCGTTCTGTGTTGTCTCTGTCTGACT  
GTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGTTACCACTCCCTTAAGTTTGACC  
TTAGGTCACTGGAAGATGTGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAG  
AGACGTTGG

45 **PCGCLNGFR (SEQ ID No 57)**

50 GTTACCTTCTGCTCTGCAGAATGGCCAACTTTAACGTTCGGATGGCCGCGAGACGGCACC  
TTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTACCTGGCCCCGATGGA  
CACCCAGACAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCC  
TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCTCCATCCGCCCCGTCT  
CTCCCCCTTGAACCTCCTCGTTGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
CCTTCTCTAGGCGCCGGAATTTCGTTAACTCGAGGATCCACCGGTGCGCCACCATGGTGAGC  
AAGGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTA  
55 AACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTG  
ACCCTGAAGTTTCACTGCAACACCGCAAGCTGCCCGTGCCCTGGCCACCCCTCGTGACC  
ACCCTGACCTACGGCGTGCAGTGCTTACGCCGTACCCCGACCATGAAGCAGCACGAC  
TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGACCATCTTCTCAAGGAC  
GACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGC  
60 ATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAG

TACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAG  
GTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC  
CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGC  
ACCCAGTCCGCCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAG  
5 TTCGTGACCGCCGCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCCT  
AGGGGTCTTTCCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCA  
GTTCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGG  
AACCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACCGAGTTGGTTACAGCTGC  
TGCTGAGGCTGGACGACCTCGCGGAGTTCTACCGGCAGTGCAAATCCGTGCGCATCCAG  
10 GAAACCAGCAGCGGCTATCCGCGCATCCATGCCCCGAACTGCAGGAGTGGGGAGGCACG  
ATGGCCGCTTTGGTTCGAGGCGGATCCGGCCATTAGCCATATTATTTCATTGGTTATATAGC  
ATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACAT  
TTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTA  
ATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGTTCGCGCTTACATA  
15 ACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAAT  
AATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGA  
GTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCC  
CCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTT  
ATGGGACTTTTCTACTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTC  
20 CGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTC  
TCTCCACCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCC  
AAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCATGTACGGTGGGA  
GGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACG  
CTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTAC  
25 CATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCGCGCCTGCTGCTGTTGCTGCT  
TCTGGGGGTGTCCCTTGGAGGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACACACAG  
CGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTTGTGGAGCCAA  
CCAGACCGTGCTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGAC  
CGAGCCGTGCAAGCCGTGCACCGAGTGCCTGGGGCTCCAGAGCATGTGCGCGCCGTGCGT  
30 GGAGGCCGACGACGCCGTGTGCCGCTGCGCCTACGGCTACTACCAGGATGAGACGACTGG  
GCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTTCTCCTGCCAGGA  
CAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACC  
CGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTG  
CACACGCTGGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCAC  
35 ACCCCAGAGGGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGA  
ACAAGACCTCATAGCCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCCA  
GCCCCGTGGTGACCCGAGGCACCGACCACTCATCCCTGTCTATTGCTCCATCCTGGC  
TGCTGTGGTTGTGGGCCTTGTGGCCTACATAGCCTTCAAGAGGTGGAACAGCTGCTGAGT  
CGACTCTAGAGGATCCCCAACATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAA  
40 GGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTG  
CAAGGCATGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTCAGGAACAGA  
TGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTC  
AGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAG  
TTCTTCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCA  
45 GTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGC  
CTTATTTGAATAACCAATCAGTTTCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCG  
AGCTCAATAAAAGAGCCCAACAACCCCTCACTCGGGGCGCCAGTCTCCGATTGACTGAGT  
CGCCCCGGGTACCCGTGTATCCAATAAACCCCTCTTGACGTTGCATCCGACTTGTGGTCTCG  
CTGTTCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGTCAGCGGGGTCTTTTATT  
50 TGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCCAGGGACCACCGACCCACCACGGGAG  
GTAAGCTGGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCT  
CCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGG  
CGCGTCAGCGGGTGTGGCGGGTGTGCGGGCGCAGCCATGACCCAGTCACGTAGCGATAG  
CGGAGTGTATACTGGCTTAACATATGCGGCATCAGAGCAGATTGTACTGAGAGTGACCAT  
55 ATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCC  
GCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGCGGCTGCGGCGAGCGGTATCAGCT  
CACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAGAACATG  
TGAGCAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTC  
CATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGA  
60 AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT



CCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTCTCCCTTCGGGAAGCGTG  
GCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAG  
CTGGGCTGTGTGCACGAACCCCCGTTACGCCCCGACCGCTGCGCCTTATCCGGTAACTAT  
CGTCTTGAGTCCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC  
5 AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAAC  
TACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTC  
GGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTT  
TTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATC  
TTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACTCAGTTAAGGGATTTTGGTCATG  
10 AGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA  
ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCA  
CCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAG  
ATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAC  
CCACGCTCACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGC  
15 AGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT  
AGAGTAAGTAGTTCCGCGAGTTAATAGTTTGGCGAACGTTGTTGCCATTGCTGCAGGCATC  
GTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTAGCTCCGGTTCCTCAACGATCAAGG  
CGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC  
GTTGTGCAAGTAAGTTGGCCGAGTGTATCATTACTCATGGTTATGGCAGCACTGCATAAT  
20 TCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG  
TCATTCTGAGAATAGTGATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGAT  
AATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGG  
CGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCA  
CCCAACTGATCTTCAGCATCTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGGA  
25 AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTC  
TTCCTTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACATA  
TTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTG  
CCACCTGACGTCTAAGAAACATTATTATCATGACATTAACCTATAAAAAATAGGCGTATC  
ACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAG  
30 CTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAG  
GGCGCGTCAGCGGGTGTGGCGGGTGTGGGGCTGGCTTAACCTATGCGGCATCAGAGCAG  
ATTGTACTGAGAGTGCACCATATGGACATATTGTCTGTTAGAACGCGGCTACAATTAATAC  
ATAACCTTATGTATCATACACATACGATTTAGGTGACACTATAGAACTCGACTCTAGAGT  
CCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCCAACGACCCCCGCCAT  
35 TGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGACGTC  
AATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTACATCAAGTGTATCATATGC  
CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCTGGCATTATGCCAGT  
ACATGACCTTATGGGACTTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTA  
CCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGG  
40 GATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAAC  
GGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAAATGGGCGGTAGGCGTG  
TACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGCGCCAGTCTTCCGATAG  
ACTGCGTCGCCCCGGGTACCCGATTTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCG  
TGGTCTCGCTGTTCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCACGACGGGGGTC  
45 TTTCAATTGGGGGCTCGTCCGGGATTTGGAGACCCCTGCCAGGGACCACCGACCCACCA  
CCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGTT  
TGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGTATCTGGCGGACCCG  
TGGTGGAACGACGAGTTCTGAACACCCGCGCCGCAACCCTGGGAGACGTCCAGGGACTT  
TGGGGGCCGTTTTTGTGGCCGACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTC  
50 AGGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATT  
TTTGCTTTCGGTTTGGAAACGAAGCCGCGCTCTGTCTGCTGCAGCGCTGCAGCATCGT  
TCTGTGTTGTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGT  
TACCACTCCCTTAAGTTTGACCTTAGGTCACTGGAAAGATGTGAGCGGATCGCTCACAA  
CCAGTCCGTAGATGTCAAGAAGAGACGTTGG

55

**PLTRloxP (SEQ ID No 58)**

60 GCTAGCATAACTTCGTATAATGTATGCTATACGAAGTTATTCTAGAGAACCATCAGATGT  
TTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGT



TCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAAC  
CCCTCACTCGGGGCGCCAGTCCCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAA  
TAAACCCTCTTGCACTGCATCCGACTTGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTC  
TGAGTGATTGACTACCCGTGACGCGGGGTCTTTTCAATTTGGGGGCTCGTCCGGGATCGGGA  
5 GACCCCTGCCCAGGGACCACCGACCCACCACCGGGAGGTAAGCTGGCTGCCTCGCGCGTT  
TCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTC  
TGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGT  
GTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACATA  
TGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAG  
10 ATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCT  
GCGCTCGGTTCGTTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTT  
ATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGC  
CAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGA  
GCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATA  
15 CCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCGTGCCGCTTAC  
CGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCAGCTG  
TAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC  
CGTTCAGCCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG  
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGT  
20 AGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT  
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTG  
ATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTAC  
GCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA  
GTGGAACGAAAACCTACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCAC  
25 CTAGATCCTTTTAAATTAATAAATGAAGTTTAAATCAATCTAAAGTATATATGAGTAAAC  
TTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATT  
TCGTTTCATCCATAGTTGCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTT  
ACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTT  
ATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC  
30 CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA  
TAGTTTGCACAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTTGG  
TATGGCTTCATTACGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTT  
GTGCAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGC  
AGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTGATGCCATCCGT  
35 AAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCG  
GCGACCGAGTTGCTCTTGCCCCGGCTCAACACGGGATAATACCGCGCCACATAGCAGAAC  
TTTAAAAGTGTCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACC  
GCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTT  
TACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGG  
40 AATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAG  
CATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAA  
ACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCAT  
TATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGA  
ATTATACAGATCACCGAAAACGTCTCTCAAATGTGTCCCCCTCACACTCCCAAATTC  
45 GCGGGCTTCTGCTCTTAGACCACTCTACCCTATTCCCCACACTCACCGGAGCCAAAGCC  
GCGGCCCTTCCGTTTCTTTGCTTTTGAAAGACCCACCCGTAGGTGGCAA

### LTR plasmid (SEQ ID No 59)

GCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAGAATAGAGAA  
50 GTTCAGATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGT  
GGTAAGCAGTTCCTGCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCC  
AAACAGGATATCTGTGGTAAGCAGTTCCTGCCCGGCTCAGGGCCAAGAACAGATGGTCC  
CCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCC  
CAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTT  
55 CTGTTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGG  
CGCCAGTCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAATAAACCCCTCTTGC  
AGTTGCATCCGACTTGTGGTCTCGCTGTTTCTTGGGAGGGTCTCCTCTGAGTGATTGACT  
ACCCGTGACGCGGGGTCTTTCAATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCAG  
GGACCACCGACCCACCACCGGGAGGTAAGCTGGCTGCCTCGCGGTTTCCGGTGATGACGG

TGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGC  
CGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGCGGGCGCAGC  
CATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAAGTATGCGGCATCAGAG  
CAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGA  
5 AAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTGT  
CGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCA  
GGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAA  
AAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAAT  
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTTCC  
10 CCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCC  
GCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGT  
TCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCCGAC  
CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCG  
CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACA  
15 GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGC  
GCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAA  
ACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAA  
GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAAC  
TCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTA  
20 AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGT  
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTGCTTCATCCATA  
GTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCC  
AGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAAC  
CAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAG  
25 TCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAAC  
GTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTC  
AGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCG  
GTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGCAGTGTTATCACTC  
ATGGTTATGGCAGCACTGCATAATTCTCTTACTGTGATGCCATCCGTAAGATGCTTTTCT  
30 GTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGC  
TCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTC  
ATCATTTGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCC  
AGTTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTACCCAGC  
GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGACA  
35 CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT  
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTT  
CCGCGCACATTTCCCCGAAAAGTGCCACCTGACGCTAAGAAACCATTATTATCATGACA  
TTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTCATACCAGAT  
CACCGAAAACGTCTCCTCAAATGTGTCCCCCTCACACTCCCAAATTCGCGGGCTTCTGCC  
40 TCTTAGACCACTCTACCCTATTCCCCCACTCACCGAGCCAAAGCCGCGGCCCTTCCGT  
TTCTTTGCTTTTGAAAGACCCCCACCCGTAGGTGGCAA

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03837

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/867 C12N15/90 C12N5/10 C12N7/01 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>VANIN E. F. ET AL.: "Development of high-titer retroviral producer cell lines by using Cre-mediated recombination." JOURNAL OF VIROLOGY, vol. 71, no. 10, 1997, pages 7820-7826, XP002161355 ISSN: 0022-538X cited in the application the whole document</p> <p style="text-align: center;">--- -/--</p>	1-51

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

26 February 2001

Date of mailing of the international search report

13/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

## INTERNATIONAL SEARCH REPORT

Patent Application No

PCT/GB 00/03837

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KARREMAN S. ET AL.: "ON THE USE OF DOUBLE FLP RECOGNITION TARGETS (FRTS) IN THE LTR OF RETROVIRUSES FOR THE CONSTRUCTION OF HIGH PRODUCER CELL LINES" NUCLEIC ACIDS RESEARCH, vol. 24, no. 9, 1 May 1996 (1996-05-01), pages 1616-1624, XP000616161 ISSN: 0305-1048 cited in the application the whole document	1-51
A	----- IWAKUMA T. ET AL.: "SELF-INACTIVATING LENITVIRAL VECTORS WITH U3 AND U5 MODIFICATIONS" VIROLOGY, vol. 261, no. 1, 15 August 1999 (1999-08-15), pages 120-132, XP000882897 ISSN: 0042-6822 the whole document	1-51
A	----- BOAST K. ET AL.: "CHARACTERIZATION OF PHYSIOLOGICALLY REGULATED VECTORS OF THE TREATMENT OF ISCHEMIC DISEASE" HUMAN GENE THERAPY, vol. 10, no. 13, 1 September 1999 (1999-09-01), pages 2197-2208, XP000876772 ISSN: 1043-0342 the whole document -----	1-51

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 45-48

Said claims 45-48 could not be searched because they were not present in the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.